<SEC-DOCUMENT>0001047469-17-003004.txt : 20170428
<SEC-HEADER>0001047469-17-003004.hdr.sgml : 20170428
<ACCEPTANCE-DATETIME>20170427181904
ACCESSION NUMBER:		0001047469-17-003004
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		9
CONFORMED PERIOD OF REPORT:	20170613
FILED AS OF DATE:		20170428
DATE AS OF CHANGE:		20170427
EFFECTIVENESS DATE:		20170428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMICUS THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001178879
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				200422823
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33497
		FILM NUMBER:		17790829

	BUSINESS ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
		BUSINESS PHONE:		(609) 662-2000

	MAIL ADDRESS:	
		STREET 1:		1 CEDAR BROOK DRIVE
		CITY:			CRANBURY
		STATE:			NJ
		ZIP:			08512
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>a2231878zdef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<FONT SIZE=3 ><A HREF="#17ZAD74201_1">QuickLinks</A></FONT>
<font size=3> -- Click here to rapidly navigate through this document</font>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> SCHEDULE 14A</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Proxy
Statement Pursuant to Section 14(a) of<BR>
the Securities Exchange Act of 1934 (Amendment No.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2> Filed by the Registrant <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Filed by a Party other than the Registrant <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 style="font-family:times;"><FONT SIZE=2><BR>
Check the appropriate box:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Preliminary Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2><B> Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Proxy Statement</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Definitive Additional Materials</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>Soliciting Material under &sect;240.14a-12<BR></FONT>
</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="17pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> Amicus Therapeutics,&nbsp;Inc.</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Registrant as Specified In Its Charter)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><BR><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>


<HR NOSHADE SIZE="1.0pt" WIDTH="100%" COLOR="#000000">

</FONT> <FONT SIZE=2> (Name of Person(s) Filing Proxy Statement, if other than the Registrant)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=5 style="font-family:times;"><FONT SIZE=2><BR>
Payment of Filing Fee (Check the appropriate box):</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#253;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>No fee required.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&nbsp;0-11.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Title of each class of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Aggregate number of securities to which transaction applies:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Proposed maximum aggregate value of transaction:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Total fee paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;"><BR><FONT SIZE=2>Fee paid previously with preliminary materials.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2> <FONT FACE="WINGDINGS">&#111;</FONT></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD COLSPAN=3 style="font-family:times;text-align:justify;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Check box if any part of the fee is offset as provided by Exchange Act Rule&nbsp;0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or
 Schedule and the date of its filing.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;"><BR><FONT SIZE=2>(1)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><BR><FONT SIZE=2>Amount Previously Paid:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Form, Schedule or Registration Statement No.:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>Filing Party:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 Date Filed:<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;</TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1043200,FOLIO='blank',FILE='DISK125:[17ZAD1.17ZAD74201]BA74201A.;5',USER='PJAMES',CD='24-APR-2017;19:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g399823.jpg" ALT="LOGO" WIDTH="349" HEIGHT="117">
  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>April&nbsp;28,
2017 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Dear
Stockholder: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are pleased to invite you to attend our 2017 Annual Meeting of Stockholders to be held at the offices of Amicus Therapeutics,&nbsp;Inc., located at 1 Cedar Brook Drive, Cranbury,
New Jersey 08512 on Tuesday, June&nbsp;13, 2017, at 9:00&nbsp;a.m. Eastern Daylight Time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enclosed
are the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Our Notice of Annual Meeting of Stockholders and Proxy Statement for 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Our Annual Report on Form&nbsp;10-K for 2016; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> A proxy card with a return envelope to record your vote. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
accompanying notice of the 2017 Annual Meeting and Proxy Statement describe the business we will conduct at the meeting and provide information about Amicus Therapeutics,&nbsp;Inc.
that you should consider when you vote your shares. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Your
vote is important. When you have finished reading the Proxy Statement, please promptly vote your shares by marking, signing, dating and returning the proxy card in the enclosed
envelope or vote via telephone or Internet according to the instructions in the Proxy Statement. If you attend the Annual Meeting, you may vote your shares in person even though you have previously
voted by proxy if you follow the instructions in the Proxy Statement. We encourage you to vote by proxy so that your shares will be represented and voted at the meeting, whether or not you can attend
in person. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Sincerely,<BR></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><B>
<IMG SRC="g918867.jpg" ALT="GRAPHIC" WIDTH="178" HEIGHT="72">
  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>John
F. Crowley<BR></FONT> <FONT SIZE=2><I>Chairman and Chief Executive Officer</I></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=655143,FOLIO='blank',FILE='DISK125:[17ZAD1.17ZAD74201]BC74201A.;12',USER='PJAMES',CD='24-APR-2017;19:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
</FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g399823.jpg" ALT="LOGO" WIDTH="349" HEIGHT="117">
  </B></FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>April&nbsp;28,
2017 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="be74201_notice_of_2017_annual_meeting_of_stockholders"> </A>
<A NAME="toc_be74201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  NOTICE OF&nbsp;2017 ANNUAL MEETING OF STOCKHOLDERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>To
our Stockholders: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
2017 Annual Meeting of Stockholders of Amicus Therapeutics,&nbsp;Inc. will be held at the offices of Amicus Therapeutics,&nbsp;Inc., located at 1 Cedar Brook Drive, Cranbury, New
Jersey 08512 on Tuesday, June&nbsp;13, 2017 at 9:00&nbsp;a.m. Eastern Daylight Time. The purpose of this meeting is to vote on the following: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Elect
two Class&nbsp;I directors as nominated by the Board of Directors each to serve a three</FONT><FONT SIZE=2><B>-</B></FONT><FONT SIZE=2>year term expiring at
the 2020 Annual Meeting or until their respective successors have been elected;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Ratify
the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as the Company's independent registered public accounting firm for the fiscal year ending
December&nbsp;31, 2017;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Approve,
on an advisory basis, the Company's executive compensation;
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Approve,
on an advisory basis, the frequency of the vote on executive compensation; and
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consider
and act upon any other business that is properly presented at the meeting. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
items of business are more fully described in the Proxy Statement accompanying this Notice. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
record date for the 2017 Annual Meeting is April&nbsp;17, 2017. Only stockholders of record at the close of business on that date are entitled to notice of and to vote at the
meeting or any adjournment thereof. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>BY ORDER OF THE BOARD OF DIRECTORS:</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>
<IMG SRC="g20428.jpg" ALT="GRAPHIC" WIDTH="169" HEIGHT="58">
 </B></FONT><FONT SIZE=2><BR>
<BR>
Ellen Rosenberg<BR></FONT> <FONT SIZE=2><I>General Counsel and Corporate Secretary</I></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>Cranbury,
New Jersey<BR>
April&nbsp;28, 2017 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are cordially invited to attend the meeting in person. Whether or not you expect to attend the meeting, please complete, date, sign and return the proxy card or vote by telephone or
the Internet as instructed in the accompanying materials as promptly as possible in order to ensure your representation at the meeting. You can revoke a proxy at any time prior to its exercise by
following the instructions in the Proxy Statement. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must provide
a valid proxy issued in your name from that record holder. </FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=160875,FOLIO='blank',FILE='DISK125:[17ZAD1.17ZAD74201]BE74201A.;7',USER='PJAMES',CD='24-APR-2017;19:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_da74201_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>AMICUS THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>1 Cedar Brook Drive, Cranbury, New Jersey 08512<BR>
(609)&nbsp;662-2000  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROXY STATEMENT FOR THE AMICUS THERAPEUTICS,&nbsp;INC.<BR>
2017 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>JUNE 13, 2017  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B> <A NAME="da74201_general_information_about_the_annual_meeting"> </A>
<A NAME="toc_da74201_1"> </A>
  GENERAL INFORMATION ABOUT THE ANNUAL MEETING    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Why Did You Send Me this Proxy Statement?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We sent you this Proxy Statement and the enclosed proxy card because the Board of Directors (the "Board") of Amicus Therapeutics,&nbsp;Inc.
(sometimes referred to as "we," "us," "our," "Amicus" or the "Company") is soliciting your proxy to vote at the 2017 Annual Meeting of Stockholders (the "Annual Meeting") and any adjournments of the
meeting to be held at the offices of Amicus Therapeutics,&nbsp;Inc., located at 1 Cedar Brook Drive, Cranbury, New Jersey 08512 on Tuesday, June&nbsp;13, 2017 at 9:00&nbsp;a.m. Eastern Daylight
Time. This Proxy Statement along with the accompanying Notice of Annual Meeting of Stockholders summarizes the purposes of the meeting and the information you need to know to vote at the Annual
Meeting. You are invited to attend the Annual Meeting to vote on the proposals described in this Proxy Statement. You do not need to attend the Annual Meeting to vote your shares. Instead you may
simply complete, date, sign and return the enclosed proxy card, or follow the instructions on the enclosed proxy card to submit your proxy by telephone or on the Internet. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
intend to mail this Proxy Statement, our 2016 Annual Report on Form&nbsp;10-K, as amended, the attached Notice of Annual Meeting and the enclosed proxy card to all stockholders
entitled to vote at the Annual Meeting on or about April&nbsp;29, 2017. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS<BR>
FOR THE ANNUAL MEETING TO BE HELD ON JUNE 13, 2017.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>THE PROXY STATEMENT AND FORM OF PROXY FOR OUR 2017 ANNUAL MEETING<BR>
OF STOCKHOLDERS AND OUR ANNUAL REPORT ON FORM 10-K FOR THE<BR>
YEAR ENDED DECEMBER 31, 2016 ARE AVAILABLE AT:<BR>  </B></FONT><FONT SIZE=2><I>www.sec.gov</I></FONT><FONT SIZE=2>, through the Investor Relations section of our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com</I></FONT><FONT SIZE=2> or at<BR>
http://www.amstock.com/ProxyServices/ViewMaterial.asp?CoNumber=15417. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who Can Vote?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only stockholders of record at the close of business on April&nbsp;17, 2017 are entitled to vote at the Annual Meeting. On this record date,
there were 142,829,530 shares of our common
stock ("Common Stock") outstanding and entitled to vote. Each share of Common Stock is entitled to one vote. The Common Stock is our only outstanding class of voting stock. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder of Record: Shares Registered in Your Name  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, on April&nbsp;17, 2017, your shares were registered directly in your name with our transfer agent, American Stock Transfer&nbsp;&amp; Trust
Company, then you are a stockholder of record. As a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy. Whether or not you attend the Annual Meeting, we urge you to
fill out and return the enclosed proxy card or follow the instructions on the proxy card to submit your vote by telephone or Internet to ensure your vote is counted. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=684002,FOLIO='1',FILE='DISK125:[17ZAD1.17ZAD74201]DA74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_da74201_1_2"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Beneficial Owner: Shares Registered in the Name of a Broker or Bank  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If, on April&nbsp;17, 2017, your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer, or other
similar organization, then you are the beneficial owner of shares held in "street name" and these proxy materials are being forwarded to you by that organization. The organization holding your account
is considered the stockholder of record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent on how to vote the shares in your
account. A number of brokers and banks enable beneficial owners to give voting instructions&nbsp;via telephone or the Internet. Please refer to the voting instructions provided by your bank or
broker. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are also invited to attend the Annual Meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the meeting unless you provide a valid
proxy from your broker, bank or other custodian. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What am I voting on?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There are four matters scheduled for a vote:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Elect two Class&nbsp;I directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Ratify of the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm for our fiscal year ending
December&nbsp;31, 2016; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Approval, on an advisory basis, of the Company's executive compensation; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Approve, on an advisory basis, the frequency of the vote on executive compensation. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How Do I Vote?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Whether you plan to attend the Annual Meeting or not, we urge you to vote by proxy. Voting by proxy will not affect your right to attend the
Annual Meeting. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholder of Record:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If your shares are registered directly in your name, you may vote: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> By mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Complete and mail the enclosed proxy card in the enclosed postage
prepaid envelope. Your proxy will be voted in accordance with your instructions. If you sign the proxy card but do not specify how you want your shares voted, they will be voted as recommended by our
Board.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> In person at the meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;If you attend the meeting, you may deliver your
completed proxy card in person or you may vote by completing a ballot, which will be available at the meeting.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> By telephone.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may vote over the telephone by calling toll-free
1-800-PROXIES (1-800-776-9437) in the United States or 1-718-921-8500 from outside the United States and follow the recorded instructions. Please have your proxy card available when you call. Your
vote must be received by 11:59&nbsp;p.m. Eastern Daylight Time on June&nbsp;12, 2017 to be counted.  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> Internet.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You may vote via the Internet by going to </FONT> <FONT SIZE=2><I>www.voteproxy.com</I></FONT><FONT SIZE=2> and follow the
on-screen instructions. Please have your proxy card available when you access the web page. Your vote must be received
by 11:59&nbsp;p.m. Eastern Daylight Time on June&nbsp;12, 2017 to be counted. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Beneficial Owner:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;If your shares are held in "street name" (held in the name of a bank, broker or other nominee), you must provide the
bank, broker
or other nominee with instructions on how to vote your shares and can do so as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> By mail.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;You will receive instructions from your broker or other nominee
explaining how to vote your shares. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=942189,FOLIO='2',FILE='DISK125:[17ZAD1.17ZAD74201]DA74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_da74201_1_3"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I> In person at the meeting.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;Contact the broker or other nominee who holds
your shares to obtain a broker's proxy card and bring it with you to the meeting. You will not be able to vote at the meeting unless you have a proxy card from your broker. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How Many Votes do I have?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of Common Stock that you own as of April&nbsp;17, 2017, entitles you to one vote on each matter to be voted on at the Annual
Meeting. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Will My Shares be Voted if I Do Not Return My Proxy Card?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If your shares are registered in your name, they will not be voted if you do not return your proxy card by mail or vote at the meeting as
described above under "How Do I Vote?" If your shares are held in street name and you do not provide voting instructions to the bank, broker or other nominee that holds your shares as described above
under "How Do I Vote?," the bank, broker or other nominee has the authority to vote your unvoted shares only for Proposal 2. The broker, bank or other nominee will not be permitted to vote on the
other Proposals without your voting instructions. We encourage you to provide voting instructions. This ensures your shares will be voted at the meeting in the manner you desire. If your broker cannot
vote your shares on a particular matter because it has not received instructions from you and does not have discretionary voting authority on that matter or because your broker chooses not to vote on
a matter for which it does have discretionary voting authority, this is referred to as a "broker non-vote". </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


May I Revoke My Proxy?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you give a proxy, you may revoke it at any time before the Annual Meeting. You may revoke your proxy in any one of the following
ways:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> signing a new proxy card and submitting it as instructed above; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> notifying the Company's Secretary in writing before the Annual Meeting that you have revoked your proxy; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> attending the meeting in person and voting in person if you are a stockholder of record. Attending the meeting in person will not in and of
itself revoke a previously submitted proxy unless you specifically request it. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What if I Receive More Than One Proxy Card?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You may receive more than one proxy card or voting instruction form if you hold shares of our Common Stock in more than one account, which may
be in registered form or held in street name. Please vote in the manner described under "How Do I Vote?" for each account to ensure that all of your shares are voted. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How Does the Board of Directors Recommend That I Vote on the Proposals?  </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board recommends that you vote as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B>"FOR"</B></FONT><FONT SIZE=2> the election of the nominees for director; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B>"FOR"</B></FONT><FONT SIZE=2> ratification of the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent
registered public accounting firm for our fiscal year ending December&nbsp;31, 2016; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><B>"FOR"</B></FONT><FONT SIZE=2> the approval of the compensation of our named executive officers; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> "</FONT><FONT SIZE=2><B>FOR"</B></FONT><FONT SIZE=2> the approval of the frequency of the vote on executive compensation. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=6,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=936488,FOLIO='3',FILE='DISK125:[17ZAD1.17ZAD74201]DA74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_da74201_1_4"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
any other matter is properly presented, the proxy card provides that your shares will be voted by the proxy holder listed on the proxy card in accordance with his best judgment. At
the time this Proxy Statement was printed, we knew of no matters that needed to be acted on at the Annual Meeting, other than those discussed in this Proxy Statement. </FONT></P>


<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What Vote is Required to Approve Each Proposal and How are Votes Counted?  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><B>Proposal 1: Elect Directors</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The nominees for director who receive the most votes (also known as a "plurality" of the votes) will be elected. Abstentions are not counted as voting on the matter for purposes of electing directors. You may vote FOR all of the nominees, WITHHOLD
 your vote from all of the nominees or WITHHOLD your vote from any one or more of the nominees. Votes that are withheld will not be included in the vote tally for the election of directors. Brokerage firms do not have authority to vote customers'
 unvoted shares held by the firms in street name for the election of directors. These broker non-votes will have no effect on the results of this vote.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Proposal 2: Ratify Selection of Independent Registered Public Accounting Firm</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to ratify the selection of our independent registered public accounting firm.
 Abstentions will have the effect of a vote against this proposal. Brokerage firms have authority to vote customers' unvoted shares held by the firms in street name on this proposal. We are not required to obtain the approval of our stockholders to
 select our independent registered public accounting firm. However, our Board believes it is advisable to give stockholders the opportunity to ratify this selection. If our stockholders do not ratify the selection of Ernst&nbsp;&amp; Young&nbsp;LLP as
 our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2017, the Audit Committee of our Board will reconsider its selection.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><BR><FONT SIZE=2><B>Proposal 3: Approval, on an Advisory Basis, of Executive Compensation</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2><BR>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><BR><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The affirmative vote of a majority of the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter is required to adopt this resolution. Abstentions will have the effect of a vote against this
 proposal. Brokerage firms do not have authority to vote customers' unvoted shares held by the firms in street name for this proposal. If a broker does not exercise this authority, such broker non-votes will have no effect on the results of this vote.
 This advisory vote on executive compensation is not binding on our Board. However, the Board will take into account the result of the vote when determining future executive compensation arrangements.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=7,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=361970,FOLIO='4',FILE='DISK125:[17ZAD1.17ZAD74201]DA74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_da74201_1_5"> </A>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="48%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="48%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2><B>Proposal 4: Approval, on an Advisory Basis, of Frequency of the Vote on Executive Compensation</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;text-align:justify;"><FONT SIZE=2>


<!-- COMMAND=ADD_GRID,"text-align:justify;" -->


 The frequency receiving the highest number of votes from the shares present in person or represented by proxy at the Annual Meeting and entitled to vote on such matter will be considered the frequency preferred by the stockholders, even if that
 alternative does not receive the support of a majority of the shares present and entitled to vote. Abstentions will have no effect on this proposal. Brokerage firms do not have authority to vote customers' unvoted shares held by the firms in street
 name for this proposal. If a broker does not exercise this authority, such broker non-votes will have no effect on the results of this vote. This advisory vote on frequency of the vote on executive compensation is not binding on our Board. However,
 the Board will take into account the result of the vote when determining future voting frequency.</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How are votes counted?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Votes will be counted by the inspector of election appointed for the Annual Meeting, who will separately count "For" and "Withhold" and (with
respect to proposals other than the election of directors) "Against" votes, abstentions and broker non-votes. Shares represented by abstentions and broker non- votes will be counted in determining
whether there is a quorum for the Annual Meeting. Abstentions will have no effect on Proposal 1 but will have the effect of a vote against Proposal 2, 3, and 4. Broker non-votes will not be counted
towards the vote total for any proposal. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Who Will Pay the Costs of Soliciting these Proxies and How Are They Being Solicited?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will pay all of the costs of soliciting these proxies. Our directors and employees may solicit proxies in person or by telephone, fax or
email. We will pay these employees and directors no additional compensation for these services. We will ask banks, brokers and other institutions, nominees and fiduciaries to forward these proxy
materials to their principals and to obtain authority to execute proxies. We will then reimburse them for their expenses. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


What Constitutes a Quorum for the Meeting?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The presence, in person or by proxy, of the holders of a majority of the issued and outstanding shares of our Common Stock is necessary to
constitute a quorum at the meeting. Votes of stockholders of record who are present at the meeting in person or by proxy, abstentions and broker non-votes are counted for purposes of determining
whether a quorum exists. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


How can I find out the results of the voting at the Annual Meeting?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preliminary voting results will be announced at the Annual Meeting. Final voting results will be published in a Current Report on
Form&nbsp;8-K within four business days after the Annual Meeting. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


When are stockholder proposals due for next year's Annual Meeting?  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you wish to submit a proposal to be considered for inclusion in next year's proxy materials or nominate a director, your proposal must be in
proper form according to Securities and Exchange Commission ("SEC") Regulation&nbsp;14A, Rule&nbsp;14a8 and received by the Secretary of the Company no later than December&nbsp;29, 2017.
Proposals received after that date will not be included in the proxy materials we send out in connection with the 2018 Annual Meeting of Stockholders. If a proposal is received before that date, the
proxies that management solicits for the meeting may still exercise discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. To be timely in </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=8,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=686720,FOLIO='5',FILE='DISK125:[17ZAD1.17ZAD74201]DA74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_da74201_1_6"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>accordance
with our Restated By-laws, stockholder notice of any such proposal must be received by us not earlier than November&nbsp;29, 2017 and not later than December&nbsp;29, 2017; provided,
however, that in the event that the date of the 2018 Annual Meeting of Stockholders is more than 30&nbsp;days before or more than 60&nbsp;days after the anniversary date of the 2017 Annual Meeting
of Stockholders, notice by the stockholder to be timely must be delivered not earlier than the close of business on the 90th&nbsp;day prior to the 2018 Annual Meeting of Stockholders and not later
than the close of business on the later of the 60th&nbsp;day prior to the 2018 Annual Meeting of Stockholders or the 10th&nbsp;day following the day on which we make a public announcement of the
2018 Annual Meeting of Stockholders. All stockholder proposals should be marked for the attention of General Counsel and Corporate Secretary, c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive,
Cranbury, New Jersey 08512. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Attending the Annual Meeting  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Annual Meeting will be held at the offices of Amicus Therapeutics,&nbsp;Inc., located at 1 Cedar Brook Drive, Cranbury, New Jersey 08512
on Tuesday, June&nbsp;13, 2017 at 9:00&nbsp;a.m. Eastern Daylight Time. When you arrive at Amicus, signs will direct you to the appropriate meeting rooms. You are not required to attend the Annual
Meeting in order to vote. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="da74201_security_ownership_of_certain___sec02525"> </A>
<A NAME="toc_da74201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth certain information with respect to the beneficial ownership of our Common Stock as of March&nbsp;31, 2017 for
(a)&nbsp;the executive officers named in the Summary Compensation Table contained in this Proxy Statement, (b)&nbsp;each of our directors and director nominees, (c)&nbsp;all of our current
directors and executive officers as a group and (d)&nbsp;each stockholder known by us to own beneficially more than 5% of our Common Stock. Beneficial ownership is determined in accordance with the
rules of the SEC and includes voting or investment power with respect to the securities. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
deem shares of Common Stock that may be acquired by an individual or group within 60&nbsp;days of March&nbsp;31, 2017 pursuant to the exercise of options or warrants to be
outstanding for the purpose of computing the percentage ownership of such individual or group, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other
person shown in the table. Except as indicated in footnotes to this table, we believe that the stockholders named in this table have sole voting and investment power with respect to all shares of
Common Stock shown to be beneficially owned by them based on information provided to us by these stockholders. Percentage of ownership is based on 142,829,530 shares of Common Stock outstanding on
March&nbsp;31, 2017. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=9,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=38791,FOLIO='6',FILE='DISK125:[17ZAD1.17ZAD74201]DA74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dc74201_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise indicated below, the address of each of the individuals named below is: c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, NJ 08512. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Address of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage<BR>
Of Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT> <FONT SIZE=2><B>5% Stockholders</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with FMR&nbsp;LLC(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>21,348,929</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>245 Summer Street</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Boston, MA 02210</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Entities affiliated with Perceptive Advisors&nbsp;LLC(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,296,672</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12.1</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 499 Park Avenue, 25<SUP>th</SUP>&nbsp;Floor</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 New York, NY 10022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Redmile Group,&nbsp;LLC(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>14,391,130</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>One Letterman Drive, Bldg. D, Suite D3-700</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>San Francisco, CA 94129</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Entities affiliated with Black Rock&nbsp;Inc.(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11,983,911</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 55 East 52nd&nbsp;Street</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 New York, NY 10055</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Prudential Financial,&nbsp;Inc.(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>9,880,410</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.9</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>466 Lexington Avenue</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New York, NY 10017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Entities affiliated with Vanguard Group(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>8,333,811</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.8</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 100 Vanguard Blvd.</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Malvern, PA 19355</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Entities affiliated with Morgan Stanley(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7,199,838</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5.0</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>1585 Broadway</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>New York, NY 10036</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;<BR></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name of Beneficial Owner

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage<BR>
Of Shares<BR>
Beneficially<BR>
Owned </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Named Executive Officers and Directors</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John F. Crowley(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,776,525</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1.2</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird III(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>569,063</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bradley L. Campbell(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>772,020</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>294,744</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Hung Do, Ph. D.(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>593,027</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald J. Hayden, Jr.(13)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>120,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio(14)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76,933</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael G. Raab(15)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>105,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret G. McGlynn, R.Ph.(16)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>125,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted W. Love, M.D.(17)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>222,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner(18)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>*</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All directors and executive officers as a group (15 persons)(19)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>5,036,293</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3.4</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>*</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
beneficial ownership of less than one percent of our outstanding Common Stock.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided in reliance upon information included in a Schedule&nbsp;13G/A filed with the SEC on February&nbsp;14, 2017 by FMR&nbsp;LLC. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=4999,FOLIO='7',FILE='DISK125:[17ZAD1.17ZAD74201]DC74201A.;12',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_dc74201_1_8"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided in reliance upon information included in a Schedule&nbsp;13G/A filed with the SEC on February&nbsp;14, 2017 by Perceptive
Advisors&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided in reliance upon information included in a Schedule&nbsp;13G filed with the SEC on February&nbsp;14, 2017 by Redmile
Group&nbsp;LLC.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided in reliance upon information included in a Schedule&nbsp;13G/A filed with the SEC on January&nbsp;19, 2017 by Blackrock&nbsp;Inc.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided in reliance upon information included in a Schedule&nbsp;13G filed with the SEC on January&nbsp;30, 2017 by Prudential
Financial,&nbsp;Inc.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided in reliance upon information included in a Schedule&nbsp;13G filed with the SEC on February&nbsp;9, 2017 by Vanguard Group.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
information is provided in reliance upon information included in a Schedule&nbsp;13G filed with the SEC on March&nbsp;13, 2017 by Morgan Stanley.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 1,619,938 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2017, 91,692 shares held directly by
Mr.&nbsp;Crowley and 64,895 shares held by a trust f/b/o Mr.&nbsp;Crowley. Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2017 and
unvested restricted stock units as of May&nbsp;30, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(9)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 548,113 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2017 and 20,950 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2017 and unvested restricted stock units as of May&nbsp;30, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(10)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 744,070 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2017 and 27,950 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2017 and unvested restricted stock units as of May&nbsp;30, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(11)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 294,744 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2017. Excludes shares issuable upon the
exercise of stock options that are first exercisable after May&nbsp;30, 2017 and unvested restricted stock units as of May&nbsp;30, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(12)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 122,887 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2017 and 470,140 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2017 and unvested restricted stock units as of May&nbsp;30, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(13)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 120,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2017. Excludes shares issuable upon the
exercise of stock options that are first exercisable after May&nbsp;30, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(14)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 65,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2017 and 11,933 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(15)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 105,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2017. Excludes shares issuable upon the
exercise of stock options that are first exercisable after May&nbsp;30, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(16)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 115,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2017 and 10,000 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2017. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=11,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=133078,FOLIO='8',FILE='DISK125:[17ZAD1.17ZAD74201]DC74201A.;12',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_dc74201_1_9"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(17)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 80,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2017 and 142,000 shares held of record.
Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(18)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 80,000 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2017. Excludes shares issuable upon the
exercise of stock options that are first exercisable after May&nbsp;30, 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(19)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Consists
of 4,166,044 shares issuable upon the exercise of stock options exercisable within 60&nbsp;days of March&nbsp;31, 2017, and 870,249 total shares held
of record. Excludes shares issuable upon the exercise of stock options that are first exercisable after May&nbsp;30, 2017.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dc74201_management"> </A>
<A NAME="toc_dc74201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  MANAGEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


The Board of Directors  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Restated Certificate of Incorporation and Restated By-laws provide that our business is to be managed by or under the direction of our
Board. Our Board is divided into three classes and one class is elected at each Annual Meeting of Stockholders to serve for a three-year term. Prior to the resignation of Dr.&nbsp;Sol
Barer<SUP>1</SUP>, our Board consisted of eight members. Our Board is divided amongst three classes as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Class&nbsp;I directors are Dr.&nbsp;Love and Mr.&nbsp;Essner and their term will expire at the 2017 Annual Meeting of Stockholders; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Class&nbsp;II directors are Mr.&nbsp;Hayden and Mr.&nbsp;Wheeler and their term will expire at the 2018 Annual Meeting of
Stockholders; and</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> The Class&nbsp;III directors are Messrs.&nbsp;Crowley, Raab, and Sblendorio and Ms.&nbsp;McGlynn, and their term will expire at the 2019
Annual Meeting of Stockholders. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Restated Certificate of Incorporation and Restated By-laws provide that the authorized number of directors may be changed only by resolution of the Board. Our Board has authorized
that the size of the Board be set at ten members. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
April&nbsp;21, 2017, our Board, upon the recommendation of the Nominating and Corporate Governance Committee, voted to nominate Dr.&nbsp;Love and Mr.&nbsp;Essner for re-election
as Class&nbsp;I directors at the 2017 Annual Meeting for a term of three years to serve until the 2020 Annual Meeting of stockholders until their respective successors have been duly elected and
qualified. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board has determined that each of the director nominees possesses the requisite skills, personal integrity, business judgment, industry experience and willingness to devote adequate
time and effort necessary to serve as an effective member of the Board. A description of the background of each, along with other specific experiences, qualifications, attributes or skills that
contributed to the Board's decision to nominate the nominees, is set forth below, followed immediately by like disclosure for our existing directors whose terms of office extend beyond the Annual
Meeting. </FONT></P>
 <p style="font-family:times;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
<HR NOSHADE COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT"> </FONT></P>

 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2><SUP>1</SUP></FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>On
February&nbsp;7, 2017, Sol J. Barer, Ph.D. informed the Board that he had chosen to resign from the Board effective February&nbsp;9, 2017.
Dr.&nbsp;Barer's resignation was due to his appointment as Chairman of the Board of Teva Pharmaceutical Industries&nbsp;Ltd. </FONT></DD></DL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=12,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=671590,FOLIO='9',FILE='DISK125:[17ZAD1.17ZAD74201]DC74201A.;12',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_dc74201_1_10"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Nominees for Election at the Annual Meeting  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dr.&nbsp;Ted Love(1)(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>58</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>69</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Nominating/Corporate Governance Committee.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of the Audit Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chair
of the Science and Technology Committee  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Ted W. Love</I></FONT><FONT SIZE=2>, </FONT><FONT SIZE=2><I>M.D.</I></FONT><FONT SIZE=2>, has served as a member of the Board since June 2012. Dr.&nbsp;Love is
currently the CEO of Global Blood. From February 2010 to August 2012, Dr.&nbsp;Love served as Executive Vice President and Head of Research and Development of Onyx Pharmaceuticals. From 2001 to
2009, Dr.&nbsp;Love was the President, Chief Executive Officer and Chairman of the Board of Directors of Nuvelo. Before joining Nuvelo in 2001, he served as Senior Vice President of Development at
Theravance,&nbsp;Inc. Prior to that, Dr.&nbsp;Love spent six years at Genentech,&nbsp;Inc. ("Genentech") in a number of senior management positions in Medical Affairs and Product Development. As
Vice President of Product Development and Regulatory Affairs at Genentech, Dr.&nbsp;Love oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as chairman of
Genentech's Product Development Committee. In addition to Amicus, Dr.&nbsp;Love currently serves on the Board of Directors of Cascadian and Global Blood. Dr.&nbsp;Love holds a B.A. in molecular
biology from Haverford College and an M.D. from Yale Medical School. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Dr.&nbsp;Love's significant medical, scientific and drug development experience in addition to his executive
leadership experience in the pharmaceutical industry, experience as Chief Executive Officer and Chairman of a biopharmaceutical company and service on the Boards of Directors of other publicly-held
biopharmaceutical companies contributed to our conclusion that he should be re-elected to serve as a director of the Company and lead the Science and Technology Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Robert Essner</I></FONT><FONT SIZE=2> has served as a member of the Board since June 2012. Mr.&nbsp;Essner is Operating Executive to the global healthcare group
at The Carlyle Group, a global private equity firm. Mr.&nbsp;Essner retired as Chairman and Chief Executive Officer of Wyeth, now part of Pfizer, in 2008. During his 32-year career in the
pharmaceutical industry, he held several prominent leadership positions, including Chairman of the Pharmaceutical Research and Manufacturers Association. Prior to Wyeth, Mr.&nbsp;Essner spent more
than a decade in various management positions at Sandoz Pharmaceuticals Corporation and as President of Sandoz Consumer Healthcare Group. Mr.&nbsp;Essner is currently a Director at MassMutual
Financial Group (Chairman). Mr.&nbsp;Essner is also an Executive-in-Residence and Adjunct Professor at Columbia Business School, where he teaches courses in healthcare management. He received a
Bachelor's degree from Miami University and a Master's degree from the University of Chicago. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Essner's significant executive leadership experience in the pharmaceutical industry, including
building and leading pharmaceutical businesses, launching products and managing corporate risks, including as Chairman and Chief Executive Officer of a pharmaceutical company, as well as his service
on the Board of Directors of another publicly-held company in the pharmaceutical industry contributed to our conclusion that he should be re-elected to serve as a director of the Company and continue
to serve on the Audit Committee. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=13,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=67432,FOLIO='10',FILE='DISK125:[17ZAD1.17ZAD74201]DC74201A.;12',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_dc74201_1_11"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Directors Whose Terms Do Not Expire This Year  </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="20pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Age </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Position </B></FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Chairman</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald Hayden(3)(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret McGlynn, R.Ph.(3)(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>57</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael Raab(1)(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn Sblendorio(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler(1)(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>56</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Director</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Compensation Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Science and Technology Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Nominating/Corporate Governance Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Member
of Audit Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Lead
Independent Director
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chair,
Compensation Committee
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Chair,
Audit Committee  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>John F. Crowley</I></FONT><FONT SIZE=2> has served as a Director, Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since
January 2005, except for the period from April 2011 through August 2011 during which time he served as Executive Chairman. Mr.&nbsp;Crowley has also served as a director of Amicus since August 2004,
with the exception of the period from September 2006 to March 2007 when he was in active duty service in the United States Navy (Reserve). Mr.&nbsp;Crowley was President and Chief Executive Officer
of Orexigen Therapeutics,&nbsp;Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals,&nbsp;Inc., from March 2000 until that company
was acquired by Genzyme Corporation ("Genzyme") in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002. Mr.&nbsp;Crowley received a B.S. degree
in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Crowley possesses strong leadership qualities, demonstrated through his service as an executive in
the pharmaceutical industry, including his prior roles as Chief Executive Officer of development stage biopharmaceutical companies, and has extensive and intimate knowledge
of the rare disease community and the needs of people living with rare diseases. He also provides our Board with in-depth knowledge of our company through the day-to-day leadership of our executives,
all of which contributed to our conclusion that he should continue to serve as a Director of the Company. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Donald J. Hayden, Jr.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;has served as a member of our Board since March 2006 and as Lead Independent Director since February 2010.
Mr.&nbsp;Hayden
served as Chairman from March 2006 until February 2010 and from September 2006 until March 2007 as Interim President and Chief Executive Officer. From 1981 to 2006, he held several executive positions
with Bristol-Myers Squibb Company, most recently serving as Executive Vice President and President, Americas. Mr.&nbsp;Hayden is Chair of the Board of Directors of Insmed Incorporated and REGENXBIO.
Mr.&nbsp;Hayden holds a B.A. from Harvard University and an M.B.A. from Indiana University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Hayden has more than 30&nbsp;years of experience in the pharmaceutical industry, including
leadership roles in commercialization, drug launch, executive management, financial and strategic planning and business development. He also has significant Board experience through his service on the
Board of Directors of other publicly-held biopharmaceutical companies and his service as our Interim Chief Executive Officer all of which contribute to our conclusion that he should continue to </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=14,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=286255,FOLIO='11',FILE='DISK125:[17ZAD1.17ZAD74201]DC74201A.;12',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_dc74201_1_12"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>serve
as a director of the Company and is particularly well suited to serve as Lead Independent Director and Chair of the Nominating and Corporate Governance Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Margaret G. McGlynn, R.Ph.,</I></FONT><FONT SIZE=2> has served as a member of our Board since October 2009. Following a 26&nbsp;year career at Merck,
Ms.&nbsp;McGlynn served as CEO and President of The International AIDS Vaccine Initiative from July 2011 through September 2015. She previously served as President, Vaccines and Infectious Diseases
of Merck&nbsp;&amp;&nbsp;Co.,&nbsp;Inc. ("Merck") from 2005 until her retirement in 2009, where she led a global organization of 2000 employees with over $7B in sales. Ms.&nbsp;McGlynn joined
Merck in 1983, and served in a variety of executive leadership roles in marketing, sales and managed care. Currently, Ms.&nbsp;McGlynn serves as a member of the Boards of Directors of Air Products
and Chemicals,&nbsp;Inc. and Vertex Pharmaceuticals,&nbsp;Inc. She is also Chair of the Board of HCU Network America, a non-profit which provides advocacy and support for patients affected by the
rare disease homocystinuria. Ms.&nbsp;McGlynn holds a B.S. in Pharmacy and a MBA in Marketing from the State University of New York at Buffalo. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Ms.&nbsp;McGlynn has significant leadership experience in the pharmaceutical industry, including her service
as a senior executive of Merck where she led commercialization across
several therapeutic areas and geographies and managed large organizations. This experience, combined with her service on biopharmaceutical company boards and a rare disease patient advocacy
organization, give her important insights into Amicus's business and a comprehensive understanding of compensation management and the relationship of compensation practices to the organization and its
development contribute to our conclusion that she should continue to serve as a director of the Company, Chair of the Compensation Committee and member of the Nominating and Corporate Governance
Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Michael G. Raab</I></FONT><FONT SIZE=2> has served as a member of our Board of Directors since its founding. Mr.&nbsp;Raab has served as President and Chief
Executive Officer of Ardelyx,&nbsp;Inc. since March 2009. Mr.&nbsp;Raab previously served as a partner of New Enterprise Associates ("NEA") from June 2002 until December 2008, with a focus on
healthcare investing. From 1999 to 2002, he was Senior Vice President, Therapeutics and General Manager, Renagel&reg; at Genzyme Corporation. Mr.&nbsp;Raab currently serves as a member of
the Board of Directors of Ardelyx,&nbsp;Inc. Mr.&nbsp;Raab holds a B.A. from DePauw University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Raab has significant experience in drug development and commercialization of products in the rare
diseases, cardiorenal and GI diseases. He also has extensive management experience in the biopharmaceutical industry serving as Chief Executive Officer of a late-stage biopharmaceutical company and
from his prior time overseeing NEA investments in pharmaceuticals and biotechnology, all of which contributed to our conclusion that he should continue to serve as a director of the Company and a
member of the Audit and Compensation Committees. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Glenn&nbsp;P. Sblendorio</I></FONT><FONT SIZE=2> has served as a member of our Board since June 2006. On April&nbsp;24, 2017, Mr.&nbsp;Sblendorio was
appointed Chief Executive Officer of Ophthotech Corporation ("Ophthotech") effective July&nbsp;1, 2017 and was nominated to the Board of Directors of Ophthotech. Since April&nbsp;1, 2016,
Mr.&nbsp;Sblendorio had served as Executive Vice President, Chief Operating Officer and Chief Financial Officer of Ophthotech and was a member of the Board of Directors of Ophthotech until
March&nbsp;31, 2016. Prior to Ophthotech, Mr.&nbsp;Sblendorio was President and Chief Financial Officer of The Medicines Company from March, 2006 through March, 2016 and was a member of the Board
of Directors of the Medicines Company from July 2011 through December&nbsp;31, 2015. Before joining The Medicines Company, Mr.&nbsp;Sblendorio was Executive Vice President and Chief Financial
Officer of Eyetech Pharmaceuticals,&nbsp;Inc. from February 2002 until it was acquired by OSI Pharmaceuticals,&nbsp;Inc. in November 2005. Mr.&nbsp;Sblendorio also serves as a member of the
Boards of Directors of Intercept Pharmaceuticals (Chair, Audit). Mr.&nbsp;Sblendorio received his B.B.A. from Pace University and his M.B.A. from Fairleigh Dickinson University. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=15,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=128992,FOLIO='12',FILE='DISK125:[17ZAD1.17ZAD74201]DC74201A.;12',USER='PJAMES',CD='24-APR-2017;19:54' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_de74201_1_13"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Sblendorio has significant corporate leadership experience, industry knowledge and demonstrated
knowledge of financial and financing matters through his prior experience in leading pharmaceutical companies. He brings substantial expertise in the management of and financial and compliance risks
associated with global pharmaceutical operations and financial management strategies. He is the "audit committee financial expert" as defined in the SEC regulations, with particular expertise in the
matters faced by the audit committee of a company with its first commercial revenue and related expenses, all of which contribute to our conclusion that he should continue to serve as a director of
the Company and Chair of the Audit Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Craig Wheeler</I></FONT><FONT SIZE=2> has served as a member of our Board since June 2016. Since September 2006, Mr.&nbsp;Wheeler has served as President and
Chief Executive Officer of Momenta Pharmaceuticals. At Momenta, Mr.&nbsp;Wheeler led the company through the launch of its first complex drug products. He has overseen the company's growth into the
diversified business it is today. In 2011, he was an E&amp;Y Entrepreneur of the Year Regional Award winner. In May 2012, the Boston Globe named Momenta the number one company in their annual Globe 100
survey of top performing companies. Prior to joining Momenta, Mr.&nbsp;Wheeler was President of Chiron BioPharmaceuticals where during his five-year tenure he led US and European commercial
organizations and the pharmaceutical division's global sales more than doubled. Before that, he was a senior member of The Boston Consulting Group's health care practice and worked extensively in the
health care sector with focus on pharma and biotech, particularly in regard to corporate and R&amp;D strategy He began his career at Merck's MSDRL research unit. He also previously served as the Chairman
of the Board of Avanir Pharmaceuticals where he helped oversee the transition of the company from a research-based platform to a fully integrated CNS pharmaceutical company until 2015 when it was
acquired by Otsuka Pharmaceuticals for $3.5&nbsp;billion.
Mr.&nbsp;Wheeler received his BS and MS in chemical engineering from Cornell University and his MBA from the Wharton School of the University of Pennsylvania. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Skills and Qualifications:</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Mr.&nbsp;Wheeler has extensive pharmaceutical industry knowledge and leadership experience, including his
demonstrated expertise in drug development, manufacturing and the technical issues facing growing biopharmaceutical companies. Mr.&nbsp;Wheeler's deep understanding of the management and growth of
pharmaceutical companies contribute to our conclusion that he should continue to serve as a director of the Company and a member of the Science and Technology and Compensation Committees. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Independence  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board has reviewed the materiality of any relationship that each of our directors has with Amicus, either directly or indirectly as well as
other factors that may impact the independence determination for each of our directors. Based on this review, our Board has determined that the following directors are "independent directors" as
defined by the rules and regulations of The Nasdaq Stock Market&nbsp;LLC ("NASDAQ"): Messrs.&nbsp;Essner, Hayden, Raab, Sblendorio and Wheeler, Dr.&nbsp;Love, and Ms.&nbsp;McGlynn. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Committees of the Board and Meetings  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board has an Audit and Compliance Committee, a Compensation Committee, a Nominating and Corporate Governance Committee and a Science and
Technology Committee, each of which has the composition and responsibilities described below. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Audit and Compliance Committee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Audit and Compliance Committee ("ACC") met eight times during 2016. The current members of our ACC
are
Messrs.&nbsp;Sblendorio, Essner and Raab. Mr.&nbsp;Sblendorio is the Chair of the ACC. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has determined that Mr.&nbsp;Sblendorio is an Audit Committee financial expert within the meaning of Item&nbsp;407(d)(5) of Regulation&nbsp;S-K and has "accounting or
related financial management expertise" within the meaning of the rules and regulations of NASDAQ. Our Audit Committee was </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=16,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=696923,FOLIO='13',FILE='DISK125:[17ZAD1.17ZAD74201]DE74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_de74201_1_14"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>established
in accordance with Section&nbsp;3(a)(58) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Our ACC assists our Board in its oversight of the integrity of our
financial statements, our independent registered public accounting firm's qualifications and independence and the performance of our independent registered public accounting firm. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ACC's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> appointing, approving the compensation of, and assessing the independence of our independent registered public accounting firm; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing the work of our independent registered public accounting firm, including through the receipt and consideration of certain reports
from our independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and discussing with management and the independent registered public accounting firm our annual and quarterly financial statements
and related disclosures; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> monitoring our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Monitoring our Compliance Program; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> establishing policies regarding hiring employees from our independent registered public accounting firm and procedures for the receipt and
retention of accounting related complaints and concerns; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> meeting independently with our independent registered public accounting firm and management; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> preparing the Audit Committee report required by SEC rules. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
audit and non-audit services to be provided to us by our independent registered public accounting firm must be approved in advance by our Audit Committee. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NASDAQ
rules require that all members of the Audit Committee be independent directors, as defined by the rules of NASDAQ and the SEC. Our Board has determined that all the members of the
Audit Committee satisfy the independence requirements for service on the Audit Committee. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of the ACC written charter is publicly available on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com.</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation Committee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Compensation Committee met four times during 2016. Ms.&nbsp;McGlynn, Mr.&nbsp;Raab and Mr.&nbsp;Wheeler are
the
members of our Compensation Committee. Prior to his resignation from the Board in February 2017, Dr.&nbsp;Barer was a member of the Compensation Committee. Ms.&nbsp;McGlynn is the chair of the
Compensation Committee. Our Compensation Committee assists our Board in the discharge of its responsibilities relating to the compensation of our executive officers. The Compensation Committee has
retained Pay Governance,&nbsp;LLC ("Pay Governance") as its independent executive compensation consultant. Pay Governance reports directly to the Compensation Committee and provides guidance on
matters including trends in executive and non-employee director compensation, the development of certain executive compensation programs and other matters as directed by the Compensation Committee.
Pay Governance does not provide any other services to the Company. Based on the consideration of the various factors as set forth in the rules of the SEC, the Compensation Committee has determined
that its relationship with Pay Governance and the work of Pay Governance on behalf of the Compensation Committee has not raised any conflict of interest. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and approving executive officer compensation including the compensation of our Chief Executive Officer; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing the evaluation of performance of our senior executives; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=17,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=406549,FOLIO='14',FILE='DISK125:[17ZAD1.17ZAD74201]DE74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_de74201_1_15"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing and administering, and making recommendations to our Board with respect to our cash and equity incentive plans; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and approving potential executive and senior management succession plans; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and approving non-routine employment agreements, severance agreements and change in control agreements. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and recommending to the Board for approval the annual corporate goals and objectives; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing the Company's performance against the annual corporate goals and objectives and recommending to the Board a corporate multiplier
which represents the percentage of achievement against the corporate goals and objectives. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has determined that the members of our Compensation Committee qualify as independent directors under the rules and regulations of NASDAQ and the SEC. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of the Compensation Committee's written charter is publicly available on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com.</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further
discussion of the process and procedures for considering and determining executive compensation, including the role that our executive officers play in determining compensation
for other executive officers, is included below in the section entitled "Compensation Discussion and Analysis." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Please
also see the report of the Compensation Committee set forth elsewhere in this Proxy Statement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nominating and Corporate Governance Committee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Nominating and Corporate Governance Committee met four times during 2016.
Mr.&nbsp;Hayden,
Dr.&nbsp;Love and Ms.&nbsp;McGlynn are the members of our Nominating and Corporate Governance Committee. Mr.&nbsp;Hayden chairs the Nominating and Corporate Governance Committee. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Nominating and Corporate Governance Committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> recommending to our Board the persons to be nominated for election as directors and to each of the Board's Committees; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> conducting searches for appropriate directors; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing the size, composition and structure of our Board; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> developing and recommending to our Board corporate governance principles; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing a periodic self-evaluation of our Board and any Board Committees; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing compensation and benefits for directors and Board Committee members. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has determined that the members of our Nominating and Corporate Governance Committee qualify as independent directors under the rules and regulations of NASDAQ and the SEC. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
copy of the Nominating and Corporate Governance Committee's written charter is publicly available on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com.</I></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Science and Technology Committee.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Science and Technology Committee was reconstituted in 2016 and met two times in 2016.
Dr.&nbsp;Love and
Mr.&nbsp;Wheeler are currently members of our Science and Technology Committee. Prior to his resignation from the Board in February 2017, Dr.&nbsp;Barer was a member of the Science and Technology
Committee. Dr.&nbsp;Love serves as Chair of the committee. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>15</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=18,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=417135,FOLIO='15',FILE='DISK125:[17ZAD1.17ZAD74201]DE74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_de74201_1_16"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Science and Technology Committee's responsibilities include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> identifying and discussing new and emerging trends in pharmaceutical science, technology and regulation to ensure that the Company makes well
informed choices in the investment of its Research and Development resources; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing, evaluating and advising the Board regarding the quality, direction and competitiveness of the Company's Research and Development
programs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing, evaluating and advising the Board regarding the Company's progress in achieving its strategic Research and Development goals and
objectives; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> reviewing and making recommendations to the Board on the Company's internal and external investments in science and technology. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board has determined that the members of the Science and Technology Committee qualify as independent directors under the rules and regulations of NASDAQ and the SEC. A copy of the
Science and Technology Committee's written charter is publicly available on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com.</I></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Board Leadership Structure  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In February 2010, the Board elected Mr.&nbsp;Crowley as chairman of the Board in addition to his role as chief executive officer to succeed
Donald J. Hayden, Jr. Simultaneous with Mr.&nbsp;Crowley's election to chairman, the Board appointed Mr.&nbsp;Hayden as Lead Independent Director. As Lead Independent Director, Mr.&nbsp;Hayden
is responsible for, among other things:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> leading executive sessions of the Board's independent directors, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> advising the independent Board Committee chairs in fulfilling their responsibilities to the Board, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> assisting the Board and the Company's officers in complying with the Company's governance guidelines, and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> overseeing the process of evaluating, developing and compensating the chief executive officer. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Company combines the chairman and chief executive officer positions because it believes that, at this critical juncture in the Company's development, Mr.&nbsp;Crowley is best
suited to oversee the development and implementation of the Company's strategic vision including our ongoing transition from a development stage entity into a commercial biotechnology company.
Mr.&nbsp;Crowley's tenure as chairman also reflects the Board's confidence in his leadership and vision for the Company and recognizes his accomplishments since joining the Company. However, the
Company wished to maintain the strong independent leadership provided by Mr.&nbsp;Hayden during his tenure as chairman. The Company believes that by creating a Lead Independent Director position
held by Mr.&nbsp;Hayden, it has designed a governance structure that best advances the objectives of the Company while maintaining proper checks and balances on senior management, and providing the
independent members of the Board with open and transparent communication regarding the Company's strategic planning activities. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risk Oversight Management  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board provides risk oversight for the Company primarily through the Audit and Compliance Committee. Under our Enterprise Risk Management
Action Plan, the Company identifies risks throughout our organization utilizing various methodologies, including interviews with senior employees and members of the Board. We then evaluate the
identified risks and implement procedures and activities, as necessary, which are designed to manage and mitigate such risks. We present reports on this risk identification, management and mitigation
process along with regular updates on compliance issues generally to the Audit and Compliance Committee, who provides guidance and feedback to senior management. The Audit and Compliance Committee
apprises the Board of any developments under this </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>16</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=19,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=473203,FOLIO='16',FILE='DISK125:[17ZAD1.17ZAD74201]DE74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_de74201_1_17"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>plan
throughout the year. The Chief Compliance Officer has a dotted line reporting to the Audit and Compliance Committee and provides quarterly updates on the development of the Compliance Program and
any reports of violations of the Code of Conduct or other policies. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policies Governing Director Nominations  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Director Qualifications.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Nominating and Corporate Governance Committee is responsible for reviewing with the directors from time to
time the
appropriate qualities, skills and characteristics desired of members of the Board in the context of the needs of the business and the composition of the Board. This assessment includes consideration
of the following minimum qualifications that the Nominating and Corporate Governance Committee believes must be met by all directors:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> a reputation for integrity, honesty and adherence to high ethical standards; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the ability to exercise sound business judgment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> substantial business or professional experience and the ability to offer meaningful advice and guidance to the Company's management based on
that experience; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> the ability to devote the time and effort necessary to fulfill their responsibilities to the Company. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Nominating and Corporate Governance Committee also considers numerous other qualities, skills and characteristics when evaluating director nominees, including whether the nominee has
specific strengths that would augment existing skills and experience of the Board, such as an understanding of and experience in technology, drug development, accounting, governance, finance or
commercialization and whether the nominee has leadership experience with public companies or other sophisticated and complex organizations. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Process for Identifying and Evaluating Director Nominees.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Our Nominating and Corporate Governance Committee has established a process
for identifying
and evaluating nominees for director. Although the Nominating and Corporate Governance Committee will consider nominees recommended by stockholders, it believes that the process it uses to identify
and evaluate nominees for director is designed to produce nominees that possess the educational, professional, business and personal attributes that are best suited to further the Company's mission.
Our Nominating and Governance Committee may identify nominees through the use of professional search firms that may utilize proprietary screening techniques to match candidates to the Nominating and
Governance Committee's specified qualifications. The Nominating and Governance Committee may also receive recommendations from existing directors, executive officers, key business partners, and trade
or industry affiliations. Our Nominating and Corporate Governance Committee will evaluate nominations at regular or special meetings, and in evaluating nominations, will seek to achieve a balance of
knowledge, experience and capability on the Board and to address the membership criteria set forth above under
"Director Qualifications." The Board itself is ultimately responsible for recommending candidates for election to the stockholders or for appointing individuals to fulfill a vacancy. Although the
Board does not have a policy with regard to the consideration of diversity in identifying director nominees, among the various factors the Nominating and Corporate Governance Committee considers in
selecting candidates for nomination to the Board are the benefits to the Company of national origin, gender, race, scientific and pharmaceutical experience and cultural diversity in board composition. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Procedures for Recommendation of Director Nominees by Stockholders.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;The Nominating and Corporate Governance Committee will consider
director
candidates recommended by our stockholders. In evaluating candidates recommended by our stockholders, the Nominating and Corporate Governance Committee applies the same criteria set forth above under
"Director Qualifications." Any stockholder recommendations of director nominees proposed for consideration by the Nominating and Corporate Governance Committee should include the nominee's name and
qualifications for Board membership and should be addressed in writing to the Nominating and Corporate Governance Committee, care of: Amicus </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>17</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=20,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=663617,FOLIO='17',FILE='DISK125:[17ZAD1.17ZAD74201]DE74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_de74201_1_18"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Therapeutics&nbsp;Inc.,
1 Cedar Brook Drive, Cranbury, New Jersey 08512, Attention: Secretary. In addition, our Restated By-laws permit stockholders to nominate directors for consideration at an
annual stockholder meeting in accordance with certain procedures described in this Proxy Statement under the heading "Stockholder Proposals and Nominations for Director." </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Meeting Attendance.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;During the year ended December&nbsp;31, 2016, there were nine meetings of our Board, and the various committees of
the Board
met a total of twelve times. No director attended fewer than 79% of the total number of meetings of the Board and of Committees of the Board on which he or she served during 2016. The Board has
adopted a policy under which each member of the Board is strongly encouraged to attend each Annual Meeting of our Stockholders. All of the directors attended our 2016 Annual Meeting of Stockholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Compensation Committee Interlocks and Insider Participation.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;None of our executive officers serves as a member of the Board of
Directors or
Compensation Committee, or other committee serving an equivalent function, of any entity that has one or more of its executive officers serving as a member of our Board or our Compensation Committee.
None of the members of our Compensation Committee has ever been an officer or employee of the Company. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stockholder Communications to the Board  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board provides a process for stockholders to send communications to the Board. Any stockholders who wish to address questions regarding our
business directly with our Board, or any individual director, should direct his or her questions in writing to the Chairman of the Board or the Secretary of the Board, c/o Amicus
Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512. Communications will be distributed to the Board, or to any individual director or directors as appropriate, depending on the
facts and circumstances outlined in the communications. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Officers  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a brief summary of the background of each of our executive officers: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>John F. Crowley, 50,</I></FONT><FONT SIZE=2> has served as Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January
2005, except for the period during April 2011 through August 2011 during which time he served as Executive Chairman, Mr.&nbsp;Crowley has also served as a director of Amicus since August 2004,with
the exception of the period from September 2006 to March 2007 when he was not an officer or director of Amicus while he was in active duty service in the United States Navy (Reserve).
Mr.&nbsp;Crowley was President and Chief Executive Officer of Orexigen Therapeutics,&nbsp;Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme
Pharmaceuticals,&nbsp;Inc., from March 2000 until that company was acquired by Genzyme Corporation in September 2001; thereafter he served as Senior Vice President of Genzyme Therapeutics until
December 2002. Mr.&nbsp;Crowley received a B.S. degree in Foreign Service from Georgetown University's School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A.
from Harvard Business School. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Bradley L. Campbell, 41,</I></FONT><FONT SIZE=2> has served as President and Chief Operating Officer since January 2015. Mr.&nbsp;Campbell served as Chief
Operating Officer since December 2013 and, prior thereto, as Chief Business Officer since February 2012. From January 2010 to February 2012, Mr.&nbsp;Campbell served as Senior Vice President,
Business Operations; from May 2007 to January 2010, as Vice President, Business Planning and from April 2006 until May 2007, as Senior Director, Business Development. Mr.&nbsp;Campbell served as
Senior Product Manager of Myozyme&copy; for Pompe Disease and later as Business Director of CV Gene Therapy at Genzyme Corporation from 2002 to 2006. Mr.&nbsp;Campbell has also worked in
sales&nbsp;&amp; marketing for Bristol-Myers Squibb and as a business strategy consultant for Marakon Associates. Mr.&nbsp;Campbell is also a director for Progenics (NASDAQ:&nbsp;PGNX)
and a board member of BioNJ. Mr.&nbsp;Campbell received his B.A. from Duke University and his M.B.A. from Harvard Business School. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>18</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=21,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=708562,FOLIO='18',FILE='DISK125:[17ZAD1.17ZAD74201]DE74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_de74201_1_19"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>William D. "Chip" Baird III, 45,</I></FONT><FONT SIZE=2> has served as Chief Financial Officer since April 2012. Prior to joining Amicus, Mr.&nbsp;Baird served
as Chief Financial Officer of PTC Therapeutics,&nbsp;Inc. ("PTC") from April 2005 until April 2012. Before that, Mr.&nbsp;Baird held various positions of increasing responsibility with PTC from
2002 to 2005. Mr.&nbsp;Baird previously worked at L.E.K. Consulting, a strategy consulting firm, from 1999 to 2002 and at First Union National Bank as a corporate underwriter from 1994 to 1997.
Mr.&nbsp;Baird received a B.S. from Georgetown University's Edmund A. Walsh School of Foreign Service and an M.B.A. from The Wharton School of the University of Pennsylvania. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Jay Barth, M.D., 53,</I></FONT><FONT SIZE=2> has served as Chief Medical Officer since March 2014. Prior to joining Amicus, Dr.&nbsp;Barth held roles of
increasing responsibility at PTC from 2009 to 2014. He most recently served as PTC's Senior Vice President, Clinical Development. Previously Dr.&nbsp;Barth served as Executive Director of Clinical
Research at Merck; as Vice President, Clinical Research and Medical Affairs at Altana Pharma US,&nbsp;Inc.; and as Senior Director, Global Head of Gastroenterology Clinical Research at Eisai Medical
Research&nbsp;Inc. Dr.&nbsp;Barth received a B.A. from Columbia University and an M.D. from the University of Pennsylvania School Of Medicine. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Hung Do, Ph.D., 49</I></FONT><FONT SIZE=2>, has served as Chief Science Officer since July 2015. Previously, he served as Senior Vice President, Discovery Biology
since December 2013. Prior to joining Amicus, Dr.&nbsp;Do was a co-founder and Chief Scientific Officer of Callidus Biopharma,&nbsp;Inc. ("Callidus") a privately held biologics company that was
acquired by Amicus. Prior to founding Callidus, he headed early discovery research to decipher the mechanism of action for small molecule pharmacological chaperones at Amicus. He previously helped to
demonstrate proof of concept for ERTs, and served as the project leader for a second generation Pompe ERT at Genzyme. Dr.&nbsp;Do also led molecular biology, cell culture and purification work and
helped develop an in vitro protein modification process for improving drug targeting for protein therapeutics at Novazyme Pharmaceuticals,&nbsp;Inc., which was acquired by Genzyme. Dr.&nbsp;Do
holds a Ph.D. in medical biochemistry and genetics from Texas A&amp;M University and was a post-doctoral fellow in Hematology/Oncology at Emory University. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Ellen S. Rosenberg, 54</I></FONT><FONT SIZE=2>, has served as our General Counsel and Corporate Secretary since February 2016. Prior to joining Amicus, she served
as Senior Vice President, Associate General Counsel of Shire Pharmaceuticals. Prior to Shire, Ms.&nbsp;Rosenberg was Associate General Counsel for the Metabolic Endocrinology division at EMD
Serono&nbsp;Inc., the U.S. affiliate of Merck KGaA. Ms.&nbsp;Rosenberg brings extensive and broad ranging legal experience in the biopharmaceutical and medical device industry including mergers
and acquisitions, licensing, product launches, risk management, and compliance matters. Ms.&nbsp;Rosenbereg also has significant experience building and developing legal teams and the
in-house legal function. Ms.&nbsp;Rosenberg received a B.A. from the University of Connecticut and a J.D. from the University of Pennsylvania Law School. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Daphne Quimi, 51</I></FONT><FONT SIZE=2>, currently serves as our Senior Vice President, Finance and Controller and has been employed with Amicus since September
2007. Prior to Amicus, Ms.&nbsp;Quimi served as Director of Consolidations and External Reporting at Bristol-Myers Squibb. She also held roles of increasing responsibility in the finance department
at Johnson&nbsp;&amp; Johnson. Ms.&nbsp;Quimi brings extensive experience in public accounting and financial reporting. Ms.&nbsp;Quimi received a B.S. in Accountancy from Monmouth University and an
M.B.A. from the Stern School of Business of New York University. She is a certified public accountant in New Jersey and a member of the American Institute of Certified Public Accountants and the
Institute of Management Accountants. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Kurt J.W. Andrews, 48,</I></FONT><FONT SIZE=2> has served as our Senior Vice President, Human Resources since February 2016. Prior to joining Amicus,
Mr.&nbsp;Andrews served as Vice President, Human Resources at Valeritas,&nbsp;Inc. Previously Mr.&nbsp;Andrews was Vice President, Human Resources and Administration at PTC
Therapeutics,&nbsp;Inc. Mr.&nbsp;Andrews brings experience working in leadership roles at biotechnology and technology companies including business and commercial strategy, implementation of
organization-wide goals and strategies, performance management, and compensation planning. Mr.&nbsp;Andrews earned a B.A. and M.A. from The University of Illinois at Urbana-Champaign. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>19</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=22,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1023257,FOLIO='19',FILE='DISK125:[17ZAD1.17ZAD74201]DE74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<A NAME="page_de74201_1_20"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="de74201_compensation_discussion_and_analysis_#151;2016"> </A>
<A NAME="toc_de74201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION DISCUSSION AND ANALYSIS&#151;2016    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Summary  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee, in consultation with the Board, is responsible for establishing, implementing and overseeing our overall
compensation strategy and policies, including our executive compensation program, in a manner that supports our business objectives. Based on the events described below, our Compensation Committee
determined that in&nbsp;2016, the Company made significant progress towards the goal of becoming a leading orphan and rare disease company with
global commercial operations and a diversified product pipeline. Specific milestones achieved in 2016 in support of the Company's business strategy include the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> In April 2016, we received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) for approval of Galafold
(migalastat) for the treatment of Fabry patients with amenable mutations. The positive opinion included a broad label covering 269 disease-causing mutations. The CHMP opinion supported commercial
launch in Germany in May of 2016 and in select other European countries during the balance of 2016. By the end of 2016, 61 Fabry patients were receiving reimbursed Galafold and we recorded
$5.0&nbsp;million in product revenue for the year. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> In July 2016, we completed the asset purchase of a preclinical program to treat CDKL5. The early-stage program would be a potential
first-in-class protein replacement therapy for CDKL5 deficiency, a devastating rare genetic neurological disorder with no approved treatments. We believe that this acquisition significantly
strengthens our early-stage pipeline and fits with our overall corporate strategy of developing innovative therapies for rare and orphan diseases. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> In November 2016, we announced that based on feedback from the FDA, we would be need to collect additional gastrointestinal symptoms data in a
new clinical study to support a New Drug Application (NDA) for regulatory approval of migalastat in the U.S. In 2017, we plan to continue to refine and finalize the most expeditious path to approval
for migalastat in the U.S. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> We made substantial progress on enrollment of the Phase&nbsp;3 SD&nbsp;101 trial for the treatment of Epidermolysis Bullosa. However,
despite significant investment in the opening of additional clinical trial sites to offset lower than targeted enrollment, the clinical trial was not completed in&nbsp;2016. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> In December 2016, we announced positive preliminary data from our Phase 1/2 studies of ATB200 in patients with Pompe disease. Safety data from
the study showed no infusion associated reactions following more than 100 infusions and the pharmacokinetic profile was as predicted based on preclinical models. Biomarkers of muscle damage were
trending toward improvement or were stable through the first 14&nbsp;weeks of treatment. This early data exceeded expectations but was tempered by enrollment that was slower than the internal
target.</FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> We substantially strengthened our financial position in 2016. In July 2016, we completed a $100.0&nbsp;million At the Market "ATM" public
stock offering, and in December 2016, we completed a $250.0&nbsp;million convertible debt offering. Through careful expense management, our net cash spend for 2016 was $154.2&nbsp;million, which
was within the full-year guidance range of $135&nbsp;million to $155&nbsp;million. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Compensation Committee adheres to a long-standing pay-for-performance philosophy. The Compensation Committee continually evaluates our compensation program, taking into consideration
best practices and emerging trends, stockholder input as well as data and feedback provided by our independent executive compensation consultant, Pay Governance. In the past year, we have continued to
take measures to align our compensation program with best practices and stockholder interests including the following actions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Base salaries comprise less than 25% of our named executive officers' total compensation, with Mr.&nbsp;Crowley's 2016 salary representing
approximately 15% of his total compensation and, for our other named executive officers, representing between 24% and 30% of their total compensation. Approximately 19% of Mr.&nbsp;Crowley's total
compensation in 2016 was represented by payments we make to him for medical expenses and associated tax liabilities incurred for the treatment of a rare medical condition afflicting two members of
Mr.&nbsp;Crowley's immediate family. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>20</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=23,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=857578,FOLIO='20',FILE='DISK125:[17ZAD1.17ZAD74201]DE74201A.;11',USER='PJAMES',CD='24-APR-2017;19:54' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dg74201_1_21"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> A large portion of our named executive officers compensation was represented by long-term incentives, including the grant date fair value of
equity awards, which are inherently performance based. 58% of Mr.&nbsp;Crowley's total compensation was in the form of long-term incentives. For our named executive officers other than
Mr.&nbsp;Crowley, 60% to 63% of their total compensation for 2016 was represented by long-term incentives. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> For our named executive officers including Mr.&nbsp;Crowley, Amicus Compensation Committee approved utilizing Performance Restricted Stock
Units (PRSU) starting in 2017. Adding PRSUs aligns the management team with shareholders and strengths our pay-for-performance philosophy because these awards only deliver value to our named executive
officers, if the Company achieves certain performance goals selected. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2016, the Compensation Committee determined that Mr.&nbsp;Crowley would receive an increase in his base salary of 3.2%. In addition, similar to the prior year, the Compensation
Committee determined that Mr.&nbsp;Crowley's January 2016 option grant would be granted with a strike price that was 130% of the
closing price on the date of grant. In July of 2016, the Compensation Committee determined that one-third of Mr.&nbsp;Crowley's grant would be granted with a strike price that was 130% of the
closing price on the date of grant, one-third in fair market value options, and one third in restricted stock units. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2017, the Compensation Committee determined that Mr.&nbsp;Crowley, along with the Senior Leadership team, including all of our named executive officers, would receive one-third of
the value of their equity grant in Performance Restricted Stock Units, which historically were premium priced options. This was part of an overall strategic shift which encompassed using 1/3 the value
of annual grants in Stock Options, 1/3 of the value in Restricted Stock Units and 1/3 in Performance Restricted Stock Units. The Performance Restricted Stock Units utilized performance measures of
relative total shareholder return and strategic pipeline metrics. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent
with our pay-for-performance philosophy and in recognition of our good performance against stated corporate objectives, with most corporate objectives fully accomplished, the
Compensation Committee determined that the corporate multiplier used in determining cash bonuses for our named executive officers for 2016 should be set at 83%, resulting in bonuses for such officers
below their target levels. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results of our compensation program in 2016 show a clear heavy weighting on Performance Based Compensation for not only the CEO, but all named executive officers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g512034.jpg" ALT="GRAPHIC" WIDTH="523" HEIGHT="285">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>21</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=24,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=91663,FOLIO='21',FILE='DISK125:[17ZAD1.17ZAD74201]DG74201A.;13',USER='DSLOAN',CD='25-APR-2017;11:18' -->
<A NAME="page_dg74201_1_22"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g987977.jpg" ALT="GRAPHIC" WIDTH="523" HEIGHT="285">
  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
describe our executive compensation program below and provide an analysis of the compensation paid and earned in 2016 by our "named executive officers"&#151;our chief executive
officer, chief financial officer, and three other most highly compensated executive officers. In 2016, our named executive officers were:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Chairman and Chief Executive Officer, John F. Crowley; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Chief Financial Officer, William D. Baird, III; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> President and Chief Operating Officer, Bradley L. Campbell; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Chief Medical Officer, Jay Barth, M.D.; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Chief Science Officer, Hung Do, Ph.D. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Compensation Good Governance Practices  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Below we summarize certain executive compensation-related good governance practices that we follow and that we believe serve our stockholders'
long-term interests. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What
We Do:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Maintain an Executive Compensation Program Designed to Align Pay with Performance </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Conduct an Annual Say-on-Pay Vote </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Seek Input from, Listen to and Respond to Stockholders </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Have Double-Trigger on Executive Severance Arrangements and Executive Stock Option Grants </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Prohibit Hedging and Pledging of Company Stock </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Retain an Independent Compensation Consultant </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;What
We Do Not Do:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provide Executives with Tax Gross-ups other than for Company required relocations </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provide Guaranteed Bonuses </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>22</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=25,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=108487,FOLIO='22',FILE='DISK125:[17ZAD1.17ZAD74201]DG74201A.;13',USER='DSLOAN',CD='25-APR-2017;11:18' -->
<A NAME="page_dg74201_1_23"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


"Say-on-Pay" Consideration</I></FONT><FONT SIZE=2>. </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
our 2016 annual meeting of stockholders, approximately 99% of the shares voted at the meeting approved, on an advisory basis, the compensation of the named executive
officers. In addition to the voting at the annual meeting, we proactively engaged with major stockholders representing approximately 80% of shares outstanding on the Company's pay practices. The great
majority of the shares voted approved the 'say-on-pay' advisory proposal and the Compensation Committee continues to focus on pay practices that align compensation with performance. The Compensation
Committee placed a continued emphasis on performance-based pay, in making premium-priced option grants to Mr.&nbsp;Crowley in 2015 and 2016. The Compensation Committee monitors the results of the
annual advisory 'say-on-pay' proposal and feedback received from stockholders and refers to such results and feedback as important factors considered, along with peer group benchmarking, in connection
with the discharge of its responsibilities, although the Compensation Committee does not assign a quantitative weighting to any such factors. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Objectives and Philosophy of Executive Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a global, commercial stage, patient-focused biotechnology company engaged in the discovery and development of a diverse set of novel
treatments for patients living with devastating rare and orphan diseases. We operate in an extremely competitive, rapidly changing and heavily regulated industry, and the long-term success of our
business requires a high degree of innovation and adaptability. We believe that the skill, talent and dedication of our executive officers are critical factors affecting our long-term success,
especially at this critical time in our history as we execute our business strategy. Therefore, our compensation program for our executive officers, including our named executive officers, is designed
to attract, retain and motivate the best possible executive talent. Utilizing a pay-for-performance compensation philosophy, we have designed a program that provides the ability to differentiate the
total compensation mix of our named executive officers based on their demonstrated performance and their potential to contribute to our long-term success. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
compensation philosophy is to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> provide our executives a competitive total compensation opportunity relative to the organizations with which we compete for executive talent; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> attract and retain individuals of superior ability and managerial talent who can successfully perform and succeed in our environment; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> increase the incentive to achieve key strategic and financial performance measures by linking compensation opportunities and actual
compensation earned through our pay for performance compensation program to the achievement of corporate goals; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> deliver pay in a cost efficient manner that aligns employees' compensation with stockholders' long-term interests. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
compensation program is designed to reward the accomplishment of our corporate goals in a manner consistent with the Company's values, which stresses not only results but also how
those results are attained. In order to meet the objectives of our compensation philosophy, we maintain a robust goal setting and performance management program. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
chief executive officer established general individual goals for the named executive officers other than himself at the beginning of 2016 that were specific to such executive
officer's area of expertise and supported our corporate goals for the year. For 2016, annual cash incentive bonuses for our named executive officers other than Mr.&nbsp;Crowley were determined by
the combination of both the corporate and an individual multiplier. For Messrs.&nbsp;Baird and Campbell, and Drs. Do and Barth, the attainment of individual goals was assessed with a 0-150%
multiplier for each individual; this multiplier was applied to the final corporate multiplier to determine final annual incentive bonus payouts. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>23</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=26,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=111453,FOLIO='23',FILE='DISK125:[17ZAD1.17ZAD74201]DG74201A.;13',USER='DSLOAN',CD='25-APR-2017;11:18' -->
<A NAME="page_dg74201_1_24"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee believes that the corporate multiplier should continue to be the dominant factor in determining bonus payouts because it closely aligns our named executive
officers' compensation with the interests of our stockholders, and that some portion of an executive's compensation should be linked to individual performance, which we believe is consistent with our
peers. The Compensation Committee believes that including the individual multiplier as a component of named executive officers' bonus payouts is important to incentivize our officers during this
crucial time in Amicus' history as we continue our transformation into a global commercial biotechnology company. However, because of Mr.&nbsp;Crowley's influence on the overall performance of
Amicus, the Compensation Committee believes it is appropriate and in the best interests of our stockholders to continue to base Mr.&nbsp;Crowley's cash bonus solely on the Compensation Committee's
determination regarding the achievement of corporate objectives. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risk Analysis of Compensation Policies and Practices  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee is aware that compensation arrangements, if not properly designed, could encourage inappropriate or excessive risk
taking. We believe that our overall compensation program encourages our named executive officers and other employees to focus on both short-term and long-term objectives and does not encourage
excessive risk taking. While the value of stock options is inherently tied to the performance of the Company and an important part of our current and future performance based compensation, our stock
options vest over multiple years and the value is not directly linked to the achievement of short term defined metrics. To enhance this posture, the Committee made the decision in 2017 to award
performance-based restricted stock grants in addition to market priced options and restricted stock units. In addition, cash incentive bonuses tied to the achievement of Company and individual goals
have historically made up a small percentage of our employees' total compensation package. For example, in 2016, payouts under our cash incentive bonus plan represented approximately 10% of the total
compensation awarded to our named executive officers. Further, we operate as a single business unit and therefore are not exposed to the risks that may be associated with operating through several
segments, such as one business unit being significantly more profitable than another or having a compensation structure that is significantly different than that of other units. The Compensation
Committee will continue to review risk as one of the elements it considers in the planning process for executive compensation in the future. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Compensation Program Elements and Pay Level Determination  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each year, the Compensation Committee reviews and determines base salaries, annual cash incentive and long-term incentive awards for all
executive officers. In setting our executive compensation programs, the Compensation Committee reviews market data at the 25<SUP>th</SUP>, 50<SUP>th</SUP>, and
75<SUP>th</SUP>&nbsp;percentile and generally targets aggregate total direct compensation for the named executive officers as a group to approximately the 50<SUP>th</SUP>&nbsp;percentile of
our peer group (as discussed below). Actual compensation levels for each named executive officer depend on factors such as individual performance, Company performance, skills/capabilities, overall
impact/contribution, experience in position, criticality of position and internal equity. For 2016, the base salaries, annual cash incentives and long-term incentive awards determination for all named
executive officers, including our chief executive officer, were approved by our Compensation Committee, which is comprised solely of independent directors. The Compensation Committee considered all
the information presented (including external competitiveness, the individual's performance, Company performance and internal equity) and applied its collective knowledge and discretion to determine
the compensation for each named executive officer. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of the compensation evaluation process, the chief executive officer presents to the Compensation Committee an individual assessment of each named executive officer's performance,
excluding the chief executive officer's performance, over the prior year, as well as the recommended compensation action for each such named executive officer. Based on corporate and individual </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>24</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=27,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=637135,FOLIO='24',FILE='DISK125:[17ZAD1.17ZAD74201]DG74201A.;13',USER='DSLOAN',CD='25-APR-2017;11:18' -->
<A NAME="page_dg74201_1_25"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>performance,
the chief executive officer makes a compensation recommendation for each such named executive officer which includes actions on base salary, bonus and long-term incentive grant target
value. Individual goals and objectives are established at the beginning of each year and are designed to support the achievement of the corporate goals. All employees, including the named executive
officers, participate in annual individual goal setting as well as mid-year and annual performance reviews. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
results of the named executive officer's performance (other than the performance of the chief executive officer) are a determination by his supervisor, the chief executive officer,
with input from other peers, and direct reports, as appropriate, but the final determination is made by the Compensation Committee. The chief executive officer's performance is assessed by all
independent directors under the leadership of our Lead Independent Director while the chief executive officer compensation recommendation to the Board is made by the Compensation Committee based upon
this assessment. Long-term incentive grants are based on an executive's level within the organization, and in the case of our named executive officers, several other factors which are more fully
described below under "Long-Term Incentive Programs". Long-term incentive grants are designed to motivate the
executive team to best achieve the Company's goals and implement our business strategy, thereby increasing stockholder value. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Developments in Company Leadership in 2016  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2016, we made several changes to our leadership structure. In February 2016, Ellen Rosenberg joined the Company as General Counsel and
Corporate Secretary and Kurt Andrews joined as Senior Vice President, Human Resources. In August 2016, Bradley Campbell, President and COO, began a one year assignment working from the Company's
United Kingdom office to oversee and ensure the successful commercialization of Galafold. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Role of Independent Compensation Consultant  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee has engaged Pay Governance to assist the Compensation Committee by providing ongoing executive compensation
consulting. The Compensation Committee has concluded that Pay Governance's work does not raise any conflict of interest. The Compensation Committee has also considered the independence of Pay
Governance. Because of policies and procedures that Pay Governance and the Compensation Committee have in place, the Compensation Committee is confident that the advice it receives from executive
compensation consultants at Pay Governance is objective and not influenced by Pay Governance's or its affiliates' relationships with the Company or its officers. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Peer Group  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee, with the help of its independent executive compensation consultant, Pay Governance, established the peer group set
forth below as a reference point for assessing named executive officer target compensation against market competitive data. The Compensation Committee, upon advice of Pay Governance, selected the
companies that comprise our peer group through a robust screening process that considered publicly traded U.S. biopharmaceutical companies that were similar to Amicus in size, market capitalization
and business operating model and operate in geographic locations that generally have similar pay levels. Two companies (Aegerion Pharmaceuticals and Synageva BioPharma) were removed from the peer
group established last year due primarily to acquisition or changes in structure or size, including market capitalization. The
Compensation Committee replaced these entities with three companies (Acceleron Pharmaceuticals, Bluebird Bio and Sage Therapeutics) upon the recommendation of Pay Governance. The Compensation
Committee intends to continue reviewing and </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>25</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=28,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=839524,FOLIO='25',FILE='DISK125:[17ZAD1.17ZAD74201]DG74201A.;13',USER='DSLOAN',CD='25-APR-2017;11:18' -->
<A NAME="page_dg74201_1_26"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>revising
the peer group periodically to ensure that it continues to reflect publicly traded companies of similar size and business model. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="31%" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>ACADIA Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Insmed</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sarepta Therapeutics</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Acceleron Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>PTC Therapeutics</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ultragenyx Pharmaceutical</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Agios Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Raptor Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Ziopharm Oncology</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Bluebird Bio</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Rigel Pharmaceuticals</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>CellDex Therapeutics</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sage Therapeutics</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><FONT SIZE=2>Cytokinetics</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>Sangamo Biosciences</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Elements of Compensation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive compensation consists of base salary, annual cash incentive plan, and long-term incentive program, each of which plays an
important role in our pay-for-performance philosophy and in achieving our compensation program objectives. For each element of compensation, we target an overall executive compensation program that is
competitive with market data. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Base Salaries  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Base salaries are paid to our named executive officers to provide a level of compensation that is both competitive with the external market and
is commensurate with each executive officer's scope of responsibilities, past performance, experience and skills. The base salary for each of our named executive officers was as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Base salary at<BR>
December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>582,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>601,037</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
385,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
396,550</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
415,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
427,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
415,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
431,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Hung Do, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
360,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
370,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Science Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2016, Messrs.&nbsp;Baird and Campbell and Dr.&nbsp;Do each received a base salary market increase of 3% while Dr.&nbsp;Barth received an increase in base salary of 4% in
recognition of his leadership in the approval process of Galafold. Mr.&nbsp;Crowley received a base salary increase of 3.2% reflecting his strong overall leadership of the company. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Annual Cash Incentive Plan  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We maintain an annual cash incentive program to motivate and reward the attainment of annual strategic, operational, financial and individual
goals. For all program participants, annual target cash incentive opportunities are expressed as a percentage of base salary, which we believe is consistent with market practice. The target bonus
percentages of base salary were generally determined by level in the organization in accordance with market based considerations and contractual entitlements. However, the target bonus percentages
were reevaluated for 2016 and a new level was added for our President, Bradley </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>26</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=29,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=665292,FOLIO='26',FILE='DISK125:[17ZAD1.17ZAD74201]DG74201A.;13',USER='DSLOAN',CD='25-APR-2017;11:18' -->
<A NAME="page_dg74201_1_27"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Campbell
and his target bonus percentage increased from 40% of base salary to 50% of base salary. The target bonus percentage for all other executive officers remained the same. The target bonus
percentages for 2016 are as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 Target<BR>
Bonus % of<BR>
Base Salary </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief executive officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>President</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Other chief officers</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Senior vice presidents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>35</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Vice presidents</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2016, bonuses awarded under the plan to our named executive officers, other than Mr.&nbsp;Crowley, were determined based on both the corporate multiplier and an individual
multiplier. The corporate multiplier may range from 50% to 150%, with the Compensation Committee having final discretion to adjust the range lower or higher as appropriate. For bonuses related to 2016
performance, the corporate multiplier was determined to be 83% based on the Company's performance for the reasons discussed below. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
order to determine bonus calculations under the plan, the target bonus for each eligible named executive officer, other than Mr.&nbsp;Crowley, was determined by first multiplying
the officer's target bonus by the 83% corporate multiplier and then applying his or her individual multiplier. Mr.&nbsp;Crowley's bonus was determined by multiplying the 83% corporate multiplier by
his target bonus percentage of 60% of base salary, which results in a 2016 bonus of approximately 50% of Mr.&nbsp;Crowley's base salary. The table below titled "Calculation of Annual Cash Incentive
Bonuses" illustrates further how 2016 awards under the plan were calculated for our named executive officers. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


 </I></FONT><FONT SIZE=2><U>The Corporate Multiplier</U> </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
an annual basis, the Board works with management to set Company goals and objectives that are challenging and reflect an ambitious timetable for the execution of the
Company's strategies commensurate with our short and long-term business plan. The Company's internal goals and objectives reflect complex assumptions based on internal analyses and projections, and
are intended to encourage the Company to pursue its business plan in an expedited, aggressive manner. Once the Company's goals and objectives have been developed, they are reviewed by the Compensation
Committee and finally approved by the full Board. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At
the time the goals and objectives are set, the Compensation Committee believes that their full attainment will be appropriately challenging and may not be reached, despite great
effort, due in part to internal and external factors, many of which may be out of the Company's control. The objectives are set with the understanding that some objectives, especially those tied to
timing of events, may need to be altered as events throughout the course of the year shape the best path for the development of the Company's product candidates. However, while total achievement of
all goals and objectives set at the beginning of the year may not be expected, the Compensation Committee considers the achievement of the corporate objectives in its sole discretion in setting the
corporate multiplier and holds management accountable to significantly advance the Company's business objectives throughout the year in order to achieve a 100% corporate multiplier. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
2016, our corporate objectives were as follows: </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Launch
Galafold in select International geographies, submit NDA filing, and pursue approvals in other geographies
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Complete
successful Phase&nbsp;3 study of our development candidate SD-101 </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>27</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=30,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=288901,FOLIO='27',FILE='DISK125:[17ZAD1.17ZAD74201]DG74201A.;13',USER='DSLOAN',CD='25-APR-2017;11:18' -->
<A NAME="page_dg74201_1_28"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Generate
proof-of-concept data from Phase 1/2 study and define clinical development strategy for ATB200 for the treatment of Pompe
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Evaluate
research opportunities to develop clinical candidates for 2018-2020
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>5.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Build
and sustain an organization to support our long-term strategies
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>6.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Finish
2016 with 18&nbsp;months of cash necessary to operate our business </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee then reviews corporate performance against each of the pre-established targets and weighting to determine the extent to which such goals were attained. The
Compensation Committee's rationale behind its determination of both the attainment of corporate goals and the percentage completed for each such goal is described below. In reaching its determination
on the corporate multiplier for 2016, the Compensation Committee applied the percentage that the Compensation Committee determined was completed against the pre-established weighting of the corporate
objectives as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="47pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="28pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Objective

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Weighting </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Percentage<BR>
Completed </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Score </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Launch Galafold in select International geographies, submit NDA filing, and pursue approvals in other geographies</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>90</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Complete successful Phase&nbsp;3 study of our development candidate SD-101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Generate proof-of-concept data from Phase 1/2 study and define clinical development strategy for ATB200 for the treatment of Pompe</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>25</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>90</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>22.5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Evaluate research opportunities to develop clinical candidates for 2018-2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Build and sustain an organization to support our long-term strategies</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>5.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Finish 2016 with a minimum of 18&nbsp;months of cash</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>15</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>87</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>13.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>TOTAL SCORE</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>100</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>83.0</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>%</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


</I></FONT><FONT SIZE=2><U>2016 Corporate Objectives Measurement</U> </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
establishing the 2016 corporate objectives at the end of 2015, the Company and the Compensation Committee believed that the three most important goals for Amicus in
2016 were related to the three most advanced programs: Galafold (migalastat), SD-101, and ATB200, and weighted success on these program objectives equally, at 25% for each program. The objective for
Galafold (migalastat) was global in scope and included the successful international launch of Galafold, the submission of an NDA for U.S. regulatory approval, and the pursuit of regulatory approvals
in other geographies. Based on the regulatory approval of Galafold by European regulatory authorities in the second quarter and the subsequent success of the launch in early markets like Germany as
well as the progress in obtaining regulatory approvals in countries outside the U.S., the Compensation Committee felt that the Company outperformed on the Galafold objective in regions outside the
U.S. That outperformance was offset by a setback with the U.S. Food and Drug Administration (FDA), which prevented the Company from submitting an application for marketing approval in the U.S. in
2016. Taking all of these factors into consideration, the Compensation Committee determined that this objective was 90% completed and determined a score of 22.5% by multiplying the 25% weighting of
this goal by the 90% achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
September 2015, Amicus completed the acquisition of Scioderm and the Phase&nbsp;3 SD-101 program in the treatment of Epidermolysis Bullosa. The Company and the Compensation
Committee established the goal for 2016 to complete the Phase&nbsp;3 trial for SD-101. Despite significant investment in the opening of additional clinical trial sites to offset lower than targeted
enrollment, the clinical trial was not completed in 2016. The Company projects the completion of the trial by the middle of 2017. Therefore, the Compensation Committee determined a score of 15% by
multiplying the 25% weighting by a 60% achievement percentage. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>28</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=31,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=26860,FOLIO='28',FILE='DISK125:[17ZAD1.17ZAD74201]DG74201A.;13',USER='DSLOAN',CD='25-APR-2017;11:18' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_di74201_1_29"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given
the significant level of unmet need in Pompe disease and our belief that we have a differentiated product candidate (ATB200 plus chaperone) that could offer meaningful improvements
over the current standard of care, we have identified Pompe disease as an area of long-term strategic importance to the Company. The Pompe goal for 2016 was to generate proof-of-concept data from
Phase&nbsp;1/2 study and define the clinical development strategy for ATB200 for the treatment of Pompe. In 2016, we successfully initiated a Phase 1/2 study in patients with Pompe disease and
generated safety and early proof-of-concept data in the initial patients enrolled. The early data exceeded expectations but was tempered by enrollment that was slower than the internal target. The
Compensation Committee weighed these factors and determined that this objective was 90% completed and determined a score of 22.5% by multiplying the 25% weighting by a 90% achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Given
the Company's stated objective of being at the forefront of rare and orphan disease, we believe that development of the earlier-stage pipeline is an important objective. In setting
pipeline development goals for 2016, the Compensation Committee felt the goal of evaluating research opportunities to develop clinical candidates for 2018-2020 balanced the Company's strategic needs
with its financial resources. Based upon the asset purchase of our CDKL5 program in July 2016, a promising early-stage program for a devastating and rare neurological disorder, the Compensation
Committee subjectively determined that 100% of the goal was complete and determined a score of 5% by multiplying the 5% weighting by a 100% achievement percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
discussed above, we believe that our employees are central to executing on our corporate strategy. During 2016, we made significant progress in hiring the required commercial,
administrative, and medical personnel for the International commercial organization to aggressively launch Galafold, while at the same time strengthening the U.S.-based leadership and maintaining a
low level of turnover. As a result, the Compensation Committee determined a score of 5% by multiplying the 5% weighting by a 100% subjectively determined completion percentage. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
cash position directly affects our ability to establish commercial infrastructure, conduct our clinical and preclinical activities, hire and retain qualified and talented employees
and pursue business development opportunities. Even though we have commercial sales, careful management of our cash is critical to our operations. Due to our careful expense management, a successful
$250&nbsp;million convertible debt financing in December 2016, and a successful $100&nbsp;million At the Market (ATM) equity financing completed in the second and third quarters of 2016, we
achieved our goal of ending the year with enough cash to fund our operations for a period of 18&nbsp;months. Although the cash goal was met, due to the nature and timing of the convertible debt
financing, the Compensation Committee determined a score of 13% by multiplying the 15% weighting by an 87% subjectively determined completion percentage. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


 </I></FONT><FONT SIZE=2><U>The Individual Multiplier</U> </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Design  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While we believe that the corporate multiplier should remain the dominant factor in the bonus calculation, the Compensation Committee believes
it is important to recognize and incentivize individual performance (other than with respect to our chief executive officer) as we advance towards our goal of becoming a fully integrated
pharmaceutical company. We therefore determined that the individual multiplier for Messrs.&nbsp;Baird and Campbell and Drs. Do and Barth would range from 0-150% based on performance described below.
As noted above, the Compensation Committee continues to believe that Mr.&nbsp;Crowley's bonus should be determined solely by reference to the corporate multiplier. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
individual multiplier for each executive is determined after considering several factors including achievement of individual objectives, departmental or organizational performance,
and other significant accomplishments. Individual objectives are necessarily tied to the particular area of expertise of the executive and are designed to support the Company's achievement of its
corporate goals. Individual goals </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>29</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=32,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=374383,FOLIO='29',FILE='DISK125:[17ZAD1.17ZAD74201]DI74201A.;15',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_di74201_1_30"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>are
evaluated based on leadership and performance on specific functional goals that are tied to the corporate goals. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;These
objectives are set with the belief that full achievement will be difficult and challenging, but attainable, so long as the officer is fully committed to the accomplishment of such
objectives through significant effort and dedication to the Company's strategies, and an ability to quickly adapt to a constantly evolving business environment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Individual
performance objectives of our named executive officers, other than Mr.&nbsp;Crowley, are set by the executive officer to whom each such named executive officer reports,
which for 2016 was Mr.&nbsp;Crowley. These objectives are neither reviewed nor approved by the Compensation Committee. Rather, these objectives serve as a measuring tool for our chief executive
officer in formulating his recommendation to the Compensation Committee as to the appropriate individual multiplier for each named executive officer. During the annual review process, the Company's
chief executive officer discusses with the Compensation Committee his overall evaluation for each executive which includes each such executive's performance and accomplishments as they relate to the
Company's corporate goals, departmental performance, and other significant accomplishments. While the Compensation Committee relies in part on the chief executive officer's evaluation of the other
named executive officers, it also considers the degree of difficulty in attaining the Company's goals and such executive's accomplishments. In considering the degree of difficulty, the Compensation
Committee considers factors such as the influence of external events, including unanticipated clinical events and regulatory timelines, and the effort expanded by executives. The Compensation
Committee reviews and discusses their evaluation of the Company's chief executive officer's performance and accomplishments in executive session along with the Lead Independent Director of the Board
and without the presence of the chief executive officer. Upon the completion of such process the Compensation Committee subjectively determines the individual multiplier for each named executive
officer, other than the chief executive officer, based on the Compensation Committee's subjective determination of such officer's satisfaction of the applicable goals. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


2016 Determinations  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In determining the individual multiplier for our named executive officers, the Compensation Committee noted each executive officer's individual
and departmental performance throughout the year, and how those performances supported the Company's achievement of its
corporate goals. The specific individual factors that the Compensation Committee noted in subjectively determining each named executive officer's individual multiplier were as follows: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Bradley L. Campbell, President and Chief Operating Officer (100% Individual Multiplier)  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provided overall leadership of the build out of the international commercial organization and successful launch of Galafold Ex-US, with high
level of patient uptake in areas with reimbursement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Oversaw the program management function including the successful integration of development activities across miglastat, SD 101, and ATB200
programs; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> At the request of the company, in August 2016 moved to the United Kingdom to increase Senior Leadership Team presence in Amicus International
Headquarters to lead the globalization process, provide more direct oversight of the launch and expand Amicus' presence with key stakeholders throughout Europe. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


William D. Baird, III, Chief Financial Officer (100% Individual Multiplier)  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Significantly strengthened the balance sheet through the leadership and execution of a $100&nbsp;million equity financing and a
$250&nbsp;million convertible debt financing. Successfully increased equity research coverage with three top-tier analysts initiating coverage in 2016; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>30</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=33,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=419697,FOLIO='30',FILE='DISK125:[17ZAD1.17ZAD74201]DI74201A.;15',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_di74201_1_31"> </A>
<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Established International Finance organization which provided key support for the commercial launch, International operations, and product
revenue recognition; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provided strategic and financial leadership to the Board, the Senior Leadership Team, and the program steering teams throughout the year. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Jay Barth, Chief Medical Officer (95% Individual Multiplier)  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Led efforts among the clinical and regulatory teams to ensure and on-time and successful MAA approval of Galafold in April 2016; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Designed and oversaw implementation of clinical strategy for ATB200 for Pompe disease, soliciting and incorporating feedback from Pompe key
opinion leaders; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Led clinical development of SD-101 and implemented changes to the Phase&nbsp;3 protocol for SD-101 which may improve the probability of
success of the study. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hung Do, Chief Science Officer (95% Individual Multiplier)  </I></FONT></P>

<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Provided key leadership role in the successful production of GMP batches of ATB200 to supply Pompe Phase&nbsp;1/2 clinical studies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Collaborated with clinical research team to design optimal Pompe clinical studies including analysis of factors to better understand muscle
damage in Pompe disease and to develop new strategies to monitor pertinent disease biomarkers; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Successfully completed creation and master cell banking of proprietary Fabry ERT for future manufacturing. </FONT></DD></DL>
</UL>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


 </I></FONT><FONT SIZE=2><U>Calculation of Annual Cash Incentive Bonuses</U> </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
calculation of the named executive officers' individual cash incentive payments for service in 2016 is summarized in the table below. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="31pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Corporate<BR>
Multiplier<BR>
(%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Individual<BR>
Multiplier<BR>
(%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Target<BR>
Bonus<BR>
(%) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Base<BR>
Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Payout<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>N/A</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>601,037</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>299,316</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman&nbsp;and&nbsp;Chief&nbsp;Executive&nbsp;Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
396,550</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
131,655</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief&nbsp;Financial&nbsp;Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
100</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
50</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
427,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
177,392</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President&nbsp;and&nbsp;Chief&nbsp;Operating&nbsp;Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
95</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
431,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
136,127</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief&nbsp;Medical&nbsp;Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Hung Do, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
83</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
95</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
40</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
370,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
116,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief&nbsp;Science&nbsp;Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Cash Incentives  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the recommendation of the CEO and approved by the Compensation Committee, additional cash payments in the form of retention or performance
bonuses may be granted to individuals. In March 2016, Dr.&nbsp;Barth received a one-time retention/performance bonus of $200,000 in recognition of Dr.&nbsp;Barth's achievements and the important
long term role he plays with Amicus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>31</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=34,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=658415,FOLIO='31',FILE='DISK125:[17ZAD1.17ZAD74201]DI74201A.;15',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_di74201_1_32"> </A>
<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Long Term Incentive Programs  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We believe that long-term performance will be achieved through an ownership culture that rewards our executives for maximizing stockholder value
over time and that aligns the interests of our employees and management with those of stockholders. Our 2007 Amended and Restated Equity Incentive Plan, or the 2007 Plan, authorizes us to grant stock
options, restricted stock, RSUs and other equity-based awards. We have historically elected to use stock options as the primary long-term equity incentive vehicle. We typically grant an initial stock
option award to new employees and annual long-term incentive awards as part of our overall compensation program as well as option grants to reflect promotions, as necessary. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2016
was a transition year for the Company's long-term incentive program. In early 2016, the Company evaluated its long term incentive strategy to align to its transition to a commercial
stage company. Starting in the summer of 2016 we have adjusted our strategy by granting Restricted Stock Units, along with Stock Options, as part of the mix of annual equity grants to employees. For
the named executive officers, our stock option awards generally vest over a four-year period with 25% vesting one year after the vesting commencement date and the remainder vesting ratably each month
thereafter in equal installments over a three-year period subject to continued employment or association with us. The stock options expire ten years after the date of grant. Restricted stock unit
awards generally vest over a four-year period with 25% vesting each year upon the anniversary of the grant. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have used stock options and restricted stock units as long-term incentive vehicles because we believe that:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Per the LTI strategy for 2016, the Committee believes that stock options and RSUs, along with their four- year vesting periods, provide a
balanced mix to attract, motivate and retain executives; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Stock options are inherently performance based. Because all the value received by the recipient of a stock option is based on the growth of the
stock price, stock options enhance the executives' incentive to increase our stock price and maximize stockholder value; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Restricted stock units help enhance executive actual stock ownership while helping to retain executives. Final value depends on the change in
stock price over the vesting period; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Stock options and RSUs help to provide a balance to the overall executive compensation program as base salary and our annual performance bonus
program focus on short-term compensation, while stock options and RSUs reward executives for increases in stockholder value over the longer term. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>As
in past years, the Compensation Committee determined that Mr.&nbsp;Crowley's January 2016 option grant would be granted with a strike price that was 130% of the closing price on the date of
grant. After reevaluation of our compensation strategy due to commercialization, the Compensation Committee determined that a new mix of equity vehicles was appropriate for Mr.&nbsp;Crowley, the
other named executive officers, as well as all other employees, as discussed more fully below. As a transition away from premium priced stock options, Mr.&nbsp;Crowley's June 2016 grant was
one-third Stock Options that were priced at 130% of the closing price on the date of the grant, one-third priced at the fair market value on the date of the grant, and one-third as restricted stock
units. Completing the transition away from premium priced options, for 2017, the Compensation Committee approved utilizing performance based restricted stock units for all named executive officers
with goals linked to relative total shareholder return and long-term strategic pipeline goals. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Initial Stock Option Grants  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Executives who join us are typically awarded initial stock option grants. These grants have an exercise price equal to the closing price of our
Common Stock on the date of grant. Our goal is to create a total compensation package for new employees that is competitive with other biotechnology companies and that will enable us to attract high
quality people. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>32</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=35,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=719788,FOLIO='32',FILE='DISK125:[17ZAD1.17ZAD74201]DI74201A.;15',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_di74201_1_33"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stock Option and Restricted Stock Unit Awards  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee believes that providing annual stock option and restricted stock unit grants beyond the initial stock option grant
provides management with a strong link to long-term corporate performance and the creation of stockholder value, as well as providing continued retention via long-term vesting. Our practice had been
to make semi-annual stock option awards to our named executive officers in connection with company-wide grants in the form of non-qualified stock options within the meaning of Section&nbsp;422 of
the Internal Revenue Code, as amended (the "Code"). In 2016, the Compensation Committee reevaluated our Long Term Incentive Strategy based on being a commercial stage company and approved the granting
of restricted stock units to employees as part of the annual grant. For 2016, the Compensation Committee continued our past practice of utilizing a semi-annual grant cycle, which spread the incentives
of the stock option grants across a broader time horizon and takes into account the historical volatility of our stock price. Starting in 2017, the Compensation Committee decided that Amicus should
move to an annual grant cycle along with the new mix of equity vehicles consisting of fair market value stock options, restricted stock units, and performance restricted stock units as part of a
performance share program. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Compensation Committee determines the number of shares subject to options or restricted stock units that are granted to our named executive officers in its sole discretion. In
applying that discretion, the Compensation Committee takes into account a number of factors including the current price of our Common Stock, peer group data, individual role and performance and recent
Company developments. All of the stock option and restricted stock unit awards are subject to four-year vesting schedules. The 2016 stock option and restricted stock unit grants are described in the
section entitled "Grants of Plan-Based Awards." With the introduction of restricted stock units, the committee moved to approving 2017 LTI grants based on a fixed dollar value instead of its
historical approach of granting on a fixed number of shares basis. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have typically awarded the largest number of stock options in each grant to our chief executive officer in recognition of his role as our principal executive officer, Chairman of the
Board and primary decision maker for the Company. For these reasons, the Compensation Committee awarded Mr.&nbsp;Crowley options to purchase 250,000 shares of Common Stock in our company-wide grants
in January 2016 granted with a strike price that was 130% of the closing price on the date of grant. In June 2016, the Compensation Committee adjusted the mix in Mr.&nbsp;Crowley's June grant and he
received: options to purchase 83,333 shares of Common Stock in June 2016 granted with a strike price that was 130% of the closing price on the date of grant; options to purchase 83,333 shares of
Common Stock granted with a strike price that was at fair market value on the date of grant; and 41,667 restricted stock units. The 2016 equity grants for all other NEOs are described in the section
entitled "Grants of Plan-Based Awards." </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Factors
that the Compensation Committee and our chief executive officer considered in making these stock option grants included (i)&nbsp;relative contribution toward achievement of
current year corporate objectives, (ii)&nbsp;breadth of internal and external responsibilities, (iii)&nbsp;management responsibilities including managing direct reports, (iv)&nbsp;external
benchmarking, and (v)&nbsp;tenure with Amicus. The specific individual
factors that the Compensation Committee relied on for granting each award are substantially similar to those factors that contributed to a determination of the individual multiplier for each named
executive officer discussed above under "2016 Determinations." </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Qualified Deferred Compensation Plans  </I></B></FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amicus Therapeutics,&nbsp;Inc. Restricted Stock Unit Deferral Plan  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains the Amicus Therapeutics,&nbsp;Inc. Restricted Stock Unit Deferral Plan (the "Stock Deferral Plan"). The Stock Deferral
Plan provides eligible executives, including each of the named executive officers, with the voluntary opportunity to defer the receipt of RSUs otherwise payable to such eligible executives. After a
deferral election is made, an executive's account is credited with the deferred </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>33</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=36,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=523270,FOLIO='33',FILE='DISK125:[17ZAD1.17ZAD74201]DI74201A.;15',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_di74201_1_34"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>RSUs.
All RSUs deferred under the Stock Deferral Plan are fully vested. The Company does not otherwise contribute to the Stock Deferral Plan and the amount an executive receives at the end of a
deferral period is based solely on the value of the Company's stock at the end of the deferral period. Generally, an executive may voluntarily elect to re-defer any previously deferred RSUs for an
additional period of not less than five years if, as required under the Code, such an election is made at least 12&nbsp;months before the year in which the RSUs would otherwise be delivered. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Not
only does the Stock Deferral Plan allow our named executive officers to defer the Federal income taxes otherwise payable upon the delivery of RSUs, but, the Compensation Committee
believes that with respect to executives who avail themselves of the deferral features of the Stock Deferral Plan, such executives will necessarily hold Company stock for a longer period of time.
Accordingly, any RSUs deferred under the Stock Deferral Plan will continue to align such portion of our named executive officers' compensation with the interests of our stockholders for a longer
period of time than would be provided by typical vesting periods. Regardless of an executive's election, any deferred RSUs will be distributed following the executive's death, disability or separation
of service from the Company. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
amounts deferred under the Stock Deferral Plan will continue for all purposes to be a part of the general funds of the Company and the executive's deferral will be subject to the
general creditors of the Company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Amicus Therapeutics,&nbsp;Inc. Cash Deferral Plan  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company maintains the Amicus Therapeutics,&nbsp;Inc. Cash Deferral Plan, as amended (the "Cash Deferral Plan"). The Cash Deferral Plan
provides eligible executives, including each of the named executive officers, and non-employee directors, with the voluntary opportunity to defer receipt of such participant's base salary, bonus
and/or director's fees, as applicable. Any such deferrals are credited to a bookkeeping account maintained for the participant. The participant may make periodic hypothetical investments of the
account and gains and losses on such hypothetical investments will be credited to the participant's account. A Participant is fully vested in all amounts, including earnings deferred under the Cash
Deferral Plan. Distribution of the deferred amounts will generally be made on the distribution date elected by the participant. Generally, a participant may voluntarily elect to re-defer any
previously deferred amount for an additional period of not less than five years if, as required under the Code, such an election is made at least 12&nbsp;months before the year in which the amount
would otherwise be delivered. Regardless of a Participant's election, any deferred amount will be distributed following a change in control of the Company or upon the Participant's death, disability
or separation of service from the Company. The Company does not match when a participant defers any salary or bonus amounts in the Cash Deferral Plan. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
amounts deferred under the Cash Deferral Plan will continue for all purposes to be a part of the general funds of the Company and the amounts deferred by the participants, including
all deemed gains and losses attributable thereto, will be subject to the general creditors of the Company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Compensation  </I></B></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent with our compensation philosophy, we intend to continue to maintain our current benefits for our named executive officers, including
medical, dental, vision and life insurance coverage. All employees receive Company paid term life insurance equal to two times annual base salary, up to a maximum benefit of $1,000,000. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we provide a Company match for our 401(k) Plan, subject to Federal guidelines and plan maximums. We match $1 for each $1 a participant defers into the plan up to 5% of each
participant's salary and bonus paid during the year. The match vests 100% on the participant's one-year anniversary of employment at Amicus. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>34</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=37,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=802293,FOLIO='34',FILE='DISK125:[17ZAD1.17ZAD74201]DI74201A.;15',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_di74201_1_35"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Additional Chief Executive Officer Benefits  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Company is engaged in a highly competitive industry developing medicines for unique and complicated genetic disorders. As chief executive
officer, Mr.&nbsp;Crowley has significant responsibility for leading our Company and managing its progress toward achieving our corporate goals. Mr.&nbsp;Crowley's compensation reflects this
responsibility and takes into account his unique circumstances. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
part of his overall compensation, Mr.&nbsp;Crowley receives significant payments and benefits from the Company related to the healthcare and other associated costs incurred by his
family. These amounts reflect substantial costs incurred for the treatment of a rare medical condition afflicting two members of Mr.&nbsp;Crowley's immediate family. We continued to make monthly
compensation payments of $66,667 to Mr.&nbsp;Crowley to help defray the substantial out-of-pocket medical expenses incurred by Mr.&nbsp;Crowley and his family which we refer to as the Monthly
Medical Payments. We agreed to make the Monthly Medical Payments to Mr.&nbsp;Crowley when we amended his employment agreement in December 2010 in order to compensate him for the loss of certain
medical benefits previously afforded to Mr.&nbsp;Crowley resulting from the passing of federal legislation in 2010, as well as to limit the Company's exposure to Mr.&nbsp;Crowley's expected growth
in future medical expenses. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Secondment Agreement with Mr.&nbsp;Campbell  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During 2016, the Company requested that Mr.&nbsp;Campbell temporarily relocate himself and his family to the United Kingdom to oversee and
ensure the successful launch of Galafold in the pivotal first year of its international launch. Accordingly, on August&nbsp;22, 2016, the Company entered into a secondment letter with Bradley
Campbell outlining the relocation and tax equalization benefits for such assignment over the expected twelve month term of the agreement. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to such agreement, the Company paid Mr.&nbsp;Campbell a lump sum relocation payment of $15,000 to assist with miscellaneous transition expenses, as well as providing him with
a per diem. In addition, the Company has reimbursed Mr.&nbsp;Campbell for, or directly paid, certain other expenses incurred in connection with such relocation. Pursuant to the Agreement,
Mr.&nbsp;Campbell will also be entitled to certain tax equalization payments, including a gross-up, and other payments and/or reimbursements upon his eventual relocation back to the United States,
which are intended to defray the costs he would otherwise incur in connection with this Company-requested relocation. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Termination Based Compensation  </I></B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon termination of employment under certain circumstances, our named executive officers are entitled to receive varying types of compensation.
Elements of this compensation may include payments based upon a number of months of base salary, bonus amounts, acceleration of vesting of equity, health care coverage and other similar benefits. We
believe that our termination-based compensation and acceleration of vesting of equity arrangements are in line with severance packages offered to named executive officers of other similar companies
based upon market information, and are otherwise appropriate given the executive's role and service to the Company. We also have granted severance and acceleration of vesting of equity benefits to our
named executive officers in the event of a change of control if the executive is terminated within a certain period of time following the change of control. We believe that change of control-related
benefits are necessary in order for our named executive officers to direct their full attention to the successful consummation of a transaction without distraction, and that this "double trigger"
requirement maximizes stockholder value because it prevents an unintended windfall to management in the event of a friendly or non-hostile change of control. Unlike the severance arrangements and the
options, for 2016 and years prior, the RSUs granted to our named executive officers from time to time generally do accelerate upon a change in control. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>35</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=38,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=378994,FOLIO='35',FILE='DISK125:[17ZAD1.17ZAD74201]DI74201A.;15',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_di74201_1_36"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Executive Compensation  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="di74201_summary_compensation_table"> </A>
<A NAME="toc_di74201_1"> </A></FONT> <FONT SIZE=2><B>  Summary Compensation Table    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information regarding the compensation that we paid to each person serving as our principal executive officer, our
principal financial officer and each of our other three most highly compensated executive officers during the years indicated below (collectively, the "named executive officers"). </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="30pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="42pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="67pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fiscal<BR>
Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus(1)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock<BR>
Awards(2)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards(2)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Change in<BR>
Pension<BR>
Value&nbsp;&amp; Non-<BR>
Qualified<BR>
Deferred<BR>
Compensation<BR>
Earnings </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Compensation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>601,037</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>299,316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>254,169</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,198,129</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>31,539</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(3)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>815,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,199,368</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>582,400</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>314,496</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>3,013,039</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>815,166</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>4,725,101</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>561,350</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>522,055</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>851,630</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>815,445</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2,750,480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>William D. Baird III</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
396,550</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
131,655</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
91,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
832,036</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
15,316</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>(5)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
1,467,056</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Financial Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>385,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>141,680</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,264,576</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,805,906</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>351,002</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>217,621</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>215,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>343,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,142,673</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
427,450</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
177,392</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
152,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
960,178</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
53,146</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>(6)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
1,770,666</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>415,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>152,720</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,346,302</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,166</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,929,188</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Operating Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>386,957</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>248,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>509,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>343,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,503</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,503,260</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Jay Barth, M.D.,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
431,600</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
336,127</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>(7)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
91,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
832,036</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
14,566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
1,505,828</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Medical Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>415,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>154,380</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,205,793</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,789,823</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2014</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>323,077</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>384,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>107,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>387,500</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>15,232</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,217,309</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Hung Do, Ph.D.,</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
2016</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
370,800</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
116,950</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
76,250</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
693,363</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
14,566</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1><BR>(8)</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1><BR>
1,271,929</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Science Officer</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>2015</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>360,000</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>132,480</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>906,857</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>14,650</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=1>1,413,987</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
2016 amount represents bonuses earned in 2016 and paid in 2017.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
grant date fair value of restricted stock unit awards and option awards granted to our named executive officers was computed in accordance with FASB ASC Topic
718, Compensation&#151;Stock Compensation. Assumptions made in this valuation are discussed in our annual report for the year ended December&nbsp;31, 2016, filed with the SEC on
Form&nbsp;10-K on March&nbsp;1, 2017, at Item&nbsp;7&#151;Management's Discussion and Analysis of Financial Condition and Results of Operations&#151;Stock-Based Compensation. These
amounts reflect the stock price at the time of the grant.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Consists
of gains on investments in Mr.&nbsp;Crowley's deferred compensation plan account; please see the "Nonqualified Deferred Compensation" table below.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
$13,000 of 401(k) employer match, $800,000 of payments made in connection with reimbursements for medical expenses under Mr.&nbsp;Crowley's current
employment agreement, $750 for health care savings account and $1,428 in life insurance premiums.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
$13,000 of 401(k) employer match, $1,500 for health care savings account and $816 in life insurance premiums.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
$13,000 of 401(k) employer match, $750 for health care savings account, $1,428 in life insurance premiums, $25,032 relocation bonus related to his
secondment agreement and $12,936 per diem payments related to his secondment agreement.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>In
March 2016, Dr.&nbsp;Barth received a one-time retention/performance bonus of $200,000 in recognition of Dr.&nbsp;Barth's achievements and the important long
term role he plays with Amicus.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Includes
$13,000 of 401(k) employer match, $750 for health care savings account and $816 in life insurance premiums. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>36</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=39,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=757303,FOLIO='36',FILE='DISK125:[17ZAD1.17ZAD74201]DI74201A.;15',USER='PJAMES',CD='24-APR-2017;19:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dk74201_1_37"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Grants of Plan-Based Awards  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents information concerning grants of equity awards to each of the named executive officers during 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="44pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Stock<BR>
Awards:<BR>
Number of<BR>
Shares of<BR>
Stock or<BR>
Units(1)<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>All Other<BR>
Option<BR>
Awards:<BR>
Number of<BR>
Securities<BR>
Underlying<BR>
Options(2)<BR>
(#) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Exercise<BR>
Price of<BR>
Equity<BR>
Awards<BR>
($/Sh)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Grant<BR>
Date Fair<BR>
Value of<BR>
Stock and<BR>
Option<BR>
Awards(4)<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1/4/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>250,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>11.74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,505,153</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman&nbsp;and&nbsp;Chief&nbsp;Executive&nbsp;Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/15/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>83,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>356,939</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/15/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>83,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>7.93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>336,037</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/15/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>41,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>254,169</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/4/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
90,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
575,039</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief&nbsp;Financial&nbsp;Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/15/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>256,997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/15/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>91,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/4/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
638,931</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President&nbsp;and&nbsp;Chief&nbsp;Operating&nbsp;Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/15/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>75,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>321,247</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/15/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>25,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>152,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.,</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/4/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
90,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
575,039</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief&nbsp;Medical&nbsp;Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/15/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>256,997</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/15/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>15,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>91,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:10pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Hung Do, Ph.D.,</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1/4/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
75,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
479,199</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief&nbsp;Science&nbsp;Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/15/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>214,164</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>6/15/2016</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>76,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Vesting
of the RSU is subject to the participant's continuous service with the Company through the applicable vesting date with the following schedule: 25% of the
total number of shares vest on the first anniversary of the Grant Date, with 25% on each successive Grant Date anniversary.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Each
option has a term of ten years and vests in accordance with the following schedule: 25% of the total number of shares vest on the first anniversary of the Grant
Date and 1/48<SUP>th</SUP>&nbsp;of the total number of shares vest on the first day of the following 36&nbsp;months.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
Compensation Committee determined that certain of Mr.&nbsp;Crowley's 2016 option grants would be granted with a strike price that was 130% of the closing price
on the date of grant, continuing a practice from previous years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Amounts
represent the grant date fair value calculated in accordance with FASB ASC 718. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>37</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=753972,FOLIO='37',FILE='DISK125:[17ZAD1.17ZAD74201]DK74201A.;22',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_dk74201_1_38"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Outstanding Equity Awards at Year-End  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table presents the outstanding equity awards held by each of the named executive officers as of December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:57%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"140%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="140%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="14pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="40pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="50pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=11 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Stock Awards </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options<BR>
(#)<BR>
Exercisable </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Securities<BR>
Underlying<BR>
Unexercised<BR>
Options<BR>
(#)<BR>
Unexercisable(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Exercise<BR>
Price<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Expiration<BR>
Date </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Units of<BR>
Stock<BR>
That Have<BR>
Not Vested<BR>
(#)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Market<BR>
Value of<BR>
Units of<BR>
Stock<BR>
That Have<BR>
Not Vested<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>200,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>13.425</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4/25/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>41,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>207,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>125,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/5/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>103,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>103,975</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/19/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>136,807</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/15/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>150,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/4/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>161,545</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3,455</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/28/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>144,360</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>20,640</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/18/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>156,389</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>58,711</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>143,738</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>86,262</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.82</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>110,201</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>119,799</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11.19</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>86,246</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>143,754</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>15.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>250,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>11.74</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>83,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>83,333</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>7.93</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>William D. Baird III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
175,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
4.66</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
4/16/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
15,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
74,550</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/4/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>36,639</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,609</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/28/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>36,639</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9,585</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/18/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>39,625</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>24,375</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>56,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>33,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>43,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>46,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>8.61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>33,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>56,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>90,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
26,667</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
13.425</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
4/25/2017</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
25,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
124,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>32,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.21</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/5/2018</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>36,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10.36</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/3/2019</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>30,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>5.96</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/19/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.06</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/16/2021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>70,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2/15/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>80,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>4.38</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/4/2022</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>76,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>3.53</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/28/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>74,350</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>10,650</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.52</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/18/2023</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>65,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>24,375</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.45</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/3/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>56,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>33,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>43,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>46,875</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>8.61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>37,498</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>62,502</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>75,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
120,295</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
54,705</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>(12)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
2.29</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
3/7/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
15,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
74,550</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>31,238</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>18,762</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>2.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>38,326</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>41,674</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>8.61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>33,750</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>56,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>90,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>60,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:9pt;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Hung Do, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
28,116</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
16,884</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
2.94</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
6/26/2024</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
12,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1><BR>
62,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:16pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Science Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>23,951</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>26,049</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(8)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>8.61</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/2/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>28,122</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>46,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(9)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>12.28</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/1/2025</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>75,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(10)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>9.03</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>1/4/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:8pt;text-indent:-8pt;"><FONT SIZE=1> </FONT><FONT SIZE=1>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


</FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>(11)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6.10</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>6/15/2026</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>25%
of the total number of shares subject to the option vest on the first anniversary of the date of grant; the remainder vest&nbsp;1/36<SUP>th</SUP>&nbsp;per
month thereafter. </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>38</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=31318,FOLIO='38',FILE='DISK125:[17ZAD1.17ZAD74201]DK74201A.;22',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_dk74201_1_39"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>Vesting
of the RSU is subject to the participant's continuous service with the Company through the applicable vesting date with the following schedule: 25% of the
total number of shares vest on June&nbsp;15, 2017, with 25% on each successive June&nbsp;15<SUP>th</SUP>&nbsp;for the next three years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
market value is based on the closing stock price of $4.97 on December&nbsp;31, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was January&nbsp;28, 2013.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was June&nbsp;18, 2013.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was January&nbsp;3, 2014.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was June&nbsp;26, 2014.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(8)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was January&nbsp;2, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(9)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of the grant was June&nbsp;1, 2015.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(10)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was January&nbsp;4, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(11)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was June&nbsp;15, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-9pt;'><FONT SIZE=1>(12)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=1>The
date of grant was March&nbsp;7, 2014. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Option Exercises and Stock Vested at Year End  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our executive officers must use pre-established trading plans to sell shares of Amicus Therapeutics,&nbsp;Inc. stock. Trading plans may only
be entered into when the executive is not in possession of material non-public information about the Company, and we require a waiting period following the establishment of a trading plan before any
trades may be executed. Our policy is designed to provide safeguards that will allow our executives an opportunity to realize the value intended by the Company in granting equity-based awards. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows information regarding option exercises and stock vested for each named executive officer during the year ended December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="54pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="49pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Acquired on<BR>
Exercise </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value<BR>
Realized<BR>
upon<BR>
Exercise(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Number of<BR>
Shares<BR>
Vested </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value<BR>
Realized<BR>
upon<BR>
Vesting(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 William D. Baird III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>3,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>19,425</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
903,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
value realized is the difference between the fair market value of a share of our common stock at the time of exercise and the option exercise price, multiplied
by the number of shares acquired on each exercise.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>The
value realized on vesting on stock awards is based on the closing price on the date of vesting. The receipt of 100,000 shares with a value of $903,000 for
Mr.&nbsp;Campbell was deferred until January&nbsp;3, 2017. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Qualified Deferred Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Non-Qualified Cash Deferral Plan (the "Deferral Plan") covers our executive officers and our non-employee directors. The Deferral Plan,
which provides the participants with an opportunity to defer the receipt of such participant's base salary and/or bonus. The Company does not match participants' voluntary contributions to the
deferral plan. Earnings are determined solely by an executive's hypothetical </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>39</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=42,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=362796,FOLIO='39',FILE='DISK125:[17ZAD1.17ZAD74201]DK74201A.;22',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_dk74201_1_40"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>investment
of any amount deferred in any pre-selected investment permitted under the Deferral Plan. All amounts in the Deferral Plan are fully vested at all times. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="78pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="56pt" style="font-family:times;"></TD>
<TD WIDTH="16pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="74pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="6pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="58pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Executive<BR>
Contributions in<BR>
Last Fiscal<BR>
Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Earnings in<BR>
Last Fiscal<BR>
Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Distributions in<BR>
Last Fiscal<BR>
Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Balance at<BR>
Last Fiscal<BR>
Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>360,021</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>31,539</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(2)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,195,757</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(3)</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman&nbsp;and&nbsp;Chief&nbsp;Executive&nbsp;Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:11pt;margin-left:9pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
903,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
(406,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>)(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
497,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(6)</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:18pt;text-indent:-9pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>President&nbsp;and&nbsp;Chief&nbsp;Operating&nbsp;Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>$210,363
of this amount is included in the salary column and $149,658 of this amount is included in the bonus column, respectively, in the summary compensation
table.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
investments gains determined by the hypothetical investments elected by Mr.&nbsp;Crowley in the last fiscal year as permitted under the Deferral Plan.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
column includes $804,197 compensation earned and deferred in prior years, which was disclosed in prior year Proxy statements.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
the value of Mr.&nbsp;Campbell's RSUs as of July&nbsp;1, 2016, the date such RSUs vested. This amount is also reported above in the Option Exercises
and Stock Vested at Year End table.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
investment loss equal to the decrease in value of the shares of our common stock of which Mr.&nbsp;Campbell deferred receipt.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
the value of the 100,000 deferred shares valued using the closing stock price of $4.97 on December&nbsp;31, 2016. This column includes $294,000 in
compensation, which was disclosed in prior year Proxy statements. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Severance Benefits and Change of Control Arrangements  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have agreed to provide severance benefits and change of control arrangements to our current executives as described below. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;John F. Crowley.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We employ Mr.&nbsp;Crowley as our chief executive officer pursuant to an employment agreement. The agreement will
continue for
successive one-year terms until either Mr.&nbsp;Crowley or the company provide written notice of termination to the other in accordance with the terms of the agreement. Upon the termination of his
employment by the company other than for cause, or if the company decides not to extend Mr.&nbsp;Crowley's agreement at the end of any term, or if Mr.&nbsp;Crowley resigns for good reason,
Mr.&nbsp;Crowley has the right to receive (i)&nbsp;a severance payment in an amount equal to his then current base salary payable over 18&nbsp;months in accordance with the company's regular
payroll practices, (ii)&nbsp;an additional payment equal to 150% of the target bonus for the year in which the termination occurs, (iii)&nbsp;continued Monthly Medical Payments for a period of
18&nbsp;months, and (iv)&nbsp;continuation of health care coverage under COBRA with premiums to be paid by the Company for up to 29&nbsp;months. Further, the vesting of all options then held by
Mr.&nbsp;Crowley shall accelerate by one year. Mr.&nbsp;Crowley is not entitled to severance payments if the company terminates him for cause or if he resigns without good reason. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
if upon the termination of Mr.&nbsp;Crowley's employment by the company other than for cause, or if the company decides not to extend his employment agreement at the end of
any term, or if Mr.&nbsp;Crowley resigns for good reason, in each case within twelve months following a change of control in the Company, then Mr.&nbsp;Crowley has the right to receive
(i)&nbsp;a severance payment in an amount equal to two times his then current base salary payable over 24&nbsp;months in accordance with our regular payroll practices, (ii)&nbsp;an additional
payment equal to 200% of the target bonus for the year in which the termination occurs, (iii)&nbsp;continued Monthly Medical Payments for a period of 24&nbsp;months, and (iv)&nbsp;continuation
of health care coverage under COBRA with premiums to be paid by the Company for up to 29&nbsp;months. Further, the vesting of all remaining unvested options and restricted stock grants then held by
Mr.&nbsp;Crowley would accelerate in full. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>40</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=43,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=929303,FOLIO='40',FILE='DISK125:[17ZAD1.17ZAD74201]DK74201A.;22',USER='PJAMES',CD='24-APR-2017;19:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dm74201_1_41"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
if Mr.&nbsp;Crowley's employment ceases due to his death or disability, he (or his estate, as applicable) will be entitled to (i)&nbsp;continuation of the Monthly Medical
Payments for 12&nbsp;months, and (ii)&nbsp;continuation of health care coverage under COBRA with premiums to be subsidized by the Company for up to 12&nbsp;months. We believe that the severance
package for our chief executive officer is appropriate considering his role, responsibilities and his excellent historical service to the Company. </FONT></P>

<UL>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Named Executive Officers.  </I></FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Baird, Barth, Campbell and Do.</I></FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;We employ Mr.&nbsp;Baird as our Chief Financial Officer, Dr.&nbsp;Barth as Chief Medical Officer,
Mr.&nbsp;Campbell as our President and Chief Operating Officer and Dr.&nbsp;Do as our Chief Science Officer, pursuant to their respective employment agreements. If any of these executive officers
is terminated without cause, then the executive officer has the right to receive:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continuation of such executive's base salary for 12&nbsp;months; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an amount equal to the target bonus for such executive officer pro-rated for the number of months actually worked in the year of termination; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> vesting of option awards then held by them will automatically accelerate by twelve months; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continuation of health care coverage under COBRA with premiums to be paid by the Company for a period of 12&nbsp;months. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, if any of these executive officers is terminated other than for cause within 12&nbsp;months following certain corporate changes or, if following those changes, the
executive officer resigns for good reason, then the executive officer has the right to receive:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continuation of such executive's base salary for 18&nbsp;months; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> an amount equal to such executive officer's target bonus; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> any outstanding unvested stock options and restricted stock grants held by the executive officer will fully vest; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> continuation of health care coverage under COBRA with premiums to be paid by the Company for a period of 18&nbsp;months. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Finally,
if the executive's employment ceases due to death or disability, such executive will be entitled to continuation of health care coverage under COBRA with premiums to be
subsidized by the Company for up to 12&nbsp;months. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
a condition to the payment of the foregoing severance benefits, a departing executive officer is required to execute a general release of claims against the Company and its
affiliates. Each named executive officer is bound by non-disclosure, inventions transfer, non-solicitation and non-competition covenants that prohibit the executive officer from competing with us
during the term of his or her employment and for twelve months after termination of employment. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential Payments upon Termination without Cause or Resignation for Good Reason  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For each named executive officer the following table sets forth quantitative estimates of the benefits that would have accrued to each of our
named executive officers if such executive's employment had been terminated without cause or, in the case of Mr.&nbsp;Crowley, he resigned for good reason, on December&nbsp;31, </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>41</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=44,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=426090,FOLIO='41',FILE='DISK125:[17ZAD1.17ZAD74201]DM74201A.;17',USER='MKEANE',CD='24-APR-2017;20:27' -->
<A NAME="page_dm74201_1_42"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>2016
other than in connection with a change of control. Amounts below reflect potential payments pursuant to the severance agreements for such named executive officers. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:67%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"120%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="120%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="55pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
Continuation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Benefit<BR>
Continuation<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Stock Option<BR>
Vesting<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>901,556</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>540,933</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,273,067</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>217,095</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,932,652</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
396,550</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
131,655</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
31,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
128,191</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
688,202</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
427,450</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
177,392</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
24,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
131,060</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
760,779</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
431,600</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
136,127</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
31,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
142,582</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
742,115</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Hung Do, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
370,800</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
116,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
31,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
22,825</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
542,382</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Science Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Bonus
component paid in lump sum.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Other
than with respect to Mr.&nbsp;Crowley, benefits to be continued consist of COBRA premiums paid by the Company for 12&nbsp;months.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Value
of the options that would accelerate upon such event are valued using the closing stock price of $4.97 on December&nbsp;31, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over an 18&nbsp;month period following such termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Benefits
to be continued consist of estimated healthcare costs and health insurance premiums for Mr.&nbsp;Crowley's family, which primarily consists of the Monthly
Medical Payments paid over 18&nbsp;months.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over a 6&nbsp;month period following such termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over a 12&nbsp;month period following such termination of employment.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential Payments upon Termination Due to Change of Control  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth quantitative estimates of the benefits that would have accrued to each of our named executive officers, if his
employment had been terminated due to a termination without cause or a resignation with good reason on December&nbsp;31, 2016, assuming that such termination occurs within </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>42</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=45,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=545,FOLIO='42',FILE='DISK125:[17ZAD1.17ZAD74201]DM74201A.;17',USER='MKEANE',CD='24-APR-2017;20:27' -->
<A NAME="page_dm74201_1_43"> </A>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>twelve
months following a change of control or, in the case of Mr.&nbsp;Crowley, within three months prior to or twelve months following the date on which the change of control occurs. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:54%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"150%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="150%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="24pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Salary<BR>
Continuation<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Bonus<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Benefit<BR>
Continuation<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
RSU<BR>
Vesting<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Value of<BR>
Stock Option<BR>
Vesting<BR>
($)(3) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,202,074</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(4)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>721,244</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,673,069</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>(5)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>207,085</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>258,182</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,061,654</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
594,825</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
131,655</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
47,709</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
74,550</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
155,754</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,004,492</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
641,175</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(6)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
177,392</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
37,317</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
124,250</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
158,622</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,138,756</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
647,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
136,127</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
47,709</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
74,550</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
184,696</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
1,090,482</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Hung Do, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
556,200</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>(7)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
116,950</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
47,709</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
62,125</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
34,275</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
817,259</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>



<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Science Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Bonus
component paid in lump sum.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Other
than with respect to Mr.&nbsp;Crowley, benefits to be continued consist of COBRA premiums paid by the Company for 18&nbsp;months.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Value
of the options and RSUs that would accelerate upon such event are valued using the closing stock price of $4.97 on December&nbsp;31, 2016.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(4)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over a 24&nbsp;month period following such termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(5)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Benefits
to be continued consist of estimated healthcare costs and health insurance premiums for Mr.&nbsp;Crowley's family, which primarily consists of the Monthly
Medical Payments paid over 29&nbsp;months.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(6)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over an 18&nbsp;month period following such termination of employment.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(7)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Base
salary paid in installments over a 12&nbsp;month period following such termination of employment.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>43</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=46,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1011670,FOLIO='43',FILE='DISK125:[17ZAD1.17ZAD74201]DM74201A.;17',USER='MKEANE',CD='24-APR-2017;20:27' -->
<A NAME="page_dm74201_1_44"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Potential Payments upon Termination Due to Death or Disability  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following sets forth quantitative estimates of the benefits that would have accrued to each of our named executive officers, if his
employment had been terminated due to death or disability on December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Benefit<BR>
Continuation<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 John F. Crowley</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>830,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>830,236</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chairman and Chief Executive Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>William D. Baird, III</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
31,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
31,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Financial Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Bradley L. Campbell</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
24,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
24,878</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 President and Chief Operating Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Jay Barth, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
31,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
31,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Chief Medical Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Hung Do, Ph.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
31,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2><BR>
31,806</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Chief Science Officer</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Benefits
to be continued consist of COBRA and HSA premiums paid by the Company for 12&nbsp;months following such termination. For Mr.&nbsp;Crowley, this also
includes the Monthly Medical Payments.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Director Compensation  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to our Director Compensation Policy, each non-employee member of our Board received the following cash compensation for Board services
during 2016, as applicable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $30,000 per year for service as lead independent director; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $37,500 per year for service as a Board member; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $30,000 per year for service as chairperson of the Audit Committee (inclusive of committee membership fees described below); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $20,000 per year for service as chairperson of the Compensation Committee (inclusive of committee membership fees described below); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $12,500 per year for service as chairperson of the Nominating/Corporate Governance Committee or the Science and Technology Committee (inclusive
of committee membership fees described below); and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> $10,000 per year for service as a member of the Audit Committee and $5,000 per year for service as a member of the Compensation Committee, the
Nominating and Corporate Governance Committee or the Science and Technology Committee. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to the 2007 Director Option Plan, each director automatically receives an annual grant of options to purchase 20,000 shares, subject to adjustment, on the date of our Annual
Meeting of Stockholders and the each grant will vest in full at the next Annual Meeting of Stockholders. The exercise price of each option granted to a non-employee director will be equal to 100% of
the fair market value on the date of grant of the shares covered by the option. Options will have a maximum term of 10&nbsp;years measured from the grant date, subject to termination in the event of
the optionee's cessation of Board service. All of our directors are also eligible to participate in our 2007 Equity Incentive Plan. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>44</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=47,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=405073,FOLIO='44',FILE='DISK125:[17ZAD1.17ZAD74201]DM74201A.;17',USER='MKEANE',CD='24-APR-2017;20:27' -->
<A NAME="page_dm74201_1_45"> </A>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
of our new, independent Board members receives options to purchase 30,000 shares of our Common Stock in connection with their election to the Board. In 2016, this initial grant only
applied to Mr.&nbsp;Wheeler. The exercise price of these stock options is equal to 100% of the fair market value on the date of grant of the shares covered by the stock option. Unlike the annual
grant to our directors, but consistent with our grants to our named executive officers, these initial grant awards vest over a four year period with 25% vesting one year after the vesting commencement
date and the remainder vesting ratably each month thereafter in equal installments over a three year period subject to continued service as a director. We expect to make additional initial grants of
stock options to any new Board members in the future. </FONT></P>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Summary of Non-Employee Director Compensation Table  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table provides information regarding the compensation that we paid to each of our non-employee directors during the year ended
December&nbsp;31, 2016. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="45pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Fees<BR>
Earned<BR>
($)(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Option<BR>
Awards<BR>
($)(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Total<BR>
($) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>67,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94,372</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>161,872</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94,372</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>141,872</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael G. Raab</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>52,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94,372</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>146,872</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted W. Love, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>47,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94,372</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>141,872</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sol J. Barer, Ph.D(3)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>42,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94,372</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>136,872</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald J. Hayden, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94,372</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>174,372</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret G. McGlynn, R.Ph.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>62,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>94,372</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>156,872</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>24,433</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>141,559</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>165,992</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
fees paid to non-employee director pursuant to Director Compensation Policy.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Represents
the aggregate grant date fair value computed in accordance with FASB ASC Topic 718, Compensation&#151;Stock Compensation. Assumptions made in this
valuation are discussed in our annual report for the year ended December&nbsp;31, 2016, filed with the SEC on Form&nbsp;10-K on March&nbsp;1, 2017, at Item&nbsp;7&#151;Management's
Discussion and Analysis of Financial Condition and Results of Operations&#151;Stock-Based Compensation. Subject generally to continued service, annual director grant options vest one year from
date of grant while the initial director grant options vest over four years.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(3)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Dr.&nbsp;Barer
tendered his resignation from the Board effective February&nbsp;9, 2017.  </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
of December&nbsp;31, 2016, our non-employee directors had the following number of stock options outstanding: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="59pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="83pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Options<BR>
Outstanding </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Vested/Unvested </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Michael G. Raab</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>125,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>105,000/20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>85,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>65,000/20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Sol J. Barer, Ph.D(1)</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>145,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>125,000/20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Donald J. Hayden, Jr.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>140,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>120,000/20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Margaret G. McGlynn, R.Ph.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>135,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>115,000/20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Ted W. Love, M.D.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,000/20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Robert Essner</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>100,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>80,000/20,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Craig Wheeler</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>0/30,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>Non-employee
directors are also eligible to defer board fees pursuant to the terms of the Cash Deferral Plan, described more fully above. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>45</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=48,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=456930,FOLIO='45',FILE='DISK125:[17ZAD1.17ZAD74201]DM74201A.;17',USER='MKEANE',CD='24-APR-2017;20:27' -->
<A NAME="page_dm74201_1_46"> </A>
 <DIV style="padding:0pt;position:relative;text-align:left;margin-left:15%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Dr.&nbsp;Barer
tendered his resignation from the Board effective February&nbsp;9, 2017. </FONT></DD></DL>
 </DIV>
 <P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Non-Qualified Deferred Compensation for Non-Employee Directors  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Deferral Plan covers our executive officers and members of our Board. The Company's Deferral Plan, which provides the participants with an
opportunity to defer the receipt of such participant's base salary, bonus and director's fees, as applicable. The Company does not match participants' voluntary contributions to the deferral plan. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="65pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="63pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="53pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:times;"><DIV style="border-bottom:solid #000000 1.0pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=1><B>Name and Principal Position

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Director<BR>
Contributions<BR>
in Last Fiscal<BR>
Year(1) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Earnings<BR>
in Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Distributions<BR>
in Last<BR>
Fiscal Year </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Aggregate<BR>
Balance at<BR>
Last Fiscal<BR>
Year(2) </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Glenn P. Sblendorio</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>30,917</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>4,194</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>79,728</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="LEFT" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(1)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>Amount
deferred is reflected in the "Fees Earned" column above in the Summary Director Compensation Table.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>(2)</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2>This
column includes director fees earned and deferred in prior years.  </FONT></DD></DL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>46</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=49,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=253947,FOLIO='46',FILE='DISK125:[17ZAD1.17ZAD74201]DM74201A.;17',USER='MKEANE',CD='24-APR-2017;20:27' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_do74201_1_47"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do74201_compensation_committee_report"> </A>
<A NAME="toc_do74201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  COMPENSATION COMMITTEE REPORT    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Compensation Committee is comprised entirely of independent directors. The Compensation Committee of our Board has reviewed and discussed
the Compensation Discussion and Analysis required by Item&nbsp;402(b) of Regulation&nbsp;S-K, which appears in this Proxy Statement, with our management. Based on this review and discussion, the
Compensation Committee has recommended to the Board that the Compensation Discussion and Analysis be included in this Proxy Statement and our 2016 Annual Report on Form&nbsp;10-K, as amended. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Members
of the Amicus Therapeutics,&nbsp;Inc. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Compensation
Committee: </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Margaret
G. McGlynn, R.Ph., Chair<BR>
Michael G. Raab<BR>
Craig Wheeler </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act of 1933, as amended (the "Securities Act") or the Exchange
Act that might incorporate this proxy statement or future filings with the SEC, in whole or in part, the above report shall not be deemed to be "soliciting material" or "filed" with the SEC and shall
not be deemed to be incorporated by reference into any such filing.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>47</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=50,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=666427,FOLIO='47',FILE='DISK125:[17ZAD1.17ZAD74201]DO74201A.;14',USER='DSLOAN',CD='25-APR-2017;11:20' -->
<A NAME="page_do74201_1_48"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do74201_section_16(a)_benefici__do702032"> </A>
<A NAME="toc_do74201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  SECTION&nbsp;16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;16(a) of the Exchange Act requires our directors, executive officers and persons who own more than 10% of a registered class of
our equity securities to file reports of holdings and transactions in our Common Stock with the SEC. To our knowledge, based solely on our review of copies of the reports received by us and written
representations by these individuals that no other reports were required, all such Section&nbsp;16(a) filing requirements were met except that the Form&nbsp;4 of Redmile Group,&nbsp;LLC was
filed late in connection with its purchase of shares of our Common Stock on June&nbsp;3, 2016. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do74201_policies_and_procedure__do702276"> </A>
<A NAME="toc_do74201_3"> </A>
<BR></FONT><FONT SIZE=2><B>  POLICIES AND PROCEDURES FOR RELATED PARTY TRANSACTIONS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our Board maintains a formal policy for the review of any transaction, arrangement or relationship in which Amicus is a participant and one of
our executive officers, directors, director nominees, 5% stockholders (or their immediate family members), each of whom we refer to as a "related party," has a direct or indirect interest. If a
related party proposes to enter into such a transaction,
arrangement or relationship, which we refer to as a "related party transaction," the related party must report the proposed transaction to our Chief Financial Officer or Senior Vice President,
Finance. The proposed related party transaction must be reviewed and, if deemed appropriate, approved by the Board's Audit Committee prior to entry into such transaction, or ratified as soon as
reasonably practicable after discovery that approval is required. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit Committee may approve or ratify the transaction only if the Audit Committee determines that, under all of the circumstances, the transaction is not inconsistent with the
Company's best interests and does not violate its Code of Business Conduct and Ethics. Any related party transactions that are ongoing in nature will be reviewed annually. The Audit Committee will
review and consider such information regarding the related party transaction as it deems appropriate under the circumstances. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
October 2015, we entered into the October 2015 Purchase Agreement with Redmile Capital Fund,&nbsp;LP and certain funds and accounts managed or advised by it (collectively referred
to as "Redmile"), who beneficially owned approximately 6.7% of our common stock as of December&nbsp;31, 2015, as set forth in the October 2015 Purchase Agreement, whereby we sold, on a private
placement basis, (a)&nbsp;$50.0&nbsp;million aggregate principal amount of its unsecured promissory notes and (b)&nbsp;1.3&nbsp;million warrants that have a term of five years. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
February&nbsp;19, 2016, we entered into a Note and Warrant Purchase Agreement (the "February 2016 Purchase Agreement") with Redmile whereby we sold, on a private placement basis,
(a)&nbsp;$50&nbsp;million aggregate principal amount of unsecured promissory notes and (b)&nbsp;five-year warrants to purchase up to 37 shares of our common stock for every $1,000 of the
principal amount of notes purchased by each purchaser, for an aggregate of up to 1,850,000 shares of common stock issuable under the warrants. We agreed with Redmile that in full consideration of the
purchase price for the notes issued under the October 2015 Purchase Agreement, Redmile surrendered for cancellation all notes and warrants acquired from the October 2015 Purchase Agreement and we paid
Redmile any unpaid interest accrued thereunder. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
June&nbsp;30, 2016, following the marketing approval for migalastat in Europe, we entered into a Joinder to and Amendment of Note and Warrant Purchase Agreement (the "Amended
Purchase Agreement") with Redmile. Such amendment joined GCM Grosvenor Special Opportunities Master Fund,&nbsp;Ltd ("GCM") to the February 2016 Purchase Agreement. Pursuant to the Amended Purchase
Agreement, we sold an additional $30&nbsp;million unsecured promissory notes and five year warrants to purchase up to 42 shares of the our common stock for every $1,000 of the principal amount of
additional notes purchased, for an aggregate of up to 1,260,000 shares of common stock issuable under the additional warrants. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December&nbsp;15, 2016, we entered into a Note Purchase Agreement with GCM and Redmile, pursuant to which we agreed to prepay all outstanding principal and accrued and unpaid
interest on the notes issued by us and held by GCM and Redmile. Such prepayment was made on December&nbsp;21, 2016, which resulted in a non-cash loss of $13.3&nbsp;million. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>48</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=51,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=877365,FOLIO='48',FILE='DISK125:[17ZAD1.17ZAD74201]DO74201A.;14',USER='DSLOAN',CD='25-APR-2017;11:20' -->
<A NAME="page_do74201_1_49"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do74201_code_of_conduct_and_ethics"> </A>
<A NAME="toc_do74201_4"> </A>
<BR></FONT><FONT SIZE=2><B>  CODE OF CONDUCT AND ETHICS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have adopted a code of conduct and ethics that applies to all of our employees, including our principal executive officer and principal
financial and accounting officer, and our directors. The text of the code of conduct and ethics is posted on our web site at </FONT><FONT SIZE=2><I>www.amicusrx.com</I></FONT><FONT SIZE=2> and will
be made available to stockholders without charge, upon request, in writing to Secretary, c/o Amicus Therapeutics,&nbsp;Inc. at 1&nbsp;Cedar Brook Drive, Cranbury, New Jersey 08512. Disclosure
regarding any amendments to, or waivers from, provisions of the code of conduct and ethics that apply to our directors, principal executive and financial and accounting officers will be included in a
Current Report on Form&nbsp;8-K within four business days following the date of the amendment or waiver, unless web site posting of such amendments or waivers is then permitted by the rules of
NASDAQ. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>49</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=52,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=676454,FOLIO='49',FILE='DISK125:[17ZAD1.17ZAD74201]DO74201A.;14',USER='DSLOAN',CD='25-APR-2017;11:20' -->
<A NAME="page_do74201_1_50"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do74201_proposal_no._1_#151;election_of_directors"> </A>
<A NAME="toc_do74201_5"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 1&#151;ELECTION OF DIRECTORS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board has voted to nominate Dr.&nbsp;Ted Love and Robert Essner for election at the Annual Meeting for a term of three years to serve as
Class&nbsp;I directors until the 2020 Annual Meeting of Stockholders, and until their respective successors are duly elected and qualified. The Class&nbsp;II directors&#151;Craig Wheeler
and Donald J. Hayden&#151;and the Class&nbsp;III directors&#151;John F. Crowley, Donald Hayden, Margaret McGlynn, R.Ph., Michael Raab, and Glenn Sblendorio&#151;will serve until
the Annual Meetings of Stockholders to be held in 2018 and 2019 respectively, and until their respective successors have been elected and qualified. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
authority to vote for any of these nominees is withheld, the shares represented by the signed and dated proxy cards will be voted </FONT> <FONT SIZE=2><B>FOR</B></FONT><FONT SIZE=2> the election as directors of Dr.&nbsp;Ted Love and Robert Essner. In
the event that any nominee becomes unable or unwilling to serve, the shares
represented by the enclosed proxy will be voted at the discretion of the individuals designated as proxies on the proxy cards. We have no reason to believe that any nominee will be unable or unwilling
to serve as a director. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
plurality of the shares voted at the Annual Meeting is required to elect each nominee as a director. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>The Board recommends the vote "FOR" the election of each of </B></FONT><FONT SIZE=2>Dr.&nbsp;Ted Love and Robert Essner</FONT><FONT SIZE=2><B> as a director,
and proxies solicited by the Board will be voted in favor thereof unless a stockholder has indicated otherwise on the proxy.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="do74201_proposal_no._2_#151;independen__pro02254"> </A>
<A NAME="toc_do74201_6"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 2&#151;INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit and Compliance Committee has appointed Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, to audit our
financial statements for the fiscal year ending December&nbsp;31, 2017. The Board proposes that the stockholders ratify this appointment. Ernst&nbsp;&amp; Young&nbsp;LLP audited our financial
statements for the fiscal year ended December&nbsp;31, 2016. We expect that representatives of Ernst&nbsp;&amp; Young LLP will be present at the meeting, will be able to make a statement if they so
desire, and will be available to respond to appropriate questions. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table presents fees for professional audit services rendered by Ernst&nbsp;&amp; Young&nbsp;LLP for the audit of our annual financial statements for the years ended
December&nbsp;31, 2016 and 2015, and fees billed for other services rendered by Ernst&nbsp;&amp; Young&nbsp;LLP during those periods. All of such fees were approved by the Audit and Compliance
Committee. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="61pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="51pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>December&nbsp;31, </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2016 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>2015 </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Audit Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,578,983</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>815,500</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Tax Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>17,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&#151;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>All Other Fees</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>2,000 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>1,597,983</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>817,500 </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Fees
for audit services included fees associated with the annual financial statement audit, an audit of our internal controls over financial reporting and reviews of the quarterly
reports on Form&nbsp;10-Q for both 2016 and 2015. In 2016, audit fees also included $168,000 related to audit work for the financing transactions for the "At the Market" equity offering commenced in
February 2016 and the convertible debt financing completed in December 2016 and $16,500 related to consents required for SEC filings.&nbsp;In 2015, the audit fees also included costs of $89,500
associated with the review of our Forms&nbsp;S-3 and related Prospectus Supplement for the secondary financing completed in June 2015. Fees for tax services in 2016 included fees associated with an
IRS Code Section&nbsp;382 study and fees related to certain compliance requirements related to our Convertible Debt offering. All other fees in 2016 and 2015 were for the subscription fees paid for
access to the Ernst&nbsp;&amp; Young&nbsp;LLP on line Accounting&nbsp;&amp; Auditing Research Tool. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>50</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=53,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=856744,FOLIO='50',FILE='DISK125:[17ZAD1.17ZAD74201]DO74201A.;14',USER='DSLOAN',CD='25-APR-2017;11:20' -->
<A NAME="page_do74201_1_51"> </A>

<P style="font-family:times;text-align:justify;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Policy on Audit and Compliance Committee Pre-Approval of Audit and Permissible Non-audit Services of
Independent Registered Public Accounting Firm  </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Consistent with SEC policies regarding auditor independence, the Audit and Compliance Committee has responsibility for appointing, setting
compensation and overseeing the work of the independent registered public accounting firm. In recognition of this responsibility, the Audit and Compliance Committee has established a policy to
pre-approve all audit and permissible non-audit services provided by the independent registered public accounting firm. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to engagement of the independent registered public accounting firm for the next year's audit, management will submit an aggregate estimate of services expected to be rendered
during that year for each of four categories of services to the Audit and Compliance Committee for approval.  </FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>1.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Audit</I></FONT><FONT SIZE=2> services include audit work performed in the preparation of financial statements, as well as work that only the
independent registered public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation regarding financial accounting
and/or reporting standards.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>2.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Audit-Related</I></FONT><FONT SIZE=2> services are for assurance and related services that are traditionally performed by the independent
registered public accounting firm, including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain regulatory requirements.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>3.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Tax</I></FONT><FONT SIZE=2> services include all services performed by the independent registered public accounting firm's tax personnel
except those services specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning, and tax advice.
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>4.</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2><I>Other Fees</I></FONT><FONT SIZE=2> are those associated with services not captured in the other categories. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prior
to engagement, the Audit and Compliance Committee pre-approves these services by category of service. The fees are budgeted and the Audit and Compliance Committee requires the
independent registered public accounting firm and management to report actual fees versus the budget periodically throughout the year by category of service. During the year, circumstances may arise
when it may become necessary to engage the independent registered public accounting firm for additional services not contemplated in the original pre-approval. In those instances, the Audit and
Compliance Committee requires specific pre-approval before engaging the independent registered public accounting firm. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit and Compliance Committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must report, for informational
purposes only, any pre-approval decisions to the Audit and Compliance Committee at its next scheduled meeting. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event the stockholders do not ratify the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm, the Audit and Compliance Committee
will reconsider its appointment. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
affirmative vote of a majority of the shares voted affirmatively or negatively on the matter at the Annual Meeting is required to ratify the appointment of the independent registered
public accounting firm. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>The Board recommends the vote "FOR" to ratify the appointment of Ernst&nbsp;&amp; Young&nbsp;LLP as our independent registered public accounting firm, and proxies
solicited by the Board will be voted in favor of such ratification unless a stockholder indicates otherwise on the proxy.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>51</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=54,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=44964,FOLIO='51',FILE='DISK125:[17ZAD1.17ZAD74201]DO74201A.;14',USER='DSLOAN',CD='25-APR-2017;11:20' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;text-align:justify"><FONT SIZE=2><A
NAME="page_dq74201_1_52"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


<!-- PARA=JUSTIFY -->
 </FONT></P>

<!-- TOC_END -->
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq74201_report_of_audit_and_compliance_committee"> </A>
<A NAME="toc_dq74201_1"> </A>
<BR></FONT><FONT SIZE=2><B>  REPORT OF AUDIT AND COMPLIANCE COMMITTEE    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Audit and Compliance Committee of the Board, which currently consists entirely of directors who meet the independence and experience
requirements of the rules and regulations of NASDAQ and the Exchange Act, has furnished the following report. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Audit and Compliance Committee assists the Board in overseeing and monitoring the integrity of our financial reporting process, compliance with legal and regulatory requirements and
the quality of internal and external audit processes. This Committee reviews and reassesses our charter annually and recommends any changes to the Board for approval. The Audit and Compliance
Committee is responsible for overseeing our financial reporting process on behalf of the Board, and for the appointment, compensation, retention, and oversight of the work of Ernst&nbsp;&amp;
Young&nbsp;LLP. In fulfilling its responsibilities for the financial statements for fiscal year 2016, the Audit and Compliance Committee took the following
actions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Reviewed and discussed the audited financial statements for the fiscal year ended 2016 with management and Ernst&nbsp;&amp; Young&nbsp;LLP, our
independent registered public accounting firm; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Discussed with Ernst&nbsp;&amp; Young&nbsp;LLP the matters required to be discussed by PCAOB Auditing Standard No.16, Communications with Audit
Committees; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;text-align:justify"><FONT SIZE=2> Received written disclosures and the letter from Ernst&nbsp;&amp; Young&nbsp;LLP regarding its communications with the Audit and Compliance
Committee concerning independence as required by Rule&nbsp;3526 of the PCAOB (Communications with Audit Committees Concerning Independence). The Audit and Compliance Committee further discussed
Ernst&nbsp;&amp; Young's independence with Ernst&nbsp;&amp; Young&nbsp;LLP. The Audit and Compliance Committee also considered the status of pending litigation, taxation matters and other areas of
oversight relating to the financial reporting and audit process that the Committee determined appropriate. </FONT></DD></DL>
</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based
on the Audit and Compliance Committee's review of the audited financial statements, discussions with management and Ernst&nbsp;&amp; Young&nbsp;LLP and written disclosures and the
letter from Ernst&nbsp;&amp; Young&nbsp;LLP regarding its communications with the Audit and Compliance Committee concerning independence as required by applicable requirements of the Public Company
Accounting Oversight Board, the Audit and Compliance Committee recommended to the Board that the audited financial statements be included in our Annual Report on Form&nbsp;10-K for the fiscal year
ended December&nbsp;31, 2016, as amended, for filing with the SEC. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Members
of the Amicus Therapeutics,&nbsp;Inc.<BR>
Audit and Compliance Committee </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>Glenn
P. Sblendorio, Chair<BR>
Robert Essner<BR>
Michael G. Raab </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2><I>Notwithstanding anything to the contrary set forth in any of our previous or future filings under the Securities Act or the Exchange Act that might incorporate this proxy
statement or future filings with the SEC, in whole or in part, the above report shall not be deemed to be "soliciting material" or "filed" with the SEC and shall not be deemed to be incorporated by
reference into any such filing.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>52</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=55,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=1023341,FOLIO='52',FILE='DISK125:[17ZAD1.17ZAD74201]DQ74201A.;10',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_dq74201_1_53"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq74201_proposal_no._3_#151;ad__dq702137"> </A>
<A NAME="toc_dq74201_2"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 3&#151;ADVISORY VOTE ON EXECUTIVE COMPENSATION    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are providing our stockholders the opportunity to vote to approve, on an advisory, non-binding basis, the compensation of our named executive
officers as disclosed in this proxy statement in accordance with the SEC's rules. This proposal, which is commonly referred to as "say-on-pay," is required by the Dodd-Frank Wall Street Reform and
Consumer Protection Act of 2010, which added Section&nbsp;14A to the Exchange Act. Section&nbsp;14A of the Exchange Act also requires that stockholders have the opportunity to cast an advisory
vote with respect to whether future executive compensation advisory votes will be held every one, two or three years. In accordance with the results of this advisory vote at the 2014 Annual Meeting,
the Company's Board determined that the Company will hold an advisory vote on the compensation of the Company's named executive officers every year. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
executive compensation program for our executive officers is designed to attract, motivate, and retain individuals of superior ability and managerial talent who can successfully
perform and succeed in our environment. Our named executive officers are rewarded for the achievement of our near-term and longer-term financial and strategic goals and for driving corporate
performance. This program contains elements of cash and equity-based compensation designed to align the interests of our executives with those of our stockholders as well as increase the incentive to
achieve key strategic and financial performance measures by linking compensation opportunities and actual compensation earned through our pay-for-performance compensation program to the achievement of
corporate goals. We also make equity grants designed to align our named executive officers' compensation to the long-term performance of Amicus in addition to creating an ownership culture that helps
unify the interests of our executives and stockholders. The Company generally targets aggregate total direct compensation for the named executive officers as a group to approximately the
50th&nbsp;percentile of our peer group in setting our executive compensation programs. Our Board and the Compensation Committee regularly review the compensation programs for our named executive
officers and undertake a comprehensive annual review to ensure that our compensation policies and programs align with current market practices and the interests of our stockholders. </FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
"Compensation Discussion and Analysis" section of this proxy statement describes in detail our executive compensation program and the decisions made by the Compensation Committee
with respect to the fiscal year ended December&nbsp;31, 2016. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
2016, the Company made significant progress towards the goal of becoming a leading orphan and rare disease company with global commercial operations and a diversified product
pipeline. The Company received EU approval for its first commercial product, Galafold, initiated commercial launch and pricing and reimbursement activities in Europe, continued the build out of an
international commercial organization to support the commercial launch of Galafold, acquired MiaMed&#151;an early-stage rare disease company with a potential first-in-class therapy for CDKL,
advanced ATB200/AT2221 for Pompe disease to a Phase 1/2 clinical trial, and strengthened the balance sheet with the completion of a $100&nbsp;million At the Market offering and a $250&nbsp;million
convertible debt financing, while carefully managing expenses. These actions have provided us with more than 18&nbsp;months of cash runway at the beginning of 2017. We believe that our compensation
plan appropriately rewards our executive officers for the progress achieved in 2016 and the performance against our corporate goals, and aligns their long term incentives with shareholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board is therefore asking stockholders to approve, on an advisory basis, the following resolution: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>"RESOLVED,
that the compensation paid to the named executive officers of Amicus Therapeutics, as disclosed pursuant to the compensation disclosure rules of the SEC, including the compensation
discussion and analysis, the compensation tables and any related material disclosed in this proxy statement, is hereby approved." </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
an advisory vote, this proposal is not binding. The outcome of this advisory vote will not overrule any decision by us or our Board (or any committee thereof), create or imply any
change to our fiduciary duties or those of our Board (or any committee thereof), or create or imply any additional fiduciary duties for us or our Board (or any committee thereof). However, our
Compensation Committee and Board value the opinions expressed by our stockholders in their vote on this proposal and will consider the outcome of the vote when making future compensation decisions for
named executive officers. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>53</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=56,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=22856,FOLIO='53',FILE='DISK125:[17ZAD1.17ZAD74201]DQ74201A.;10',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_dq74201_1_54"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq74201_proposal_no._4_#151;advisory_v__pro03752"> </A>
<A NAME="toc_dq74201_3"> </A>
<BR></FONT><FONT SIZE=2><B>  PROPOSAL NO. 4&#151;ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES    <BR>    </B></FONT></P>


<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In Proposal 3, we are providing our stockholders the opportunity to vote to approve, on an advisory, non-binding basis, the compensation of our
named executive officers. In this Proposal 4, we are asking our stockholders to cast a non-binding advisory vote regarding the frequency of future executive compensation advisory votes. Stockholders
may vote for a frequency of every one, two, or three years, or may abstain. A frequency vote similar to this will occur at least once every six years. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After
careful consideration of the frequency alternatives, the Board believes that conducting a non-binding advisory vote on executive compensation every one year (annually) is
appropriate for us and our stockholders at this time. The Board believes that an annual executive compensation advisory vote will facilitate more direct stockholder input about executive compensation.
An annual executive compensation advisory vote is also consistent with our policy of reviewing our compensation program annually. Therefore, we believe an annual vote would be the best governance
practice for us at this time. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accordingly,
we are asking our stockholders to approve, on an advisory basis, the following resolution in respect of this Proposal 4: </FONT></P>

<UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>"RESOLVED,
that the stockholders be requested to recommend, in a non-binding vote, whether a non-binding stockholder vote to approve the compensation of the Company's named executive officers should
occur every one, two or three years." </FONT></P>

</UL>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;While
the Board believes that its recommendation is appropriate at this time, the stockholders are not voting to approve or disapprove that recommendation, but are instead asked to
indicate their preferences, on an advisory basis, as to whether the non-binding advisory vote on the approval of the Company's executive officer compensation practices should be held every year, every
other year or every three years. The option among those choices that receives the highest number of votes from the holders of shares present in person or represented by proxy and entitled to vote at
the Annual Meeting will be deemed to be the frequency preferred by the stockholders. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Board and the Compensation Committee value the opinions of the stockholders in this matter, and the Board intends to hold say-on-pay votes in the future in accordance with the
alternative that receives the most stockholder support, even if that alternative does not receive the support of a majority of the shares present and entitled to vote. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq74201_other_matters"> </A>
<A NAME="toc_dq74201_4"> </A>
<BR></FONT><FONT SIZE=2><B>  OTHER MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board knows of no other business which will be presented to the 2017 Annual Meeting. If any other business is properly brought before the
2017 Annual Meeting, proxies in the enclosed form will be voted in accordance with the judgment of the individuals named as proxies on the proxy card. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>54</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=57,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=140377,FOLIO='54',FILE='DISK125:[17ZAD1.17ZAD74201]DQ74201A.;10',USER='PJAMES',CD='24-APR-2017;19:55' -->
<A NAME="page_dq74201_1_55"> </A>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq74201_stockholder_proposals_and_nominations_for_director"> </A>
<A NAME="toc_dq74201_5"> </A>
<BR></FONT><FONT SIZE=2><B>  STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you wish to submit a proposal to be considered for inclusion in next year's proxy materials or nominate a director, your proposal must be in
proper form according to SEC Regulation&nbsp;14A, Rule&nbsp;14a-8 and received by the Secretary of the Company no later than December&nbsp;29, 2017. Proposals received after that date will not
be included in the proxy materials we send out in connection with the 2018 Annual Meeting of Stockholders. If a proposal is received before that date, the proxies that management solicits for the
meeting may still exercise discretionary voting authority on the proposal under circumstances consistent with the proxy rules of the SEC. To be timely in accordance with our Restated By-laws,
stockholder notice of any such proposal must be received by us not earlier than November&nbsp;29, 2017 and not later than December&nbsp;29, 2017; provided, however, that in the event that the date
of the 2018 Annual Meeting of Stockholders is more than 30&nbsp;days before or more than 60&nbsp;days after the anniversary date of the 2017 Annual Meeting of Stockholders, notice by the
stockholder to be timely must be delivered not earlier than the close of business on the 90th&nbsp;day prior to such 2018 Annual Meeting of Stockholders and not later than the close of business on
the later of the 60th&nbsp;day prior to such 2017 Annual Meeting of Stockholders or the 10th&nbsp;day following the day on which we make a public announcement of the date of the 2018 Annual
Meeting of Stockholders. All stockholder proposals should be marked for the attention of General Counsel and Corporate Secretary, c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury,
New Jersey 08512. </FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2016, as amended (other than the exhibits thereto), filed with the SEC, which provides additional
information about us, is available on the Internet at </FONT><FONT SIZE=2><I>www.amicusrx.com</I></FONT><FONT SIZE=2> and is available in paper form to beneficial owners of our Common Stock without
charge upon written request to Secretary, c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A
NAME="dq74201_delivery_of_proxy_materials"> </A>
<A NAME="toc_dq74201_6"> </A>
<BR></FONT><FONT SIZE=2><B>  DELIVERY OF PROXY MATERIALS    <BR>    </B></FONT></P>

<P style="font-family:times;text-align:justify"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Some banks, brokers, and other nominee record holders may be participating in the practice of "householding" proxy statements and annual
reports. This means that only one copy of this Proxy Statement, the Notice of 2017 Annual Meeting of Stockholders and our Annual Report to Stockholders may have been sent to multiple stockholders in
your household. Householding is designed to reduce duplicate mailings and save significant printing and postage costs. If you receive a household mailing this year and would like to receive additional
copies of this Proxy Statement, the Notice of 2017 Annual Meeting of Stockholders and our Annual Report to Stockholders, please call us at (609)&nbsp;662-2000 or send a written request to General
Counsel and Corporate Secretary, c/o Amicus Therapeutics,&nbsp;Inc., 1 Cedar Brook Drive, Cranbury, New Jersey 08512. If you want to receive separate copies of our Proxy Statement, Notice of our
Annual Meeting of Stockholders and our Annual Report to Stockholders in the future, or if you are receiving multiple copies and would like to receive only one copy for your household, you should
contact your bank, broker, or other nominee record holder, or you may contact us at the above address and phone number. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>55</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=58,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=713474,FOLIO='55',FILE='DISK125:[17ZAD1.17ZAD74201]DQ74201A.;10',USER='PJAMES',CD='24-APR-2017;19:55' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">- 1 AMICUS   THERAPEUTICS, INC. 1 Cedar Brook Drive Cranbury, NJ 08512 THIS PROXY IS   SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS The undersigned stockholder of   Amicus Therapeutics, Inc. hereby appoints Bradley L. Campbell and Ellen   Rosenberg as proxies, each with full power of substitution, to represent and   vote as designated on the reverse side, all the shares of Common Stock of   Amicus Therapeutics, Inc. held of record by the undersigned on April 17,   2017, and which the undersigned would be entitled to vote if personally   present at the Annual Meeting of Stockholders to be held at the offices of   Amicus Therapeutics, Inc., located at 1 Cedar Brook Drive, Cranbury, New   Jersey, 08512 on June 13, 2017, or any adjournment or postponement thereof.   This proxy is revocable and the undersigned may revoke it at any time prior   to the Annual Meeting by giving written notice of such revocation to the   Secretary of Amicus Therapeutics, Inc. prior to the meeting or by filing with   the Secretary of Amicus Therapeutics, Inc. prior to the meeting a later-dated   proxy. Should the undersigned be present and want to vote in person at the   Annual Meeting, or at any postponement or adjournment thereof, the   undersigned may revoke this proxy by giving written notice of such revocation   to the Secretary of Amicus Therapeutics, Inc. on a form provided at the   Annual Meeting. The undersigned hereby acknowledges receipt of a notice of   Annual Meeting of Stockholders of Amicus Therapeutics, Inc. called for June   13, 2017 and the Proxy Statement for the Annual Meeting, each dated April 28,   2017, prior to the signing of this proxy. (Continued and to be signed on the   reverse side) 14475 1.1 COMMENTS: </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1209" src="g21422bgi001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=59,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=909469,FOLIO='',FILE="DISK105:[17ZAD2.17ZAD74202]2142-2-BG_ZAD74202.CHC",USER="DSLOAN",CD='Apr 20 08:20 2017' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">ANNUAL MEETING   OF STOCKHOLDERS OF Amicus Therapeutics, Inc. June 13, 2017 GO GREEN e-Consent   makes it easy to go paperless. With e-Consent, you can quickly access your   proxy material, statements and other eligible documents online, while   reducing costs, clutter and paper waste. Enroll today via   www.astfinancial.com to enjoy online access. NOTICE OF INTERNET AVAILABILITY   OF PROXY MATERIAL: The Notice of Meeting, Proxy Statement, Proxy Card are   available at http://www.astproxyportal.com/ast/15417/ Please sign, date and   mail your proxy card in the envelope provided as soon as possible. Please   detach along perforated line and mail in the envelope provided.   20230304000000000000 6 061317 3. Approve, on an advisory basis, the Company&#146;s   executive changes to the registered name(s) on the account may not be   submitted via Note: Please sign exactly as your name or names appear on this   Proxy. When shares are held jointly, each holder should sign. When signing as   executor, administrator, attorney, trustee or guardian, please give full   title as such. If the signer is a corporation, please sign full corporate   name by duly authorized officer, giving full title as such. If signer is a   partnership, please sign in partnership name by authorized person. THE BOARD   OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; THE ELECTION OF DIRECTORS, &#147;FOR&#148;   PROPOSALS 2 AND 3, AND FOR &#147;ONE YEAR&#148; ON PROPOSAL 4. PLEASE SIGN, DATE AND   RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR   BLACK INK AS SHOWN HERE x 1. Election of Directors: NOMINEES: FOR ALL   NOMINEESO Ted W. Love, M.D. O Robert Essner WITHHOLD AUTHORITY FOR ALL   NOMINEES FOR ALL EXCEPT (See instructions below) INSTRUCTIONS: To withhold   authority to vote for any individual nominee(s), mark &#147;FOR ALL EXCEPT&#148; and   fill in the circle next to each nominee you wish to withhold, as shown here:   FOR AGAINST ABSTAIN 2. Ratify the appointment of Ernst &amp; Young LLP as the   Company&#146;s independent registered public accounting firm for the fiscal year   ending December 31, 2017 FOR AGAINST ABSTAIN compensation 1 year 2 years 3   years ABSTAIN 4. Approve, on an advisory basis, the frequency of the vote on   executive compensation To change the address on your account, please check   the box at right and indicate your new address in the address space above.   Please note that this method. Signature of Stockholder Date: Signature of   StockholderDate: </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1208" src="g21422bii001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=60,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=526084,FOLIO='',FILE="DISK105:[17ZAD2.17ZAD74202]2142-2-BI_ZAD74202.CHC",USER="DSLOAN",CD='Apr 20 08:22 2017' -->

<div>
<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
<div align="center">
<div id="container" style="width:100%;"><div id="ImgContainer" style="border:0;width:100%;height:auto;">
<p style="margin:0in 0in .0001pt;height:1px;"><font size="1" color="white" face="Times New Roman" style="color:white;font-size:1.0pt;">ANNUAL MEETING   OF STOCKHOLDERS OF Amicus Therapeutics, Inc. June 13, 2017 INTERNET - Access   &#147;www.voteproxy.com&#148; and follow the on-screen instructions or scan the QR code   with your smartphone. Have your proxy card available when you access the web   page, and use the Company Number and Account Number shown on your proxy card.   TELEPHONE - Call toll-free 1-800-PROXIES (1-800-776-9437) in the United   States or 1-718-921-8500 from foreign countries from any touch-tone telephone   and follow the instructions. Have your proxy card available when you call and   use the Company Number and Account Number shown on your proxy card. Vote   online/phone until 11:59 PM EST the day before the meeting. MAIL - Sign, date   and mail your proxy card in the envelope provided as soon as possible. IN   PERSON - You may vote your shares in person by attending the Annual Meeting.   GO GREEN - e-Consent makes it easy to go paperless. With e-Consent, you can   quickly access your proxy material, statements and other eligible documents   online, while reducing costs, clutter and paper waste. Enroll today via   www.astfinancial.com to enjoy online access. Please detach along perforated   line and mail in the envelope provided IF you are not voting via telephone or   the Internet. 20230304000000000000 6 061317 3. Approve, on an advisory basis,   the Company&#146;s executive changes to the registered name(s) on the account may   not be submitted via Note: Please sign exactly as your name or names appear   on this Proxy. When shares are held jointly, each holder should sign. When   signing as executor, administrator, attorney, trustee or guardian, please   give full title as such. If the signer is a corporation, please sign full   corporate name by duly authorized officer, giving full title as such. If   signer is a partnership, please sign in partnership name by authorized   person. THE BOARD OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; THE ELECTION OF   DIRECTORS, &#147;FOR&#148; PROPOSALS 2 AND 3, AND FOR &#147;ONE YEAR&#148; ON PROPOSAL 4. PLEASE   SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR   VOTE IN BLUE OR BLACK INK AS SHOWN HERE x 1. Election of Directors: NOMINEES:   FOR ALL NOMINEESO Ted W. Love, M.D. O Robert Essner WITHHOLD AUTHORITY FOR   ALL NOMINEES FOR ALL EXCEPT (See instructions below) INSTRUCTIONS: To   withhold authority to vote for any individual nominee(s), mark &#147;FOR ALL   EXCEPT&#148; and fill in the circle next to each nominee you wish to withhold, as   shown here: FOR AGAINST ABSTAIN 2. Ratify the appointment of Ernst &amp;   Young LLP as the Company&#146;s independent registered public accounting firm for   the fiscal year ending December 31, 2017 FOR AGAINST ABSTAIN compensation 1   year 2 years 3 years ABSTAIN 4. Approve, on an advisory basis, the frequency   of the vote on executive compensation To change the address on your account,   please check the box at right and indicate your new address in the address   space above. Please note that this method. Signature of Stockholder Date:   Signature of StockholderDate: NOTICE OF INTERNET AVAILABILITY OF PROXY   MATERIAL: The Notice of meeting, proxy statement and proxy card are available   at http://www.astproxyportal.com/ast/15417/ COMPANY NUMBER ACCOUNT NUMBER   PROXY VOTING INSTRUCTIONS </font></p>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman"><img width="935" height="1208" src="g21422bki001.gif"></font></p>    </div></div>
</div>
<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
</div>
<!-- ZEQ.=1,SEQ=61,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1",CHK=726265,FOLIO='',FILE="DISK105:[17ZAD2.17ZAD74202]2142-2-BK_ZAD74202.CHC",USER="DSLOAN",CD='Apr 20 08:23 2017' -->

<BR>
<P><br><A NAME="17ZAD74201_1">QuickLinks</A><br></P><!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_be74201_1">NOTICE OF 2017 ANNUAL MEETING OF STOCKHOLDERS</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_da74201_1">GENERAL INFORMATION ABOUT THE ANNUAL MEETING</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_da74201_2">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dc74201_1">MANAGEMENT</A></FONT><BR>

<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_de74201_1">COMPENSATION DISCUSSION AND ANALYSIS&#151;2016</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_di74201_1">Summary Compensation Table</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_do74201_1">COMPENSATION COMMITTEE REPORT</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_do74201_2">SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_do74201_3">POLICIES AND PROCEDURES FOR RELATED PARTY TRANSACTIONS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_do74201_4">CODE OF CONDUCT AND ETHICS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_do74201_5">PROPOSAL NO. 1&#151;ELECTION OF DIRECTORS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_do74201_6">PROPOSAL NO. 2&#151;INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</A></FONT><BR>
<!-- TOC_BEGIN -->
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq74201_1">REPORT OF AUDIT AND COMPLIANCE COMMITTEE</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq74201_2">PROPOSAL NO. 3&#151;ADVISORY VOTE ON EXECUTIVE COMPENSATION</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq74201_3">PROPOSAL NO. 4&#151;ADVISORY VOTE ON THE FREQUENCY OF FUTURE EXECUTIVE COMPENSATION ADVISORY VOTES</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq74201_4">OTHER MATTERS</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq74201_5">STOCKHOLDER PROPOSALS AND NOMINATIONS FOR DIRECTOR</A></FONT><BR>
<FONT SIZE=2 style="font-family:times;"><A HREF="#toc_dq74201_6">DELIVERY OF PROXY MATERIALS</A></FONT><BR>
<!-- SEQ=,FILE='QUICKLINK',USER=DSLOAN,SEQ=,EFW="2231878",CP="AMICUS THERAPEUTICS, INC.",DN="1" -->
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g399823.jpg
<DESCRIPTION>G399823.JPG
<TEXT>
begin 644 g399823.jpg
M_]C_X  02D9)1@ ! 0$! P$#  #__@!%35),3%]'4D%02$E#4SI;04U)0U53
M7U1(15)!4$555$E#4UU!34E#55-?5$A%4D%0155424-37U!-4U],3T=/+D50
M4__; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_  !$( '4!70,!(@ "$0$#$0'_Q  ?  $  @(#  ,!
M"0H("P$&!P(#!03_Q !*$   !@$# P$& P()"@0'   ! @,$!08'  @1"1(3
M(0H4%3%!418B83)Q%R,E,SF!D;'P&"12=XBALK6WP3=RDN$:)B="8M'Q_\0
M' $  04! 0$               0%!@<("0,"_\0 -A$  @(" 00" 0,# P,$
M @,  @,!! 4&$0 '$A,4(0@5(C$6(T$R46$D,T(E-$.!%_!QD:'_V@ , P$
M A$#$0 _ +_&FFFCHZ::::.CIIIKR+/&<\9[;,27C-N7[&WJV/L?PJ\U/2BP
M JX4*0Q4645$L@,5:4GYR05:Q$!#M>YW*R[UHQ;E$ZW)?:O7?;>BK52VQ9LN
M77KUT@3'/>XQ6I*EA$FQC&$(  Q)$10,1,S'7D]Z:J'6;+5HKUU,>][C%:DI
M4,FQK&%,""U@,D9%,0(Q,S,1'74=T6ZO".SO$TYF7.]Q:U6J1!?=V+1,"/;+
M;9Q4AC,*K2Z\59)[9+)(B4PMX]IVIMFR;B3E74=#LGL@VI([S_:"]XVX*=EH
M7 <NKM<Q+Y56T8SJ/PR1RS-L"G_BG=JR&[://@SM;M\WPN@-H1!@54S)>=L
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M9:\949<LL4R<1_%MASYPP> ;,0#X,)CQVW^FHJNDSU(:[U#, %EID8^$S]C
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MR3E5)*0<J**.G2ZBYSN26$B$(F0I"%*0A"@4I2@!2E*4 *4I2E  *4H  %*
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M2"/9,6)TW$QR-$>W _3_ !]O[M?--,ZIR)I)J*J*&*1-)(AE%55#F I$DDR
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MXQE%WYE S80W6[CT%4UB9BN!S)F Q2KGB'"1A#D.%$5HHZ2A?7U*H4Q1'@1
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M*9 04K:'F(G!1$E3C>;L^9H*NW6ZK;BBW;D%5597.>,A33(40Y.;_P":C<
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MZ]$:JUZJ&Y91XT3*#]GAM^T.H1!45V2F%:&W36*8/(($,LU<I]IQ*<#)&[B
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M2U4$]ISW9$45PQLPK,D4P)F3SGEA)JX*8Q>WXC7L75]X1(.XHF,-JMCAFX4
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MB(0 UUCMA(0[QQ%RS1=A+1+E:-E6#M,R+IC*1JQV4DR<HG #I.&;YNX;+IF
M#)JI'(( )1#6PJ]GWR]!Y*Z:V+*JP<M#3F$[/D+%UH9(J?YPU<EMLG=X!=PB
M<W> 256N,0Z37(7P+*%<D(;R(+IIS?\ *L+!]N<0=6)FFO:,>=GU1_;%)8O+
M+KD7C'$)]IK 9Y@/8:HCF9'J)?C4: W[,!:F(MLU^\*/9SY$X<EC3? P4\^V
M%@PI^O*%BV9F(\N9M/\ ']GRUU>ITFF4&-<0]&J59ID0ZE).==154@(FN1SF
M:FG1WTS+KL8=HR:K2DL].=Y)R"B1G;]T<SAVLJL83CVC7 B'!@Y#D ]0^H<A
MZ<ZY\09P)!!E '(D804P)$'EX20Q/!2/D7C,Q,CY%QQS/.Y9 )(3D!DP@A Y
M&)(1/Q\X$ICD8+Q'RB)B"\1YYXCC74=?233D>J9N$23243&)@L+1"@J"0?,J
MAA^GO173 @CVIF+(D3*4X^3N2,80 #% )C?97A#\#[T0Y#D+KA$1#GU !K.0
M>!$/F #P/ _7@>/D.H6NN\4Q>JCN?[BF+W!AXQ>XHE[BC@_'8 8O(!W%$0$
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MLQ$7,BBK8>\(X!OR*X-N LXF8.*[Q*A)1/# 29\#!P/7@NGR 1$0  #D1$>
M /N(CZ 'W$?334MG3JVF1UL,EG[)$0D_@HR14;XT@)%$%6<M,QC@"O;B_:J
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M!K(UZ"?MFIB&;-WL/&ND&YDT_"0R"*[51-(Q$OXHHIE*)4_R%$"^FNP
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M6X@ >")KL6TAHY+@O!0!-FR1+P4  ./0 U!?RYRX!C-.P0ERRQ>R.6:$3'[
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MLY%DK1%S[RS0[%I::;!IJ4]Y&62*C&#H6MA>J'/+Q4VD9=)L8J1$RJ$5EM(
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MSC[%-"PLT\A(BN/FJ9RRPV0 ;,LBXOR38698$[CXK8\9NN<3LPR>6MWW7)L
M!#7O*M-(D6:4$1_](P> 2ORF40$UC@&),!LC^S=;.4<N;C[=NHN$2#NF[<62
M431S.T@,T?9FN3!PF@]1*JDH@Z4HU+/(21@ Q56$Q9ZT^)PL@D8MYP     ]
M  . #[ &H_>E_M)2V6;+,/8:?,4&M[6B#7S+2R10 [S*-W(A+V=)=0"D]X"N
MD&/IK%<2%,,56F)1#DHB,@6N<_>'=9WO?<SEE-EF,JM_2<+$%R$8R@9K6Y?W
M/ W7R^_,?S$VO&?],<;X[5:B.F:3B<6Q4+R%A7ZEEIF.#G(71!C%L^N?*HJ%
M4X_F.*_,?S/36+&\W:1C/>YM\NVW_*22B$596Z;ZNV=DV0<S=#NL6"BM:N]?
M!?M+\2A7:ARKM/*@C-0SJ5K[U4&$LZ <I]-5U0O7,7=J9''V&U+U&PFW3M)+
MP;7LH8+4M67^" Q$HYB8GCB8F)F.I[=I5<C4LT+R%VJ=Q#:UJNX?);D."5M6
M<?Y$P*8GB8F/YB8F(GK6*6Z-WG=)/=)>*?!7"PX;RY!QSJ 3N=6:,EX/(F.)
M24:R$98*Z:RP\E'SM*LKF%8/BD68G7CY:-7A90K:7B7K8G9LJ]7OJ1YEK[BK
MW3=CD1O!/&QF;YE1&E2Q<K(-5 5(LW?2F.*Y6)QPBX35.BY1&4*@X1$$ETE"
M%* 7UM^_3TP/U!<6?@3*\:I$6V (_=8SRO H(?C+',T]33!=Q'BL9)O-5^3,
M@W3L=0ESFAYM%))<HQ\TSBYF/H1[VNECN[V,SDLID7'TC<,5MG"QHC../(Z1
ML&.G\=YC$:KV%9NBO(X]E%"=@.8>XHL4DW(G3BI><:E3?K=!.V?<CMUW0FD6
MU8;6*_<&JI*&'E<;C3;DC3$0%G#7K:284E,><XZ&Q9JEY0H&H"'SAKN)H&^]
MN8N#K66V!^C66.<"\;>O"O'@V>31E:E=L!$#SX#=()2\8&3);IE41QF,8QC&
M,(F,<QSF,(B)C'4,)U#F$>1,=0YC'4.81.H<QCG$QC"(\:^)3IF#N(JD<O\
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MMN-ZL^)]B6X'<?<]MFSY7%U?M2J5:LQ*#'Y)M4S%VJ0!"2LD@8(,7]@EH_\
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M;K$@5LJ0JC5"3BGS=N<I5")>0A3A*84A2%*0I0*0H 4I2@  4I0 "@ !P
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J_P!1U]NFFFCHZ::::.CIIIIHZ.FFFFCHZ::::.CIIIIHZ.FFFFCHZ__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g918867.jpg
<DESCRIPTION>G918867.JPG
<TEXT>
begin 644 g918867.jpg
M_]C_X  02D9)1@ ! 0$!1 %$  #__@ ]35),3%]'4D%02$E#4SI;04U)0U53
M7U1(15)!4$555$E#4UU*3TA.7T9?0U)/5TQ%65]+7U-)1RY%4%/_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" !( +(# 2(  A$! Q$!_\0 'P ! 0 " @,! 0$           D'" 8* 00%
M P(+_\0 ,1    <  @(! P,$ @(# 0   0(#! 4&!P ("1$2$Q0A%3%!%A<B
M46&!"G$R,W*1_\0 % $!                     /_$ !01 0
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*?'' \\<<<#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g20428.jpg
<DESCRIPTION>G20428.JPG
<TEXT>
begin 644 g20428.jpg
M_]C_X  02D9)1@ ! 0$!60%9  #__@ ^35),3%]'4D%02$E#4SI;04U)0U53
M7U1(15)!4$555$E#4UU%3$Q%3E]23U-%3D)%4D=?2U]324<N15!3_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ .0"I P$B  (1 0,1 ?_$ !\   $#!0$! 0             ("0H! @4&
M!P,+!/_$ $00  $$ P " 0(#! 0&$P    4#! 8' 0((  D1%2$3%#$*$D%1
M%A=Q@1@C4EB1EQDB,C,Y56%R<WB4H;*SM-35UO#_Q  4 0$
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:DLKD'_A)?Y&O^CRJ?^YS_P ]3_S-O+_ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g512034.jpg
<DESCRIPTION>G512034.JPG
<TEXT>
begin 644 g512034.jpg
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MOOYAK)T/$VY#VFX<W_VCK'[ !P5#BO\ LGUE_P!L?VO#D8&Y!L/3UO\ 6/\
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M(F,8PB8S\U54D$U%EE")))$.HJJJ<J:::9"B8ZASG$"D(0H"8YS"!2E 3&$
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M,(NY5W^QN^_\N.Y?]MER#PO[I/\  3_0&3AUW^QN^_\ +CN7_;9<@\+^Z3_
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MDJ)C.#="% AOD.N#FU3"/[.771-S >HI%KVW(5%PL0"E.4Q6T\SB#IB<GC%
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MF,8PB8QC")C&,(F,8PB8QC"+@0 ?X?\ G_OG@HBDJ0R:J9%2& 0,10H*$$!
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M%8= =JA5Y:0V[<%])78_&W4,OR0KEGW?6[CKVWS%2G.,#*X.KHKMS2\5,);
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'MCHM$"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g987977.jpg
<DESCRIPTION>G987977.JPG
<TEXT>
begin 644 g987977.jpg
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M$45_D0.R+^#KXF?5#7OR\>1 [(OX.OB9]4->_+R4\# ;T=>OIZ" E'I_7NF
M!Z?\>F<@("'4! 0'^8></-_Q#XNGQ^;"**_R('9%_!U\3/JAKWY>/(@=D7\'
M7Q,^J&O?EY*CC"**[R('9%_!U\3/JAKWY>/(@=D7\'7Q,^J&O?EY*CCK_+^>
M$45WD0.R+^#KXF?5#7OR\>1 [(OX.OB9]4->_+R5#K\?]/0/_C_Z^C'7X_\
M0?\ QA%%?Y$#LB_@Z^)GU0U[\O'D0.R+^#KXF?5#7OR\E/$X /3SC_+]TIC
M _T$2@(!_GTSR 0$.H" @/H$/. _YX117>1 [(OX.OB9]4->_+QY$#LB_@Z^
M)GU0U[\O)4.OQ_Z#_P", (" " ]0'T"'G#_4/MPBBO\ (@=D7\'7Q,^J&O?E
MX\B!V1?P=?$SZH:]^7DJ.,(HKO(@=D7\'7Q,^J&O?EX\B!V1?P=?$SZH:]^7
MDJ. $!#J @(?U#SAA%%=Y$#LB_@Z^)GU0U[\O'D0.R+^#KXF?5#7OR\E0ZA_
MQ_T'_P 9SA%%=Y$#LB_@Z^)GU0U[\O'D0.R+^#KXF?5#7OR\E0ZAU$.H=0Z=
M0Z^<.OHZA_+K_+.<(HKO(@=D7\'7Q,^J&O?EX\B!V1?P=?$SZH:]^7DJ.>(G
M* ]/.(]>G[I3& !_H(E 0+_F(>D/ZX118>1 [(OX.OB9]4->_+QY$#LB_@Z^
M)GU0U[\O)40$!#J ]0'S@(>@0_KC"**[R('9%_!U\3/JAKWY>/(@=D7\'7Q,
M^J&O?EY*CC"**[R('9%_!U\3/JAKWY>/(@=D7\'7Q,^J&O?EY*CC"**[R('9
M%_!U\3/JAKWY>/(@=D7\'7Q,^J&O?EY*CC"**[R('9%_!U\3/JAKWY>/(@=D
M7\'7Q,^J&O?EY*CG " ].@]0'T"'G#_4/-A%%?Y$#LB_@Z^)GU0U[\O'D0.R
M+^#KXF?5#7OR\E1QA%%=Y$#LB_@Z^)GU0U[\O'D0.R+^#KXF?5#7OR\E1QA%
M%=Y$#LB_@Z^)GU0U[\O'D0.R+^#KXF?5#7OR\E1QA%%=Y$#LB_@Z^)GU0U[\
MO'D0.R+^#KXF?5#7OR\E1QA%%=Y$#LB_@Z^)GU0U[\O'D0.R+^#KXF?5#7OR
M\E1QA%%=Y$#LB_@Z^)GU0U[\O'D0.R+^#KXF?5#7OR\E1QA%%=Y$#LB_@Z^)
MGU0U[\O'D0.R+^#KXF?5#7OR\E1QA%%=Y$#LB_@Z^)GU0U[\O'D0.R+^#KXF
M?5#7OR\E1QA%%:/8@=D7T'_Y=?$ST#_^4->_+S6W]O%QZTCQ^[5_EEJ'2>K*
M1J_6%0>Z<)5Z)3(%I"5J!)-\>]3626+&1C4I6[4)">F)26=@F4H*OG[I<0[R
MILV\)O0/Q#]F:H+PD+UTO-7Y=H?\,&E,(L[OP;CU)? KY@;"^_7:N3AY!YX-
MQZDO@5\P-A??KM7)P\(F,8PB8QC")C&,(F,8PB8QC")C&,(F0>\N?[3.9?:6
M47LYPVOM72?&/67$9CS,Y OM%7Z<U1M#>4_==QV'3NJ-+.-F5&0C[S4=8LBT
MRYVV]ITR2A92SJ!%0CJ30;^QED)PLBHYC<-N1DER?U?S[X+7+3U>Y0T745AX
MX;$UYR&;71/2G(#C_8;<ROT?5K'9]=HR5RU[<=<7=N_M- N</7+.B#B:E8:<
MAW$0Z636(K0K1K&?[*GFOP:@^-VS]S6/BGS0O>Q.,5\XO;MW9M7>-9IFVH[3
MENVEI/:6HKIM:2V5L;6Z3V7HDG3-J1R,[,U1S6YAG8$ZV$A!D.$>>J.T"[0^
MZ\<^RGW%<JI;]C[6O':F<L=2M*'KW>L3 &Y'U.O0'-6K0M(VHX9TN@4RJZ\T
M]::Y!0RKR<C+PG)575K7<)H4MH,QK))JM;\1^7F^N6.F^67:!2O'ZM->*3>_
MK\8N.G&2P[(OE0CMA;/KQ:9:MU;;VCLNHZVDKE:HRCJ2E4H-0A]=1$!44YV5
ML"LM*3*R8$MUXZ=EKR9U2CP\H]NNVBW^NN%':.<G.4="G*[);!&YW_1W(2M<
MGWZ,3;(*3IR$%7]J5W8'(-!@I&PT[(U!W4(-:4)8@FC$BWI%49IVPSW6VON;
M)>5?&U;5O(#A7>>/NO)#3^J-OQ&Z*YN>Q\M6$-_Z:F&L-H3U-U$#=W?9Z83A
M;(2[4VN-Z W;N;!,.G44@Y%O\X_:^["U6EOZN\J.+%.UOLS5W"[?7-K6<9IG
ME/6.06M]NTOC=#,9':^MWVPV^M:!-:XVE57,Y60>,9+7MAJ\A"3*D[7+'.&B
MWD6/6N5?8XV#E):NTPG;!=M8-D.6UHX$;.T.ULU3?WZ!J^P^$M44:%B]W4>4
M:,(:V:ZV),%4K5B@H>3?KOJ#/SH*E0E"MF:M'H7L?=OW.G\O"RG'CLM.%4UM
M[@MR-XH:KI?"_3\:^2D=C<A*8YJ\GN+;'("3X]:FVE UBO-"HP$%J37%<4BE
M8B8GY:XRMSD&U;C(LBF$X2\D-O\ *O3*&[=E\:Y;C+7;PA7[1INMVG959OE]
MM6KK33(&RPMRO,-4XY&,UK.OW<H\;)456;L<LSBFT?(S+N*EG[RO1,#7';F!
MR/XZ]HSS>VQO#;]POG 79_:56O@1)Q%RL4Q-0?#?;K'5&C+IQPOD$>7>/65*
MTMN.;V;;-/W]&/3A:Y7+T?6$[(*)^VKA4^2_I2AR.LM+ZIUI*O&3^5H.L:'1
MY%_'>R!CWDA4ZA#UUX[8BZ20=>PW#F.57:^R$$E_$'3\<DFIWB%L"U=V;D"Y
MH7:?:<Y)!5-DZB[0KE9M7<RM;@CRB3R&UQL72^E]:MHF4>2<8T&*O\#.:S?6
M:'F8 [U&$?\ [.R\7*%DV9R-2*#_ ) <C-JI<3N6DE<]_<DH6KQ/A+[+C_/V
M+5.Q]S-MKUWB^MN+5$3:]3:O>ZKD%MI-(0M5D9UC7:!K1)60</'GL"M0;F3=
MHM5I%.($YP);[NC[)I;=':X7.]T:I[!N;:L\H+/VLB>FY2'AJK)(SJ4_'<L(
M6$TM-22,<^47K499'*LB2=392<$V-*QB2R%#J?V-W-C7'!>3T@PY#:5VYR>A
M^U;I7:*UG;FW"[!9U&_L]:777UFK;3;2-2K!;&A=K.EK]FK=D:N@M'J/Y![[
M M2JZHR^27:)8=L#(;2KS'EJW[,UWQ\>H6)KL-IHDO*A?:3ELZKLJC#-JVAL
MOO4A1!>PJ1:,^G-$$IJZ>4*Q#VP%KA%'SP;X2CVEW&&@\_.<.\>5,MNSE/!.
M=SZXJ^F.5F]-#:PXG4"VJ2B6L*=HNE:;O-/K?MO#Z_-#/++;[]%V^=M%I>R3
MJ=!0IEVZU[/9*;JW/==>\J>/6_M@2FX=D<%>8>U>*"&ZYUHV;VC;^NJ[7:5L
M'55WO2T8T8Q#C8O[$W^-KUW<,&J1G\Q C-O#.'<NH]=T*T;Q5[57@-1WW%CA
M[)<&=W<4:=(V+_TTSW)ZY<@-=;FTI3K1;)2SM-:7J+UM0-B5[=]9UP29=1%1
MF&EIUE89J%;,XV55C2HHF;7^\!.&A>%^E[-4IZ_.MN;FW-MO8W([DAN%W$$K
MH;.WUMR0;2%SL456$G<@C5*I%LH^#I](JZ3YY[1T^M0K-P[=O2NW*Q%$SI#C
MRXYK<_.U^B=M\E><->A-'\D=-T;4U;TMS9Y+:/J5%KEEXNT&U2[2#IVMMB05
M22,XLCQ>;[[B#<D]GJKJG3.1R\3==#UGS ONK)-#AYR.V/OO?=MXO]M?QKX=
MZVW? ;<=ZKV%L'6N[]<+[=TB_P"3,C5H%G&;L0J,#,2--W!4%HR&B-O*P<!/
MS/L20377=W5LN(_:A<?>5_/G=?$^2X$V&D\S-MZ\VE%I\AI[D6VM%(<4?351
MU8+&1@-:4OVHF&[Q6!>R8H-K<U.9)5LG[.1.=0C?\6'9&[+C]>:$7F=UU/8W
M(8G:NZL[3KEKMF9KDU3H38<Y5$)F(E*)JNILEK<[J\#4Z:%/HNLX&;FSL$8F
MNN)&5DF#V46;@1?0B.VB>%K7-_>%WXE7&B\2."6P.2NF+_O9WM2HR\]M#=>C
MMG1>M:=KS2VIVT*UGK"?9TA,1;!S9;3+U*MTRZ2T=3RR5I31G9^'[KK3M6+I
M7]P4[4_-[CM1>,1-JZIW#M?6=UUCRAJG*6L-$] 4Q+96X==;A&KT&AO];;'J
M.N3N+:W)#M[[0K,VA+,Q@+NZ>Q"2;_K,GV1LILG@%V@7"7:FQ:RS'F#RTY4\
MDZ9<JS#O++'T57;'()#?NG?VFKMB:0Q+"ZJ$]#U]&]UULNG%3S!.5AF$V9N]
M*_+2#179$VJ:V:XG=Y\6.RWXE:[;:*W5J&=B.S[TQ J[-W18-ZT*0U99+E+[
M=O/'[6EKT35JS29VU_LSKK63N;E)65MCEK<;],UF)3A90BN$TEVD?,'<+;0&
MT/)P3T'QGY:MY%;0&RH_? 7/8T&UGZ+-[ T;;.4>I:OIEZST'K+<,3#-VCJ^
M0NP-JH:RDK-56-OC#.Y<&Z?WNPXY%<E^5W9SZBW#RF1:OK[99/9K1G?&]NC9
MN8O\'$;3O4"E,341!4:C1E+?UYQ&+TAE%,23/ME$UF.M2TDV>S;B*C_@<4>-
M':BZN3XD\?\ 9^ZN--=XM</XV(K,A?\ 2Z-\D-[\NZ-K:A/==ZAIFQZ+?:0C
M0M"Q*; T#:ML.J/>MCS-OL]68LZG)TZ"DI),:\]E9Q5WCPBXJQ_%K<DUJJU1
M6J-@[1;Z>N.M7MO/(VK5-RV):=C0<ELJ'M,%$-JUL%N]N$A$RT/5WUCK@-8Y
MF]9S2BCM5HV(HN]^<(82B=I9V?7'&M\J.T;;ZJY#:?YVW/9T"MVC_,UT\E[%
MI*,T&[UNYCIUQN(9>!;P[C85D.Y8Q#MHQEBN6J4LW>(,&R9:K0W:9[-T9H79
M&W]+\/[_ +U[.3A_<-@ZMNW)W9/,&1M7*"]5+0UQD:7OG=E)USL&E6^3V]2=
M<VB/M#1*9OF_JM>[O%4NP/HB"31;P*$K))N;BK<MD<^.$7+.(L588T[C!J[F
M#1K97)$9;]II^2Y%1^DVE6>5T&L>M%"QA%-92QI_VSD6"X$D(_VM1>F%S['C
M)G.S8Y]P6@.1/9M:IOG%Z+X'\A-@[U48[OG9C:1.46GM$<I-BV;9>[-4Q^HF
MU&D-:[-MC5Y>KW4Z%LF8W%46B$%8F,E8JB\>P!H^4(N_:GYU\IGG:+]IU65M
M>/\ =/%C0'%GBWNO4=5U?;V%HV \_;+7.Z;G DU3KUMK2*F+M=.2[JNHQ!JY
M-7ILPH<A5*X=E(S;:W//:BJ>ANTTW)<.4&MN*?);C+K/15WWCJ#:.TM=)ZHY
M>53DC9:JKJIE6Y&TTO>M,8:SUI)ZQL:,=:FB<?*0;R^521L43/0#2;5-'D?*
MTDWQV6?(R<V3SU8\<MLZ]U5ISFUP$TOQC8V5::V%$[DTKLKC97]BU/61JZVK
M,(I!V+65TK&P'4/L"15M,%;X9LDJ$#$RQ53HN:=<<>R\Y-ZNY1<.^0;+0/9A
M<6J7H.$W%J[86E.(L7L*/?6ZJ;DUQ7*],[B=;AD=.T=]?+S"V&E0C6NZKM='
MCH]"$F[/8)S<T]9'+9JV(KV.Q(V1?-H=DWP@V5M*ZVS8M\L^C(Z:M=VNT_*6
MJVV21">L9%Y&;L$X\=RDK(*-VR27LM^\66,5)$AU!(0.EAW!'BG%=K+QG@.T
M,Y;[GY6EV9R9E]C7G2%9TURKW;H:F<1M6H7>Z4G5-=U#4],WJK5)W=&E-BHZ
MPW.X;"B+M,3]OD';:7!:-:J,%I8^S1XL7'A/P0XQ\5;]8:U:KEI#6;"E6"Q4
MXTJ:LRLBUEI:0.ZAS3<?$RQF1TY!-,/9T<S7,8B@"B0HE$;!-7\0>U'X)UNY
M<:N!]DX0W[BDO<[Y<- R?**:WI6-K\9F.T;C*7BP:Z5K>L*?9JIO*@T>Q6"=
MD=<I.+-JV=]@/$JS/2"C)HW>$(JDMN27+KB37N+/!I]$5SM!N>UZJ^X[4I;Y
M2[_^G2B%XZ:6M3"';;LWO<S4;8\K$W%W&W+6M"=LJ;KNQ_V@[3>S$NV+ U\K
MZ00Z/9.V@FJ-JI):X</+J/*JM\^]8=GEM#BO4]L4R=?PFU]R5,UWUI<M?[0D
MX6O5N]ZVO%6?UJ=K\U88K7+I&-E)92S-:\M6'R3GT(?LS>4W%EWP[W7Q7W'0
M^0W);0VIM_Z0Y ON7<]>:3 <EJKR;VG!;]V);(NZT.N[5FM/6FL;M@4YVC0B
M%.NM?)1GIZ&Z<M2QS&74^,V[*3D!<7%,W;MC9&H5N35X[5[CEVBW(9*J%N1M
M8UZ@<>J KJBEZ$U#*R<&E9[8XJ5 CX)LQN=S@Z>G:9YW89%W%5E@:-CB$7JN
M^UMYR)V/EIJF-[,FJ3.Z^#56A=G<BXYES;@$M0$UI=M7&VKK=GJ?9S[0;6S7
M[<-MA(FXD=4&<U;1JE6DJT@^E=F"2QPS8]7C]JUM+;^T-3Z>X6<04]ZVC;_!
M'0':!P5DVEOJ,T-KF U#OB:MT'$UVW3C/6FU;"SOI7T##MJ]$P=5GF4^O)3Z
MLL^J4;4SR$U6&+X*["8[W[5G:JMNI9X?GOK+1E'US'$&>]LJ>_U;QQNFFI=W
M=P-%%: SD)VRM92-]H'$LN,2@X]EI-WOBFQXD-*:IYS<4>T"U)QOXU*<:-E[
M&T#V"79]Z<VM7MSV[9VO=:7:5U9NC?U 8W2E7ZF:_O=JAS04^QF'B$-.:W<$
MMM9L#ADN\I\LP;.UB*_=3MF&MJU5QN3U+QX=2W+;D-LGD#J![QJVON"JZDK6
MD;UQ E?:#E>KM_>R<#=H%I4=4SBT/'0DO3ZC:9[8ZEMJ(P-6:&D)1.%ZC-]M
MS(5/7;AK8>(MCEN4=9YR:-X*WCCIKC=E#NT2M=>1U(=[ T]L35>ZE(6$J=]U
MU<Z[[7.&[FRP^MY>!6&PH6]C7S5I8TA0^W]AU<E=;\5]@S$1Q"Y:<H]/;<YB
M[JWOK;E!K^0+Q/WY9>>=Q+L#<L="$<T_;%HU>YU?:H^LN])6]2D6]X#6 D$+
M%"LUK4X<Q'>J%V/VU6-8TY-N8/A'H.XU[M-N-/->U:?XHZ<BM8Z4H>F^.];L
MM;B]1U&W5W5].V#NK8<BM8I6VO\ 8NV8J#CUIZRS417(BEU9BP8.R*KDUVP%
MYT55.> <QN(ZFI]I<(=):AY!+T_3.\HK?E-VKKK><I9JC17$-L*3UYJ1Y3W\
M9?JE,P6P#VJDI0U3@&REX0E)F#15+E;]#<^.1MWKFUK1M?A>U7K=1T).;WU;
M>^%O(:O\UM:[O6KGCDW^D:K9H^@:AE&F]Y94\4XI57)7)BKV^)DSR#2XLUHQ
M\QSY.[N#O)FQ<@^;G('0VY]::PMN_P#B/Q?TCJ21M5-#8K2'N^@]H;AOEICM
MHTJPUU_6I;56T:]L%IKN<&*7D;4U@)>TR,2UB)R.@7R\=\/V-').TN^7MJ@*
MQPM[-6=WUPAV7QABJCV?EBVS)4N_[0V%::U:&NYMP$<ZST)"0B=*95N0H]78
MTFA25S+"[&O<E)W-^BHTK;@BO=TQVG6_[1R.HW%O>/$S4NK-L[ITGMK;.G*W
MKKFG5=XRC&>U)&UV5E=9<A8J/U#3932\J^):(V-1M<$SVC52S;&Q1K-S)GB2
M*.[$.SUY_;CV;I3L@K_S24V ;8>\-Q\[8^(V73^0JD%1[/4=,:<Y!W*=N'(G
M5=7UW3ZI<X:KQ5+F:52Z.\.]0@YFHUS<:<N6:7)7V]8N-/9A\G]2<JN&7(R.
MX_\ 9?\ %RG<>XS;6M=@Z2XD1FPXYY<*GM[7]9@YO<#O<3_3M'D+Y>H>?I$,
MTK>K+51XZ/;PTW9K#.[EG[&Y;-&_EQP[(7D)1JEP)U'N>Z:-G-7\&MX<]#-G
M]%E=C(VO:_'3EOI+>.O:\,LPEZFP85/;<-8=VR*=DCHV:D:HC7X=M)0U@=RB
MQXD"*K52[7G<3NGZ$Y2;%X1K:[[/CDILK6U&UUR$6Y!PLWN6LU;>EM9T;0NX
MMN\= UK%150UOLRPRU:4.-;W3=[74(*WUN6G:\*IIF/BNH[+[9K?%=K7.#;V
MM^ 2U]X[=GAOG;^G.1.RIWDY5Z'9+#%Z7>5MS=+-H?7ZVL)X;]+0-1GC66?K
M=QLVMXML[(PJU>M]KFW,H2$Z_4>S>Y^6?0G&7L[-\WCBNYX/\8[UH5PZV]KZ
M4VBIR&W[IGB;<*[=-$:KL^G)NBQNN-7S,N_I%!8;4O<5MV_)/6E9?N:U66SR
MQ$/#UKD^S'VT[X2]KCQE;7O7(6_M!M]\T=MZRG5E+0G6Z;%<E("M154C;XH6
M 6E$Y*#<PCA2Q&KL;.-"(K(C&*R!^^F4BF?@IEG8H6(GH_QHL)J,CY9D*R?B
MEA9R;-!\U%5+J;Q:HMW"8J)]XW</WB=XW3J/ULZQ2H-Q6:?5JZ[61<.H&MP,
M*Y7;>,]CK+Q42SCUE4/&E(IXE15L<Z7C"$/XLQ>^4INH!V?")C&,(F,8PB8Q
MC")C&,(F,8PB8QC"+@WH'XA^S-4%X2%ZZ7FK\NT/^&#2F;7TWH'XA^S-4%X2
M%ZZ7FK\NT/\ A@TIA%G=^#<>I+X%?,#87WZ[5R</(//!N/4E\"OF!L+[]=JY
M.'A$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81,8QA$
MQC&$3&,81,8QA$QC&$3&,81,8QA$QC&$3/1",CBR*DP5BS"559)1RLD#5N$@
MHP075<HLE'H)^RCM$7"ZRZ34RPH)K+*JD3*HH<QO>QA$QC&$3&,81,8QA$QC
M&$3&,81,8QA$QC&$3&,81,8QA$QC&$3&,81<&] _$/V9J@O"0O72\U?EVA_P
MP:4S:^F] _$/V9J@O"0O72\U?EVA_P ,&E,(L[OP;CU)? KY@;"^_7:N3AY!
MYX-QZDO@5\P-A??KM7)P\(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")
MC&,(F,8PB8QC")C&,(F,8PB8QC")C&<=0_J'^N$7.,XZ_'_H/_CS_P"6<]0
M.H^8/^/F^W">WO\ [_WL?ZIC " ^@0'XO/C")C&,(F,8PB8QC")C&,(F,8PB
M8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PBX-Z!^(?LS5!>$A>NEY
MJ_+M#_A@TIFU]-Z!^(?LS5!>$A>NEYJ_+M#_ (8-*819W?@W'J2^!7S V%]^
MNU<G#R#SP;CU)? KY@;"^_7:N3AX1,8QA$QC&$3&,81,8QA$QC&$3&,81,8Q
MA$QC&$3&,81,8QA$QC&$3&,81,9XG.4A3'.8"D* F,8P@4I2E 1,8QA$
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M,1)(AU3D(;VW3ENR;+NW:R39JU15<.7"ZA4D4$$"&56654.(%3223*910YA
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M_P!S=]_\N.Y?^VRY!X7^$G^ G_0&3AUW^YN^_P#EQW+_ -MER#PO\)/\!/\
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M2,.+VRNZ#984.'<K<V)L\N/RC+@A=-' )#<I000M=-*1'$PR4W!SW; &R 2
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MY7R0LD:TR!T!?$ &R0N.I""9-,<]K>XU?QC&: MD3&,815HX^60*SMFJKJF
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M8:T'SY  /G6_('UT-_\ (?DF,8SPOTF,8PB9QOF,"T<?:-9TRD/(ZLO$K3)
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MQA$QC&$3&,81,8QA$QC&$3&,81<&] _$/V9J@O"0O72\U?EVA_PP:4S:^F]
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M)C&,(F,8PB8QC")C&,(F,8PB8QC")C&,(F,8PB8QC")T#^@9^9TDU $JA"J
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$($7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g21422bgi001.gif
<DESCRIPTION>G21422BGI001.GIF
<TEXT>
begin 644 g21422bgi001.gif
M1TE&.#=AIP.Y!'<  "'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "P
M    IP.Y!(?___\A&2'W__?W[];W___W_^_F]_?F__?W[^_W[\7.[_=:<YSW
M[^;>[_?W_]Z]UN_WYK528X2]YO=CA+5CE,6,O>8A$"GFUK64:U)",4JMA%JM
MUN9:.DJ48T)SE+U":Y2MA&O.K82MK:W%E'/F[^9"*1G.YO?WWL4Q0FOFSIS6
MUL[6M82,O=920F/.Q;U:8V-K2CJM:TJMUO=:4G/.G'-2<ZWFO8Q[.D)[O>;W
MUJVUE(QCA*646E)S6F,A$$*4SN9C,4*,M=:MQ=YC2E)28Y3%C%J,2D+FULXI
M(1GFYO="8X1"2DJUE'-S2BGFO9R,G+U"4GL9*4IC*2&<:V-[6E*]ULYC(4(A
M(4(Q4GM:G-9S2DI"WHS6YN80WHQ"&1G.UN;.G(0A.FN,K<5*E)1:.B&$6N89
M6AF$&;5SM=ZE<VLI(6M"*2D9G(RMK;TI*4HI$!ES:WN$M8Q*.BG>O8SFYL6E
MSN;%6JU[YHS.&>:48RG%WI2<O=8A.E+%8R&$6JUSI<52YM8A(2F40B$0&6O>
MO9R$E*7FUJ4Q8Y1*E-:,C'O>K6L9[]9*(6LQ&4+%G.924F.UQ;U*A+W>*7N$
M&>9SI=:$:V,I:[496G,Q&2G.YLYCE+5K.B%S2FMC6E+%O9Q"0G/WUIQK.C'%
M:W,9$-[%:TI[6CJ,WL5:K=[.Q=Z,G-[FSJW6G'-*:\YC$!E"4FLA*3$A*1D9
M0IPAC+U[&7NEUN^]M6-S8QGW*8SW*2E*$-[.$$+.$!"4&1FUK91KC(1"2IP9
M:^890MZ,G!F,WADZWADZG!ECG!ECWAD0WAD0G!FUC"&]6N:]&;7>O2&UO2'6
MM93WC(SWC"GWWM[WUCJ,G$J4(4(9$*5*&:6M$'O6C"$9E.;>YF.UYF.,WDI*
M0M[.0D(ZWDHZG$K.0A 9O>]CG$ICWDH0WDH0G$H9O<5"6AG%YN;>[R&U[R'>
M6N;>&;7WQ9098YRM0GN,WN\96DKW_\[WC-[W*=[6G+U:M<4($! ($$HA(1GW
M_UH($"DA" @A""$(_P !"!Q(L*#!@P@3*ES(L*'#AQ C2IQ(L:+%BQ@S:MS(
ML:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-FSASZMS)LZ?/GT"#"AU*
MM*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:MW*M:O7KV##BAU+MJS9LVC3JEW+
MMJW;MW#CRIU+MZ[=NWCSZMW+MZ_?OX #"QY,N+#APX@3*U[,N+'CQY C2YY,
MN;+ERY@S:][,N;/GSZ!#BQY-NK3ITZA3JU[-NK7KU[!CRYY-N[;MV[ASZ][-
MN[?OW\"#"Q].O+CQX\B3*U_.O+GSY]"C2Y].O;KUZ]BS:]_.O;OW[^##B_\?
M3[Z\^?/HTZM?S[Z]^_?PX\N?3[^^_?OX\^O?S[^___\ !BC@@ 06:."!"":H
MX((,-NC@@Q!&*.&$%%9HX8489JCAAAQVZ.&'((8HXH@DEFCBB2BFJ.**++;H
MXHLPQBCCC#36:..-..:HXXX\]NCCCT &*>201!9IY)%()JGDDDPVZ>234$8I
MY9145FGEE5AFJ>667';IY9=@ABGFF&26:>:9:*:IYIILMNGFFW#&*>><=-9I
MYYUXYJGGGGSVZ>>?@ 8JZ*"$%FKHH8@FJNBBC#;JZ*.01BKII)16:NFEF&:J
MZ::<=NKIIZ"&*NJHI)9JZJFHIJKJJJRVZNJKL,;_*NNLM-9JZZVXYJKKKKSV
MZNNOP 8K[+#$%FOLL<@FJ^RRS#;K[+/01BOMM-16:^VUV&:K[;;<=NOMM^"&
M*^ZXY)9K[KGHIJONNNRVZ^Z[\,8K[[STUFOOO?CFJ^^^_/;K[[\ !RSPP 07
M;/#!"">L\,(,-^SPPQ!'+/'$%%=L\<489ZSQQAQW[/''((<L\L@DEVSRR2BG
MK/+*++?L\LLPQRSSS#37;//-..>L\\X\]^SSST '+?301!=M]-%()ZWTTDPW
M[?334$<M]=145VWUU5AGK?767'?M]==@ARWVV&27;?;9:*>M]MILM^WVVW#'
M+??<=-=M]]UXYZWWWGSW_^WWWX '+OC@A!=N^.&()Z[XXHPW[OCCD$<N^>24
M5V[YY9AGKOGFG'?N^>>@AR[ZZ*27;OKIJ*>N^NJLM^[ZZ[#'+OOLM-=N^^VX
MYZ[[[KSW[OOOP <O_/#$%V_\\<@GK_SRS#?O_//01R_]]-17;_WUV&>O_?;<
M=^_]]^"'+_[XY)=O_OGHIZ_^^NRW[_[[\,<O__STUV___?CGK__^_/?O__\
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MFO2D*$VI2E?*TI:Z]*4P=6 ^ O&&0.S# ON@J4UQJM.;!J*#!4B!%&[*AQ_
M):=(3:I-E;J/G'KP FEX@1S<8%2W(. -.:UI4WFJ59PB%1,@+( -W("#MQ"
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MY363>?_*24" E,D,B2\D 2%!YK$Z[DP0-]_8SEJ>\YO9[-DSOYC( S&T"*J
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MM0.]-Y'B):LV-7V4R(_[QZ)[\&1+N7#%QX;ON70_1X25QU,HL*1#&GP_2YI
M-UH:J*&'IX'&2:56.A"?V%1A4 $#0 .F%P@^$(X+<0%C6H+K2G@].5I+L("D
M>'B?4 IR"P-8>ZRMX+6K6FN_AE-CVZLV]0J\UI4D^*F>T*C8MYF]P'Y1^FP[
M-6WT$ .CI0:;JFX_UFE-N(,]V+DY!:J==@$@<+%LU0_IQJJK8&[[X 8T2X;P
M>%<W^Y8@Z@0_N 1PL(Y+5@B69K.^E:5]]W<"8;LVQ0?,AW;0R).RZ89+Y91^
MR*R$Z LDJ0.\.V,367Y.FH?I-X;@&H9J6YEC_V=3B^A\ZMJZ%+"J"" -, L
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M!T4\ &"P"6'XM6MX@01[I;\IOKSJH!M9565K;F7G 0.0=@,WC&4;P%!'"0A
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MI C$C1<6" (KFI:S(!_F K$ "R% HJ&$'G\4(P48\EFB$!U*P82//PH@I(E
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MQ%"=J:8(1!#!DRNSW+((*=Q(C%",E3"8UMQ$@%6).BY+ PDL_UCP<+1 M"0
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M-!?H!2\9M^O3M@B0FQ[ */_. 1A  GA SH<&B#>63  H2*\#IGU7*!PH6+#
M'#G[]@7"4H> 0X<%BLA1LP<C!(03WUC (J9!1H<).B )-+$D"Y0 3I2J2"NE
M*A@5U=&0X^./3(TTR P*LA)3F(\I'PZ-$@3CPU4^_S0$4&!HH$ 6]FWM9[&
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M7S@8$M144(@*$N0/N/2$1V"$#27$1/R&7CU K,"%(T*BE3U$<F0%IU!$@Q!
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M2F4 D B'!H/$#?P2Q/*!&*A "&0 Q*P$#ED()C1LUV'3BPIZX[A!(;2! J1
M"R 731A'R$8"'70 8DM:J82L&V1?"'" HT3*)VC5'+2 )JA #'QCL:Q!#B]%
M#@P!:H0$6NPT%(@!"6A :)X,![P6J9,M?E."4ZN !CQWI'4 ?WP!IPD+IGQ"
M$ S J4LV#]0 \6D U/I*)-PV"+0 4)SZ!$RV&\#![ H'IB 2"1 "#"Q %13_
MP25!YL[,P0R(0?$A;7A@0"/L0"883!@\029@ (8.0 P\9@%LNR8$R1!X@ K$
M,4$8[0YX0@\HUF9$  <=R0"0@DB'1PQDP-N!ALU>Q<'O(!4L@ D47P:(>Q6
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M5F'VJ*#1",U DR=1IE2YDF5+ER]AQI0Y\R2$&UD("(00*A(! @F,]$S!H22
M GTL-<A9\P:%G#8I)+$9J?\!  A!&[S+4"&G(2!.WQ$M , !*4MZ0B45J-7#
M@0)'4!&X2F$.HQ]/C7Q0<#5I : U%(!J\2=G 5(?>@W.>4*+IJHH"PR=4%7:
MEP(%BD!YD&)P$J.9:1GJI.D @ $BA%S@$:$4E#H"_RH 0(_' @4IAK3]'$$$
MAAT*<@SY4Q4"#\ YJ'BHZJ!(!$@=/IA@B5MW 1I0]C")(&0IR@0QB#P L*+%
MDP/?/XA/T6F"6QH1*B28LL/$"1X[JI[><R'-@B^F^^NMAO^D006![E(:H+__
M (R %K) </"$2N@SBH896%#0-=-<@,2S!-*(X($$0)A!O + >(2%"^:3S3HX
MQ)C_8@$)3!.%"!I7Z"$( @8 88$V9)1M !?:\*22\$Q#Y3&6$$BAAR<:Z-$5
MCAP88081IHB 1@0($6/)E0:PL@(+9Q"C/^D*F*,'2C)J84P0B9 - $*HR*(
M)MPTBI >_BA@!4XH*6!/2E)"X((VJK*NA1\0H.$3%@1:STX:EA@3@!2HH&"
M*7ZAL0!5[NN%$T9#R*"D D(8 @< 5*F31!1>0T %+E0JP 8I]@DDUU=J> !5
MHG)"X A$ 4!@!>% @(+& 6APTT\W&_U$!H$,Z2 23TK)@E4><$KITQLFDFD
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MB0<4^62/I129X0<G6MC1)* P">00\2BZ3[:RTE.DA<0%REP$*B;@@CPQ<AI
M@QV^&&J)IZ%&H9#[I*O5AM 35?]3#.WP3BF'3ER!(Y%*Y*C!! 6MQYB3X:R;
M00@09WQG!@I*&VCQ&4V+80%U:"!#<@^^0# E\&DT38,%3@0!CCH,,<(-IU\
M Q3\P0%I@$/]9*4#ZB$!"S\8@"C0=ZGMU>M_A.. &PJ1"!-!" Z^6@$<"%5
M.(B@$HT3B* V\0H^%$(=\E-)#GK@%&;-X#4H>D0&\3.3 3"!AD8)00_B@('_
MO: 3G7##9"[$D00(\1%$Y$ &)C  ,,#!8ZJH1 T.P*(:D$ ',_!82HZ@@T3(
M 0DH0 ,"0L")@FD113T$@!8S@0$LZ@L#"TC$J :01HX(JA.!4@4&(O&I4EB
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M%M.U]/WQGW^3V(0P.FE*3NAAH0B 'LB,%FS%"GK"<?+@='0'$Z)B+@!PH1H
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M @)!+ZRB TJ@'UQ!#FJG5D* # +A#?A@U00E%-Q "F, "2R 5Q@D.3%A']S
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M.T@S/AN@ ,[O!=; !]# +D_FN-7B),*5-%_U1%; 2?L!"_30_^# 296;.&X
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M)N4N^%7#0.=S^,/*!$#$MF # QK!,5;I-WKD$7KQ^*GBF0G@.[% !AYG :H
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M]-7#NB[-\$/%,8$@1QA!G-"#!ZI4(E[-,U3@$75RGD"%58LJ,L,>!2@2@:U
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M("$XD 6?6"J&3#D"!PN0 @[@PR>&N$$6XL*(*MG0$IW#H1P0L:@5,*)":>H
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M& .P)H&UM>O,SGG2-D>E I02HE*Q)P/ !5XK$O0\)VV3:9.&SSXA#6#3)UR
M"AJW3 ']S[I2T'XD#9G@M07@1@I*#WZ@J(:!"O@\ ,A"PP(=FP6@H'YD+%.&
M)RI5 ^H@#?]LSPEM)VWS-O5\T7M2 .WRT!E]5"==1/Q\(!^]*.^2*0&M;#RM
M*R>-)PB@ U@[)PB ;2G=1P34TJ]:!P%]_R<031A,T=#X+-5O"%LHS05FIR<(
M,-4@#=76 ]2+XD98#4;*UC8ZK2+W7%U<O:!N,\>3<BV33#D%I&P>G2G'4M,J
M;3UR_4=('=7'HLYYHM=Z<@0+72<#D D@"A2%72<(L-AT$M,M/<^J-@MJV,Z9
MK=F;W4<Y( =*=S54HH'^S-EI9!&EC=I[\KVIS=JMW3V%\*)9VSI][-JU;=M\
MDAU(*")I0).W[=N_+4BH%&+ 3=S%'=4VT$L6X /'E('OJ=:;C;C&G=KP!EK2
M;=UG5@#1O;6O2I+7[=VIO2!8' C7\=WE;=[GC=ZES=)8G=[M[=[O#=_Q+=^V
M/0 J\-7SC=_YK?_?^\W?_>W?_PW@ 2[@ T[@!6[@!X[@":[@"\[@#>[@#P[A
M$2[A$T[A%6[A%X[A&:[A&\[A'>[A'P[B(?Y'\Z/2,>W6UST #?#<F8T )[WB
M(F[AD_WB,$[C-=[@IFDM..Z&J'>9.#[C?'("H6"%K:W+2, F(>H4#BPUQFU5
MK?L*((&B=-A'$$!X?%TG^Y&VMP%2': &,*C:A,?89N82)2 H99X/RZT",4 $
M]UO; ^ ":@$1L0U(O.,![*TG#S$#Y3/2IZ4K?(XG)S 0?-!JFGT2B/=T?YIX
M0WT!0I $=)KHLCD<_AI( P"5$9N!R'&7ESX'K? L?/(@X3<Z['>L((#_1B.4
M#X+2MH'08Y(=0MF,@.&=OK&M8FCD9/MPZN0<"$G+@0@01\,MXH(F0<#^T9K"
M*=QGYWNBG,>^M:CT"6)PX@7#!X5@2#FL>L6M"&0L!"[0"Z' LD7P"^GWY0K5
M1RY!4%^@TTX  ZDKTBNM ^64@3'M"9"@<F(7; XA-K_M<@/P#$\0YH*4=(,-
M2"<!!UI^)U#7Y[ :U:W%9%:>M0Y)=)GB=9:.)PC27 -$KYF=&X8N2$Y0"-V-
M9M\AZFA&41; !_RG)RIAG,XL)_2!"7R4 HS%6*50*&^(9/^)CZ*M8@;J"0AK
M&"#0\OF5 S"?""MWS!S8ZQ_NU0H* 9L00Z%4_T2O4NPQ--;'0=ET(@WP KB
M?2#2H-,(,-8%4/6+D@3:C5= #4R=CAO&^P/8YA*)8JM3?QR(F]UJ[?77HO5B
M_=P#\-RH0F97$T04=:=X/\=C7T:/&-5WCTJ2.E&DH 08,*CG1/B=^>)>_^,^
M,?98#7*&\1'NHM8>3?9U;SV7+R>B+_A1O0I8>B!WWYEP/R=.8#$*2ODJXO4K
MS03E"/>Q;T6_,XB@,MMES_:;\P=T@OL[/?797?RJO_K8YO4C),1L":NL+]FM
M16F !P"=CP ,+_RW[_7MLY;&?TZXC_RC_]/(G]W_;/QQ>=2L/_RXL1\?P$$
MC]0%D/JP/YDF/T"Z_/\*8*ML!0.W1SU&Y0,0$(S( J#*RBD  %)809,P1:E
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M@ J.RHL7&S K-_YG!H^B015)L (88$%)'J$6=E+  R7LH9 [X(+NEC2"#,Q
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M0 M+> 36.8""&1>981?0 17D@(E#6/\P#:\'@*;AT(DEN*(3+WC^$Z(HY*B
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M93O1(ZL\J1!$X*&%9A,)H?J#C=$5L<7#2UND 1 !(2BV1&E;<),GHU(=5G
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MN)[K?C O@<@"O/C4!#[(W3*">'7LB=&[ ^FEOC8OPT.\&% \CGBE;6F1#B&
M.8 !N'#6OKXN!%D#PKX*[>B:Y'([V<" U)8.TILSX3C6M>& 0J""UYO/Y4)
MUZN0$TB#'+$+K% =WG"%(2B/TA8+O9%,!$E+#NM7T?]4$F@>:RS0OGY=DM^3
M%"J()"V1@ST)!,U,/^WV3=H.!.;KURCQ 3B @QW;EOI0&W&Q@/%0#V'!/8^0
MLB<@ 2D*CO_SB@0 D#BYKF6#ZP%X8D'[/W#YC_*V,@(H60"0!K$V%K?4V#S9
M%@O87TW;S5PJVD]ABD (9VV)DP_8M28Y*6DM6B;IAS58@HIM%C 8@C3I\$HC
M' Z ZXJX  WX%74@,R/LYI=Q%B*Q@"6P244! 36QNAZ8EO;49H10&D%YA$<
M%TB!@7PHE8]LVZ)A#R3 "45KPWLK!3YY@2' !WBAVKT5B3FPE(NQ3*$1E"6
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M(8()YD<&#B[@"^&QH!LFP 4FG+"#'_1-1+X  BD$P@(U*,[?TM )#N1/"74
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M+D%'_W1B*EE@&"N\P MAH,7!O/!*]OTM#Q9XY -4 =)^*,5,4G*%%Z,(%D-
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MP$%5Y41-4 4 K,"6S9<K4$7#\=F>$,(+4$*K=-;_GJ!"YJ3!!.Z))Z#+ (Q
M"V1$JHP' / 'OE $)!Q23=Q$"O0 Z35&?_181D!(#[# P43 !P&9V2!+?RU%
MQ$Q8,37>>KAA,;6 7JQ')_Q!+S1;,0T; OA%_T7('B  )CJ3Q7F #MQ' N@
M$8B %HS8# 0, !@"#U! &KUB+&I"Q(3(.94.!T!%SGD $]C2GJP !^"#0C#!
M)U@+GGS%ZO3,7:0 !G!.(.1. >Q,O-$ "KPB!/ ,A##"*^9 (:B#RL"!%D!5
M8/#B/ZT) JP"-@[$SM2 Z.% K?73GJ17/-[7QPE'#%B"8.S<GB@"'V0$ J@
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MBO\). $,+$%IFB4*]$ +!-\1[@#1!,M-S $GB,%:7.$9\8@-/""W&9(---]
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M,P++!;B/R%1$)-!!R-Q(=/R".C#!6+T%4@3"*R & M@ $#2((<B5YHB,P6@
M%G@"5@P *5@J+!I!/!9!G/IE^OS"J1))4ZC- E0ACYQ 'D2"=ZUJJL9"DNP)
MT!1%JGX"$P2"*ZBI'(PJA2C&CG@&(FP-)LS LHJ,TVR-&IP/!%1#2J[DMZ+$
M^7U I6:"6N9!#>2D?]CDW56&L:7=K?SD#606JMB=O*"):5@&O<H"IYY6S=7<
M'@AKY4769Q!  G@,6"06\T F_\)B5PB<EAAX0AM 0AL< *.$1@&H  AT*!9
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M@2L40O\O &$%Q :"DL04S4 <[.%K?!D<W%*:40"+P4' & (50 '$5NT>@"@
MD"X5G.X?:$Q[>6[C"D64AH"@!<8>\EP(R,$2[(#MN@(+="\=GB\"@(&P!&(+
M8@ 4% (DK&P;Z(ZSEL(2_&4GM, 2#&F!^.<S4 $EZ.C_4@%8-ALB;2(A; (*
M^(((3,$2H(&PC>(0H $$3$$-> (GT(+%G0*+? )J>0+7MEN+U%P(0X(0&,+&
ME(Z$<.HPW2<,:((&C"K$R.M#A,SYL BCEHQ1$$(A&."I9< /' '/D(#IG<\
M:, 'J$,1_,*#!H8<D-+#V9M* 4 .K(EW->OTS*J.('$3M^/_#>#  !0!"A1"
M"8N $,P,E,!%)1A0) CK !P)"<CP+8EQLQ+$DNQ([\6"!O!!&5.M$'Q'U_VD
M($2" ZQ"(85P&[0!("N-&+O=WX2"MX+K)'<$1\* +(S&$J DY4U)5]YD3B[%
M.Q#=[N0)4%+N39:+?)%&Q:(&PA(R[&5 0Q7 ,Z365!(LY1%L:[PF(3> *#=4
M#N3)') 6A=!RYGP&;EQ +>\D(X@ #+B&* ?G"33!]M2&X,&F KS#Z('%?HC!
M"F1 $/C$"6B!S&YD"\" )<R?!*UN\M37-A?!S98"I9P =VG7\PG?.,L+ 1;'
M:'R $(!" /*>"[2!"81&"G2")MP(_R$,]' <$BDH<:G4WZ;5)JND 7%\&*8(
M= B47_6E+=/.+*ZY&A6P'PU,%\<406F.F:LM8/^I"GD@H"'TP >ZVI$IQ$A(
MP':PX'= 1"'.['-*!P\F<XQ +@"<@ @\KT%/@ OXZ6?F9\$4P BLR@5\[0"F
M@5TQ 8)"+K6]0'_&!!. -+4%@195"U$[J#2)P!<,P!D/!.+N0"9, 1&<SP6<
M=1I-1+#,*!B&AB%<L-]D858,R(.(&([.P'ZBZ)F*+O2JM<&T(3Y27LA( !P&
MC).B 60+XQ#\ <!4A:WTZ ?4-0U < & 0;.QC!:$L0YP0 1@G,4%4RW=DC3T
M0M*5FL'H /\*4P&;0"(ZW1=+5)0F .-$[.*5T$0PLNHR;DRG>?.$6 4'_$"C
MXB@6W!(SZL0\)H\6!('HQ5T'I D G%P!N%86R*.U5,065\!W[TEHCO<Z'L@
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M#:\80@%V<",UOM!8G[T]-!P 8P9:LGM&"S02 *$$HA[9#  GFK#@(#@ZH:
M,#@QL*/#$A0O!B@DT&Z(]Q ((;Y]W&"!+@16V$2Y%0F "K '5FCA!Q=QS,X)
M+4XYK!0+W'@!AE.J0F .&.<C@( +>(@DOXXN_RAHGS<F0FI!3*"P,3X+4'@M
MN^V40R$K&SAH[C$4?C"S.0!4N<'( I(,I!\9"0&BN<-@?,45&'!@:*E WK@"
MOQ2 ^-,J#=Z0#XO5.AJ@"$Q0>""%37KC@Y(H&7K'"C@:Y".(X)H0](HLHBQ
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M$A;"BG(I*<)B4<(@")3""GPA/B9-GO1* >,D!:S@%";0%QKD%=K)]ZHD#,2
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MB$[ _XXP R(@$0ZQ6X:)>EZ!JAB".H#/:5P043P",_M) ]R@ E*@%;Y*!8K
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M%* \H?,&\,-JE4?L,"$T=I4,8N$!6&(-Y/^.%2VKO'PV[U"@"C0@/GMEG:#
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M6DI27A=8""%,:4(EF =T5$&)D86J$R%'%V(.9D ,U!H:'Z4L7.&HW0X %&&
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MGQA4LXT):$&!0PE@0+)+%K8:B 4OP$!!GG)8L \?05@X'4L1*<1#V [$$"<
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M%&"2#!2XA"A*"H' G07"H!$B?2<\ (*@ VB@+"*%8'N!0('+2J6%"3CI0B&
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MS6XFX M>>U(27E: \9EK *C YM=0T<QTH=,UZ%1G 53 A78BY)OVS&8!UC4
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MF-3[SNC;XA:W $6PHW&7R]SF.O>YGF5))+[@7-$:=J?0S:YVM[NN<7+W?#3
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M@HT* I5BEA7 _WB"4F!B#3\F*2EV5EZ=$A6[TRE ?VL:Z//N6C4%@(#2<HH
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M0VLF12?0!.EJ@$HS+?&S#XF!4B>@!2] !OI@%+<C<B20N]&3 TTXCTZS#U>
M=P\R=UCZ@"3S<PNAQ)BP-TSS-B72EU$PA2^#Q"W7AQ# "5>G2;C<,2(<"$O
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MY$2C)Y4^ 02/@ FND @#AR'"P^U",  Z  0O@ E00)>O'TQF\D)KTWO\TBK
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MV<KA#P3?A=HT2! #BY "BC)00% DXQP.F@B :D')K U&/W8#2& D4HH6$QI
M,/(!*5/T5XRK(X6"!0*!%,C_,3N'404'_S%<[4$@A.KHB.$3%@8((8,@$N@@
M N;F &("%3IHQ ,2YB@/.1YV^*((5_Z@*4/+DG/P+!@DI+"0+U8 (A+D-(A@
MCP% D".2+YA*0 ,HQ+@ @T8X](0##HOX!#A"AIA@/8,&V!"I!#!8(!,?.9QC
MB!T4F/&1 VF0XP-U:&C!2"NQC,$-.,3PI(<%'LA1B3;26. +!T!X1 PZ0I#C
M$B%BR*"&3 CIA,,"P/2@@12H\)-.,4C@\H,'F*HK@S%0J86,, J1$@H6YFQA
M/E5*6?.$*78P 0!5>BAT20TR.)/20!50A8H%(,$@-P!RZ,$\&CHIE! J(GC
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M: $ P9/L%,$U.;-">:52BI7<$-A#&/_.'"B%*ZA,2)G!1U'9EYT9'FA!5>B
M*-A-,"&7CB)03_K#&2DF)GB$0NF1&1C.3L*U1ZG.)/F.'*B$C4603;B$/9@#
M.U* AWF(C:(/&+@$,9P!O5J%$<4C#'@%(A!*BA"E+] 6?(I#/%I/>_$52ABF
M(7 1")B:"V73#$#<O=T &AC&1S)$&:"/(6!*>BF<7\.,0_&3$("!-+N 3P+4
M<LN99&D!TSH++4"#=_ <!1#0WG,(#,#&@[A5VX#%@E"J/_"$5%2JAG ":#44
M(T !,9@::B*$)N #RKW77FS>QMH$-RBJ%*@XG<42$." YDD(I&6"#* $".B
MH4$ EZL E\/_&X10QXLCH6=H C?0QG9$F3KPI$_ F[C ",9B"D,HA;CT!",(
MG74,G^C B(A2B:BSQ]Z:"@@H!2BH IC)'8LR!"E '#-*/:1X!SU]C/ !C$.8
MEN=!!2:"!\95A#5HJ1/..[8 U1O&X=B" +["K5! +O\YO,#"CT$IM7T(@PI
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M"@X&$D:M",QAQ0MKH, Q3DY _[M>%W3P2T<%V #$>A\9(H7K;L2A7@$I@ ^
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MT(@=@!(&$0K4)_ZPNB&P<B3\NU\A5%60=;5 EX3@9>**0,H&A( #?S@"!MP
M!S%D@@G%W&6C!N@*6$YA!D)(7R=J8 +YN&$!;:A7KZ3&B?\_N.8C17C$U0@1
MSB\D  3P_(*/;#"#/ZPK A4PF 9F606$A<$#F<  K1R0!B)$C 8M0),\)Y L
M<1D,!.(ZP10<UK ]M&1=C]D/L-22 @S\:3B=T,075$$%(DB@,1F(@!A<X#$Q
M)&$U2GB 2R.@@ MD5!TAZ(14@..PKLV@8'&; 2WB!M1,Z&!HPQF"5 BQTDPP
M[84T>$2/Z)*#2M2   Y@@A74LAHH4.:8M-0-2V7BK+ ^X )IT!D"P+ &*(@
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M$=3 ,6-/[R!8$'1-2(&)5T!!# I!R8L   $M:"*Z/]@+)S4ADB%BF2+SIQ,
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M!4 <9"" "NC '"(!%E3  .@ '%R7R,%!);B!*_1 )W0"(9$ SA5,7!65:+P
M)0S *V(47WT$Y[R"&^R .NS@0OCA!'@5#0R-181 #ZC<%,P90P C8!65="PC
M"=R5OU$C3X69=&  7X4 )RS;1ZC4C4P'-@H>:RC70JR&WG'C/TF<%M2B!DSB
M"SAA(XSC1Q#'=(E=1VR=KKA"/';"$F"!!KP")3KA$IS>V<D6;1U3TZF"$9R"
M-&C Z:G&#2!>1=@)]ZP*1"I =]U8Z*@"!Y!8)1W" 502]\R6]7F$Z_\1P'=(
M'OCH%A"XS_I4VPT@0I=IR04T 2*\QP7<@!XQ0APPP@8402P<@"&$%PO1QW^L
MBB#D),;,AT(DY93)PBI80"J^P".002PH # .'U=V)1QE7D'D""OL1.<91/,%
MF9(<CR*H'D4H0B,4@@BT05TY@CGNQ"<4C$4TGT9@8 $PQ04D@J0<@@G 7QBE
MQ I$UEX0Y@Y1F9#!WYZUT0Z(@&1" L"=  >( 0CL' U(ET&LPB<(P1S\D54T
MB1M$0"'T0BAT4:"@%JDM8%+<!;9PDJN-62N58-2L)0/"9H_!5Q%H% _DHD9D
M"5?X@AB$6QM PF94Q 7H0 N>P&_V @<L0%S_AALD<$$*<,(3(.$4I-.S2><Y
MM8&X.0NR51(JGJ9VT0)4I)/\5<("],(C:$IHE*'F> \G1*&LL:%!R$T3;E^W
M! &K0)J>P($'I A>@.+ 2( J3!H@OMO#+>)U'8&_K$$81"#&@$!:18;&^$0!
MC,#0 (<2U)4(A-L7'$Q:Q8T<N,)I5H(K&)'&C&$*]  <=,*'QN6I<0$FEDS$
MH2'%"8T,G$ EN-H#]8*B\,&6R80JA"'7\*A%K  GH $NMAO&X!S>+6,!U (G
M$ D,(9N\Y*+@2:/0>"-.(!T!B*--+N,!6(9*T5P(X(UH:,$IG( &H(!D4N=@
M$58+_),T@,!% @?7_V$ "A0")$CF<?JI9,8E)"#9!?  !N4."SP#!YQD"MS
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MX/$ 2VV>'-1Q8UA!#"8J$?C4(Z#)='A3S>E2",! W,V!.U,5P602'C8 <-2
M"_]DU,Y$% %L8OBB1QBF"(=*'1CT0'@4EDJ@E0(<@0ZLA6#$308DG%M%@ PX
MP%T1R>I2QC)3]!1  :T5(Z:%:38OLTJXE2LT]?+^)E-UHT4X@1:L1PJTLIB
MP,DY!W&H2F/HE)X870HTP9P%#2.XSUXI0#V!A^ 900VHP][M@:-V;J0>3^1\
M0!4\0Q.X@?\2CA9(A4M55G=]J@1:SP:" ".<) S-#%YNB7FT77A8#U=; >7%
MY$WJT)Y@P2P;02#HZC>6D#R47"!<Y*RRT"^HP_O F)*0=J82\5JP'APMY918
ME[&M@0YA:P__-H)PZQO;EYX808DPRE<HPAI$@0A8 13_%4D'E,B))$5Y=$@@
MT&Y%R,AQN]I!<,1[P-"VO,&$J@8,!$D$  &20  &7 F&)%G#.D"@H>2=W00$
MQ$"U] /M3DD1+T1YM VZX*I]6T 46$R@ ,DK1(!V^80-R($/Q('%8H1Z5XL%
M,"-4B. ,CHM!. $,2(O*V'<_H,OW>82&7\&HB!.777B,D4F)9&%+%&*'2%"8
MI#B+] .AQ5BK! )RVQN^8:0%6@"UB5<I^$ A)((A^C@5O.RCT2P]:-9N,FO,
MV$[4:#-^K@O#4<0*\!9[WN'59-(,J)Q%^41C^(PX30@&A$PJ?E1C11"C0#-\
M.4:E]).&0F*,(<RY?,(_55SN_UYYD$!!);SGNF3 R>B,P3S+N:! !,)IV P@
M'.S,=%A !"1"TPQ&+83*SQ1WAUS!G(D&%= C0^A&F.'N,?8 @(@.TKR"$C@?
M_G*Z08"!',@!)E@ %-PYSG7N\5*AWIC-R!QC\+:$G;"?$>M-D!AZ!&L K-\-
MB6WO\3A/$WPX\(0.D_Y38RCOV8F&I)@(VW%.^6A.);T""JA#=P6!_2[OI2YO
M*6 .',@!IN($YY0("@1!5GL74ZA/]%#,SQ6 ?42"]6;J?*2/!6>P>&%P3.:J
M=!B!V32(;,]V+#C?.UB!?5U>>!D;)JA!'"2K_,$P2:Q"Q%/0?:S*)NA/@JFY
M P&WR/_W\!%P@648AC3@$T64/)3N!Y(5R !PP<LOA -PP8"LRLR+4,R/![/E
M_'YP@54,P!>\D7A@#- C2-'_/&C4!,@9?<LSA#2H0&V2RT/$!RHL?61<_5[D
MA\&@PM,WQM@R!JZ,_& </4Y(@UM\1,H__8$4@ K<O 2J0 .\Q<$L.MIOO<U7
M!-K/Q5B4_<W?2CL5P#U +0AI(L^3"PU<J=#[]F"4?($ Q4T@0,HOQ^$W/MPC
MB"::_$>4?'94OD4<V6O.P1 H=FBD/..3B\__NP$'7P+,_![IO.?'!]MS/MG7
MONW?/N[GON[#1U_N_N.CT#J=?NWWON_+!L3MC.WG0"*0OE?_/J/S%C_T&\@@
M\1>KQ)VV#H!,7>3P>0_=/1=51S_XA[_XCS_YE[_Y%TDIN,S4GS_[DRC-LC\(
M%37\S_^J%($%L/OS!]_FF4C^7]@ % % O-EG <4>  <1)E2XD&%#AP\A1I0X
MD6)%BQ<Q9M2XD6-'CQ]!AA0Y,F(!:5\(D%2YDF5+ER]AQI3I<( *+C,1<&D
M<P 75"EG!A4ZE&A1HT>1)E6ZE&E3IT^A1I4ZE6I5JU>Q9M6ZE6M7KU_!AA4[
MEFQ9LV?1IE6[EFU;MV_AQI4[EVY=NW?;'ME)MH"*)'@!!Q9<%X&TO8,1)TXZ
M@$:)@:]J*%B9X,GAEBF:6+CT8.&)_R9JZORE",%(),L="Q1!\B:?P-;Z6)#>
M<7IQFR\).M3X E+1##% 82; L(!SQ@&0?E(\?CL-D>)(![@0 L!!FAEU7@Y@
M<IVF=. :M7/Z\1"!=XGAQS>]T %3OD!AQ.P<$*)%A8T(0G"PCQ"_?H8(+M@#
M@17\PXD0(-#8J( #$QP)@12 H$2A B"4<*L"3A!#-,462JT1#U1P@0DI+/D.
M) ?ZL(0VD@H@I:#=)K1AC4"R,!&B!-+88T./"K@ $A%Z"46)-D2 )(D$M*!@
M1:,<* (*"0;0(;Z/"EAAAB (L'&E <"H+*,":)CA!RT9*F"5&2K <0$8CZIR
M!A8 &."9)_\D<VD 4>"0H:$%>["0(^UFT'-/0JB@A$R%$ B3%J9ZQ. 3,53P
M!(,E)"P #/$V<F %3!'2E)/]$NJ1AT@*".'3H J8H\ O54E$4)$HM ('1%.0
ME:L!\BB10X8<$,22 Q J0@U:@,KIOYL0/0P!!#9L\1 %@,L) 401.+1,9 ]R
MMDZ%Z(GA PRP>,!&9K/%MD-R2UH6(@AXF."P!$IK -U0Y\TVB6:YF';")/3E
M3]Z2:( "NX66W;$ ?JU%R$HL^:N6VATC4G??,NO-MF( %(F !: *N#BAC/<8
M0(,%))"8WG[)<Y@ D[/]-U27#UI8RV5-I#DB:<Q5R $F(A@8@([_D>7S#^ Z
M1MEBB ^:EDLQ$0*:XQ1ZH"!:HY-V0 =._TMBW T]UFA!*OY Z @>(BNUA1]L
M3HCEAA!XIKZDEW4[/84NP(#4.>I;>=R<*RIXPF6=6!7H<T4K[-".D8X3:6,7
MD@: %#B8-515@)B5:@ 8)X^+<2W+/.G-">;[H &X3A'87;D5Y%F$!D )@/4P
M>2.*/T0[H8/5HC T!RM>D *V(S#8)Q\^:'> E(%\D < 59K8YXU^:I   M[E
M\ $-4L)8%( <0HG$Q!/RB#T*39*@1Q!,]K$>8N[_F",#-( ZX08XR'CCBC^8
MD ,3/E@XLC0"$J"!]A O"1#0@KL  ($;_[BK2G)X'A:$0"9X>0\A\'H$#) 0
MB$.X+H#BTT0#3F"$%\BA$4.[@!%BUP\EB(LT/= ?9"03P#7(;@>2D8T)$FB$
M&I"@"#/R02&H4(.=)  $<LC'%3ZXH% \KR"):]K"$M #.,#@#8$(5TJ(:,0K
M3&!;#$D #UP8B'X0!P!?=&$C?!'$W0P !#.$#&<2,(4A<, "'VP:#<A@ 1_\
M@0MM?,,;.X1'"UQA!QAH02>08 $LI$<[9.@'(!>"HTX@T@(?Z$4I9(? 1O[Q
M YS9Y"LZ60!%;&*0$^!"&N @A#3TH!,EZ$=!4G*"(N9C"4OXQ-S$!H(26" 0
M*/C-0@ E 0#(<O^&!!%#"#81"!\(<3YRL, K!!8G)G"@!9@@0A<3P(0U6, -
MG0A4&;7Y!@LL(0@(($0R(?.%$#@2F@/3SBZ["857C6Z:E,2"0:($A$=@0@GJ
M6.<?(4B ND53%:7X@">"*!\:G&U00*# Z4RR1@*]P)%N&-H /+&)?+P"!>.9
M#P<\FA^TK>!L^''D&I; T,D)XI&?2 00*#J\H6&.$)GI)2[Y0R#[($!5+" 0
M_?)AT93@9Q/]0"E#$< \7L*2I[Q;0T&*4$48(L )MN)I4=<P0D3,P0J^@*?4
M,%=0)NYAJ',HZBL>$;D)U>H%KKS"QL**20N$ :YJ8ZL4@EJI6G5B#6[_4)Y8
M \$'+&G'"U7\  X+(%8+")8 L?+J,[V7@#Q8H!]J$";J$O(.9RI!#&QR0 PZ
M"J;W$:!;81!":MSP PAL@@^%: ,=0'O:563 4)*%X)$$\8$O5&D-?[B (%K;
MA@: (@/]*X -/D&+'24 M&A31 :D=H$8W/,T9D(!+>BA0QA!H EN$$,F,+ &
M++3!!4:PA +@-0$2@#9DJU!#;(R@I#+&-PDYX, $#K">3C8DO=N"5R,TH4X.
M)-%%+.#I@%70@4;LH T*&$ '(G!:0L# -%]TPP<GO -UD.)1),";N[[(Q3+R
M8 <F"" 4Q' !$BN@19_X0W_^H HMU! "&%BA_[5L<*4!Q&#!7_ $A;_@ !"X
M& &*:($'EA0G#"RX :H(H@D&@($,+$ ,+IC" A0@Y$?\H0&$Z,0"H!P#-\"A
ML]\AXB,\P(4B;+G+7WX.ZT#@BB>H0,H1\'$IB .F1[B+4&14"(ZF7 4FP( /
M'@ O%%@ IAX$V,E$4 <8.L%H*A !2DQXQ&S8&($J@&#*J)"4<_2<9F1> DX)
MV5D/_I!8#!#!9ZP#PW42]0@-&0(#$69")VI8@&=T8@)?4$4E*#V $:PA B(0
M@K(@K0D2K  &6*@# L PA!=?H!("F\\0=O"%%>":"]2. "WP,P1ESZ'9. 63
M%58(@2D$:CYKD+4+>O\!@\@,%#NJX $1,I$&>;+QFSB*C$.(N 8^P&$/R@J!
M%3ZQA[K=LJ9"!-XMVW:JB(^T!2S(<)-+@0)0-8T0!M6V%0JB @TPX@<%,(01
M.DE$DG>($/Y9$ =8P%4(7@ $)*>0O!5P<C[,ZN0IKWG)"2&%,(A !$Q @8$G
MG 4*^2<%6OB  @KZ"GQPM2 78$)J,52*<"5 6"57A;P;<($\7$%R"4E!*TS+
M1C?8!WSAH@<(UKX04+0BM#3(P*Q2( 5?MB$);7^ =MS  AN,-@6AD 4 \Q N
M(<<]!W3?PQ&8T(A9B?T00C@=9A&2@RDX<!]AP,X[BGL0!^2J :!O4 )T((/_
M$VR"%<!*07%3@B(5M4A%<6H##A-X T1<(!2Z @ ]\F :XQWB-(/?C[:T%4E!
MF"8U'3V( B,AF<'#;_A?," %6CY3U-?A"*7Y"VFR4'H.R/<D6?)B? ]#FG_3
M(S<*>(>T_V*\#T"B%+H9G2?$E4,APLO^+;(DFZFC"%8HQ/XBQ!H@-92 %KY(
MB'(@TOYB (R-$%J@AN+D"YPH:7HC37A@O[KEFG* "@I!,B!01P#.6X2I22*,
MN:  CJ[,!#X0R:@C3'Y .#Y >R9D%2+@!]ZA!V;C9\YD3":D-V90 Z!@482L
M9TX  WH03'(0F$" .PR!"G)M!>" !:BMQ'XF!&:@_Q J 0O=A*RH$$X2 $^$
M@!2@8#QV1DR24(CBY EQJCR,1)J^22'N)$\*P 4@82?2\ ><H$^&:0JNZ6?F
MH$]VYFT4X@0 402?4 9Z1+BH8P28AA#Z!$<H[6?Z\ \H,8:VH]7BA 8^H=12
MH!.RP $6:E8H49@2BPJDIE3D8 D>H=0D44((Y10@PIQ* 1," 8;B) 3>YV<(
M0=I X$E^1A7LQFS&PU(^I4HX00R80!@90Z5"1<64;@5Z<4%@X!02Y1/TQ.3L
MIF;P9J=4I0*X"A\. G).@3&T41 S &U"@!&4!P ,H0.\1U6RX&=H(+56QB;,
M23\2!050D1#D( L LAX?!_\(L%$1W/'Y2@-,KNMG;$"M0J56:#&!.L 2JB0A
MRR@/6,'\LJ56"%*R+.%QK  1$&+PM <D%2'P?N8(=L,&&D%[@&\C06$DGV\3
MZA%70A+S&N((>F$3LD<17L$5>N %7$@-%, &U. =$6)Z\*&Q9&0)AO(%.& 0
M),!XX*%.,"H1J&"&9.$";D"^#L*]:,&^#"545@$%ZB EK(L6FF1U%,()Y, 5
M"B$1,  33&.^R.>X2(X VA*]C$ 35H 1*L#,C& "L*@PDZ!)UB HQ0!:^*LP
MWT4>Y<,$WX$#EN %,%,.ABY>$H(0M%)_X,'$>,". & %7*H5B7*$-&X!<>B+
ML+#_"'K&-4T@!3BA+#N%!IQ)SASS(:!HQ:@#!%9(%3AAILYC"K 0 '(L" 9@
M"FH AW8LV^9@.('""5H@"-2$34(%9"1QIH3F\A "9,:0C H !."@#@K*#1ZA
M$UX !BS*.\NH.83I!"H!@7K#"CL /3'3,N&@%/!S/1F! DK%#X]0",B3,\!$
M3* &K YTXY)&!7JA$O2'U!9B9R)@&U5 !RJ!BD@-:@REQO!SDMQ@ A  $A?E
M"$! /2. +MFP5. @/8Y !Q)!?^CJ<:)&.-Q *"<I R; !3#@WW0-:[+EU0;F
M HRS 2YE/.JF!DZ'2)6TC. .@5ZG1Q^-.R0BL33 "IZN_U0P94%*H9#^;9AZ
MM %,Q3ZTM (L90B>0 -^H4XDD4$/8CU(Q52.4<;.L0A> 3,[X1$RX$N;)G#(
M-' LSN6:[@^D04TE([&TH (&P$[Q5$\/X0 .1'+$+A#<(,(:*W!P((#6]" ,
MX0:R '+VX^2R@#'0"C,?00X.8<,^X;*\LNRRA7+2PWC6U$X?@2A=*!:Z"!XK
M)UM(84UGLD' Q )<X07RU I^01TFZPHL%0%6(2A?X!%Z@ QP]5</(@$$@20'
M@!1^12</HE4NZR!VYP]HH!$*@>C: !*,1!'4X,T2*!0HX2\4X0H\@.@\H0VJ
MX !:!!Z&J .N  X*H2<M 0)"8?\BP?4&Q-4?OR,UM%$MG40"\C57C<<-B!4S
MR0 +A$F!P,H&EH!,26&#$N K5Z"CO@/\=@+\_J)'0  &K(A=*PC]6G8"XB\&
M(D,1EF !VJ!>T57%H)2Y*O5?8>"\(" >[$B49J 2EF 'S/5<CZ1=AHAI4X/5
M#) Z&28:=4!ET1(B,E VXX04G(,VN6PBX@AF#T(1.,$ZKRR&6A!OQ !8CJL'
M4H$.6K!,?A!OGN!T;*!/(,9,T,0!AF,W4- \J2 "VN!FSY5OV @.A$D5>@ &
MK80%G*S8ZM43]J 7 E<,ZE4$&HQ%-^9P"30"3A 2^7!QV58&Z1 W/^%?'06G
MX@1/9(#_,>*R$ H! UQA#U;@!;"$UI3 7(OD"P!%3V0),W<@$>!@!]@6#.#@
M 1)%#E"@$##4%<QT.P=*=VV#VE9T4^8I3HQ74'Y-O;9#3Y)T+Y(46(Z@ R #
M][BD!42@$FK@4.2$3EB'"5H W.34$K$M3-\T3.=W0$IJ4SQ@U0[5"8 T6U0L
M3M^F )Q "R@A@);W1^IU.A"%I,B4I/:@Y=Y1%6[@% (("^I$%8Q 435@@46@
M@5,%I/C#$S8/,@C@0#QX4^'14Q^23#L5'Q"@"/A #$+X7(5 9'[ALD[.53$'
M5$='3=6!AFV8Z"#!@?FC5MYQ46/A *@U3HK NXJ$Z QB02J!_PP@HP&BV(;K
M]5P)P!"L($$*  )X01NH(U<29C#>P0HH"%SEX _>P0UP "C X#=,[S I8'HH
MX"#N^"">(3Z&;R=2$@@%MBN_<D,^2PF:X"X5 O3@JD44KV.Q,X%@@'Q*DK:.
MY"MW KD,HB_!+_L>L ,T004@,X&TX(,NX/92 B'KZL\XLUI+><>>[AU:X&L!
MP D@Y95MH)93@C1T*[M\%#A[80C T@F>8&DI\ 3()@G 9 47L $:4,0^:P$@
MP392(CIMN2&>H6P'@,1P2,@Z*0=Z0)- P,\88L><PQXC0%&'HS738 <>0)P1
MJ)E90$V^52% QA#&^5##9&H_)@+V@/^(2.9G1B#"UK!.4MD"Z1 $TEF<E41S
MDY15;[82L.Q-14 = " $!!25-FT!L$-O?P 1F]-)H< @$B))%1$*W%0[*C0'
MU%<RWH[A^@2 IL!S#^((1.#O7LT&*P@0A4G8>H9( W%G/A$ "*$2,!@X41&G
MZ^ 4L9=IU 8,"K@/*0 _,(6(=G@8>\![M*,3X$ +(N%T#*$4A'*.:<(32\T>
MQ<2JR910-*$9695L]-<^'$"JT>89AH 9Y0ESQI0AZH94\'H_FNX<F2 = 4 :
M>B&")H00;F"G -5MR-2"9;BPMQ&"LU%[VN:T,!5S<#DEV,AB(0<'^G$;G8 ,
MLF"SARD41O7_+ <&VH1@M(<QC"=D=R;R"'+% 6P@M9+FCQ-V=SX2C4,[6W([
M/=I&#%3A"1A6#=1AN'<;2Y[86K$U5]P3=3Z+D*K !3RA"6)! H /"VCAN*P@
M"\HG#P[A <S$#6A!8">RN[&#J[RG12Y!"))@\&HK!C!!%KB'($M2#O0!"/^L
M \I[0,:OL4CA*K-S+Y>R"52$-"C@+VQ@+YW%! QH AZL"$6)$5C@P9R-C=;
M>R#'783L$Y32E1N\9>7KLW3#>.XI"2"D!G1V+Q[RH=A(#JZ2--R@G,B- DA
M Q*.0K0@,G;LEF8\^E(#Q5Z<WP2$I)Y %;#-P3R1K BA$%PG.]$D_\2^F12(
M0\A*NDJD+:FDW$2^* .XS FPK0'4I#5;D-^0C@K [#K+A 8>8<Z>T, *J@98
MUDRV3 728$VH0Q1Z9F?0[ #L;:__K)PY(P<XP0/@]4T*P-*03,6@0 C@',EH
M36"J9-&XX$Z(H I0R4 AL0[ 9 )%A PN :=R8 /->YTN8:6W0P)4#-168!,N
M80_F@-<4 #]X+>QX_ >"J4-6H,MK2IZ24 E*)M8E= ZD4)V&P#1.0 -**@2
M7>NNEQ0SX)J(-%!(<08694"& ,F2D#M^'4#A=S^(Z!640#)>5+X7@GE0X FN
M&P0X0$GQ(WY]40O^8,(BH8"FP!6 #@@BP?\6.TI_^?" ,,[Y)N2$:J *^MJ
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M.AD068-2LLA<6^$%:W"#/ 9  R18P *R[5'<^#-F5TA!%@!@F2^D4)M(J*D
M&I6L&Z2R'Y%_UICZ4R!E"Z"(#(@' E) @1BX4 NQ ^!/;DP !@*!#X<5 0LF
M8 @2+%$ >N0A$G_Z0-W#/O8;N.'_[/:E!!WR@ 6%EA7Q"AUNXAT0@@R$$B,V
MX$!,P8Z".C@@!H^G@>0]TX'$3PW;D?^#P_ZD&@H.7@6EG]<)C-"(5&2% Q1H
M0)'>O((,-%CUA6B#)UI0" 7,Y ,2&( &A*U$#C!0]1[@0@B4/Z_A<DTK66C
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M"@X)DDS0DA A"$JB+01Y 3?0DWGP"K^D/P.@ [@#1I&P=H)@"7F2 %*@&N]
MD )A(TV%$>^0 17@ ((@!V$@ 2=@!14P "+@?E(0*!"P"5)GE+)  J1@":.8
M1M[D!!F <MT$-?22!VFS>6E#ECS21@__P!#Q: @<@ 9YTDUUHR=&T%P),(ZG
MD@"EH&8)U!JX44;[E ,1^!IM9 )48@F1\PZFJ";XD@2[] >E602D0T%J-ER=
MN2^>L"3T4$%?8$=*4#IWHD]UP)MJMGGD=0)4<%P,03IV,C7D-1(1J%\80%XZ
M%@-2YH ],34\X4*0TW^&9$-:B0% V)UOE$\1T L]H#@Y  >%D 81( 3!)&=V
M% %Q0 7_M1 T$ %[ '818!*%-&4^IH8.\1$[H";&!V9S4@GXN13M>7S#Q"HN
ML =JX@ '6 >G 0>9M"@22J$XH7F$QA(.P 0SL =6T8,KH("KHBV- 0 K\ B%
M4 E N%,]0 D0_S %2D T"( *><)35T*B(=(),"JCFT0!ZM$")E$ 1E@! VH:
M,D@)+Q@3-HJ&7?,' _">=?-)FL $1[H0NF$2J@!*J[(K,,0DE1 )#@ &+9!%
M<A)6!31*;LD$>IB?SA$<SJ&&<LHD&+  O:!MNM%MJ"$>2]$"<6,70T )P0&9
M&C&;1&-60/<)W3(3D7!$@7H7<6-6'I9+4<0!@>H;IZ!$+<!Q:^=*L%0? [ "
MC)!"J =T*- MLQ0)D1HUUV<)N<8!^" 0AI A6>&/ B%7LZH4*6(A*!(R*!(*
M5C(0Q0IVN]ITL#,2C( 9HV4)+",+Z*$(5S<5*A GJA *IZ (K'HA<O\ E%9@
MK#D@!59B VZ00@- 6BL@D<O*=?I3 ,^0"'OV!DS'EEU$#X(@J46@)0*1K^\*
M$3=  8; "(G@K(K ;[>8!IVP!I@@"TF@0 9WEJRP>=[4E[A1!(^*'AF+D3Z!
M0KMT'AR+$8KP"<Z830I@ W*P!"\09')0LE3171UHF12JE_/27;6B"*0S%$OP
M""V;>114>PN12"IQ=@! LM>1LWSD2A0: Y25'H20"%0@!T2G(+,YF$K1$&FH
M-+A1)++U#AS LT'& <6!$8"$ K[0@')0 PK!?R'T 9"  =ZI+>0Y!1/5G9&#
M $Z@ ST0&6U7MPZC+3FQ+;2P GZH3P^0 J7_D!P]<%Z,  >=P+.,*P<H8),T
MT!A6N@ N$&6G4@ '^(><X#\ZUA#!J11SP D>@!YST ,PN@!K!"07H -2FR0/
ML0(TVBPH$KN1@04_$#IPH! , 0<NV0/-%V4Y!A%,X+L"D0(]T -#6"O+ZP$'
M4(H6L 2G!"!S\ (+.*)U Z:,.P'H8843L*);<AH]@ ,G@ ')$62=4'!2.0-$
M,QJN 0"?= I@X08\%F1.J .>TZ6<\"-.NBI@(;]YJCB62[H"<00Z4 E-P0=H
M@+Z_4)K/T .T@ "*P FT< 08H%E@002], 0Y*HS29B\L4<$ 8Q=:@ :G 3!J
MV&L#@0&VJ &OP+*=__ (&> :\\<2*/(;?N$I)6-6I\$!.9P"X9$ZU!%DCZ"V
M#1!^0:$=1O$"2%PU,=#"$*$!OU %'< *40,!N717P8JKGJH=/=L)G9 !4YR1
ML",03H!7RRHR2YD%J1,+H+F4.(  8;P72/P+GK#&")P''@*?4\$R?U $4ZQ
MB%  ._DC!5#(#/$*>J%G+JL!:H!&"F1%]?,G4=">O;!TSQ1-V2((LB!20Y,M
MU6!Z)U($AQ "6) )1J )>Y<$TI '?)#)FS"K"A1:9XF7)XLJ)RM2T?8B)$L+
MJY(#'" &<\>8))M'/E&R^70($A!V.] &(@ );3"AV*$%ERFP:K)?3BM:1O_
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MR >G\?> .5@:N_]9:0,!" %*\)(B%OY$LHX!]FAH&N00"@!8E8/B@#3LX=#
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M+EF>S10#^S *C]B(#AA"^@ ;\1/&]KPNSZV"& C#N5E3 '@'J C$RW0!@6B
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M3C -J: "2?)MX,8$/D #)1(0994?[@X*=+48=)4*'GBT0CF!_R*X@F5,!!A
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M6Q)D(S=Q0!]B-H 8!.+_#5'P12EB1I $-"$ATEI(FK33 4SLHQ_"<A',< :
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MP5L9>D1QR!>^J:%U*1\(>)#R,4'/==L<PL_SB0^?G-P%" $11E<)7$$=I1T
M0=",;1Z^^<D:)-74S4$K2)3B<8BZ&(0A2,$K9$$:(E2K@?_=$2A*4[13VJU'
ME5D"XEU@'PA5U3U?<?20K]G@O;0,#.9,RM@60D@64_633 7"$<8=6#QA3JR!
M4+E(U:Q!:X'=W5G' .C 1>!:P7E"&_1"*41 (4 "8N"%&29><8PA/XG/$RPA
M(B:(&X)(:(#CK=%(!"")\OW%..+;?/ %R,70'3Z?$Q2".AJ$*O" (.+++GV
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M!:A"$S J!,CR1#L&$YVMUE+T%Q0'(^Q'GM6 .@";N?R"-0$!X>YL2%X "&3
M#SB!%+ T""R!/+@MMKB*FZ1 * @+:KPT #C_ >!N"+B,0;5\RPW$P>%&;<IH
MD1L\R%+7CDM+-& -"[:D@$SOP1& @%//+SKGP2MHHD&<@"# @_!,\GZ(+CSX
M1DTJH,$<@ VX 1<QQ@O:+BMPU"9H10&\@QM\B<&,VL5HQ5Q+1"X-Q%Y32D[
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MO@+7SW\-  2)*404 # (((&&*ZXZO>B4H<8!&BU^@.%$R^"%*1%54<E"X""
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M *S"CCW8\5\!NO.=\"0W).)3@TZP2I/4_!  ]#!"<W&"00#,80T^(!M[DC"
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M9N[5P9(4"%Y L3-VH@/A%SJ%$&+R%<9Z  @!".!@]9(& 7B/N-'G)8UQOV4
M 5)@$\81=5W6"E[ "U#K<YMYOR6 $"*\#=W@*!9<]BP@#*X/-16! UB@KFIJ
MP:W %TI@']Q@V4CC*,EQ0F86>P9+JS2Z*5\!27J'90/O _QG*XI "<;'+CY<
MML_C O*@*?D@"+9"R0-A$"#!"K3*>GRA$DUV9F!2K5U!"CBG4Y52"BQ "<2
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M0SE87( B:JQ:,2*XFBCRR"27;/+)**=LX@F];!*&# 7T\5,1*##)_U 1GTC
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MZ;-=#SBPA#]H;T8KZ%]P!J"!)Y7L!!I80G$N,(4: ":#M$K*'/JG(3L-;W(
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M,.+9?3GK=/[252FG8 A$.U@;3$!P51+M<&\]S5=4\H%>/")^#'%"&_3:.]5
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M%(%L)HU>["$$0P#0<1%I8A"X8E7L$H*^6C"0@UFR /8&60LK97K#V\S>D4
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M!:%3"< 8=' M=: O'( &AU$@(" 'D7  =S$7$$)36'5O6Y4WAT$8!8$"+(
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M)@SV>0K)$.(W!$1%0A+")U2@":AB)6F5/+QE/ZI0"NA5!2XP52;T*Q_@ E,
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M0N=H1$C(PT=P0X^X '!Z!3 1 @%,KXA!Q0= EP$XD$!TL2MD%";000"PIRG
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MA C8 Q< IPPE@->+O27=! M0@C;8ET!(KP9(S'Y8 DWP! S !%6ZB$T8E#:
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MEN_+G15(7P+=5XLH N#=B%EQ@WIB E+./.6UC*TT3)T\A ]]0,9K5X:5(3(
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M(^&3*0*MT'V%78:E "/;-[]#OF],9*AH #_YU[Y&,5DU.& 9O!A(M^:2?%B
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=I5_^)6 &IF .)F$6IF$>)F(FIF(N)F,N9D   #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g21422bii001.gif
<DESCRIPTION>G21422BII001.GIF
<TEXT>
begin 644 g21422bii001.gif
M1TE&.#EAIP.X!'< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y
M! $     +     "F [<$AP          ,P  9@  F0  S   _P S   S,P S
M9@ SF0 SS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9
M_P#,  #,,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S,
M9C, F3, S#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F
M_S.9 #.9,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_
M9C/_F3/_S#/__V8  &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S
M_V9F &9F,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,
M9F;,F6;,S&;,_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D S)D
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MN_?OX,.+_Q]/OKSY\^C3JU_/OKW[]_#CRY]/O[[]^_CSZ]_/O[___P &*."
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M&]565 -\YWCM2@#7QNW?QY]?_W[^_?W_!\\MAPYR+1H"!U.(!;4"B6@CS4S
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MC NQL2I)TR)+0:8.SE0HD6<K+QDG(A344=#!5BH=7FDED-4>%C9)MBJY$YO
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M\+_UD@OR02 CY'+#.U.,[='SPDSMJ:8$P$)B5K!0VC50L'#UTUE%Q<+36+-
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MJ(K0(64\B._8_WLUE7A3@B_=+? ,>40=DBT1R,.";/OJSNV"U:3AHUTI/;E
MJPG )M*L('VBVZ_J&M6X-VW=-9PWB!+2HK>ZX^L2A^O4*<?FD9Y\R$-@!]"!
MY'2:)AB@U2I+0>2M[:$8/*9NY0<W+%]!*-> )M=8\D]!Y UJUGQA &; 9BFC
M;ZT[RZ=@82N56_XUM'WDG$8J_.;3<2>CS%NB-L78'RB&1K1HOETMUXA2! *:
MN/ZEVP!3BK:GD9(B5KOA@E.G4\IA<B$*U&=N81T8L:4."TY+!$+Q;)/&TC(
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M< 1QO9=-O)D7U*F,/>L_K9=JE%";*<8#B=BFF8+4+"M)O(<^#2E-M, OW9_
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MY37O>=&;7O6NE[WM=>][X1M?^<Z7OO6U[WWQFU_]_^Z7O_WU[W\!'& !#YC
M!3;P@1&<8 4OF,$-=O"#(1QA"4^8PA6V\(4QG&$-;YC#'?;PAT$<8A&/F,0E
M-O&)49QB%:^8Q2UV\8MA'&,9SYC&-;;QC7&<8QWOF,<]]O&/@1QD(0^9R$4V
M\I&1G&0E+YG)3>ZKP@P299,T5<IB-$E63]52*Y<J&E'>IY.AJR8B!8!(+" S
M2;+CDD $@&T!5,RH6'64-K>E%50NV0K@Y2*'Z4HQ ; SF(LK+C,/FLR%9H$
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M)B46<Q9JD'(=!J;$$R,^;5H0V'ESISR-C4<Y>)!7PL\$Y4ME#/6(C9]IYI0
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MM#C]=G!R&#A[*--1PD)\-$Y'U#'4Q$X7N2EVU9\C&2B;M!W,N4XW)C1R!7M
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M[7G/H@1H6PKJEH)"!Q*^9*LAR@1)T01ZD,* I&.BD<B4L&*2FGCO5"#1CFU
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M<<5'0HJ6%9RD-Q<2H*3&;WF!5%_OD,+[1' 5B/=?00!,@7L>!S7ZURBV*P@
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MR>$C"+@HR0121>50B(_H/.@0E\24E+@!E[6$%E,,$4$P/QO$E$L1B1LT#KG
M'WAA!4"5T[XH2LW /\VHD+K8T+OL1AE\PXB8F!#1BQ84A$&Y(+4(O9;L4:R8
MBBTLS7>"#BA 35$2C+?!BC),G@0:2[UK01)1"Y/LNB<9M0><C%NUP^1,I9H
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MIF%T!'.@4EQAYF<.15/9!7==ATO(7%70!'Q6IV9L1!2U@IHXAW*>AF 8!&9
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M%,1B$$B2 J,%&"20!<.*,[ )\N(0"S8H&'72VO.RXD:#UP20U!C2H"D65UA
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M$LB*1 HLJ:"&OM,P0X,$27"EWY:";B\K6&ALJ PGY,X55D9,CKB2H(@L(U<
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M:M*QD9WI9"E;V2ZYTC,%T=45]H OY"2')FE13D:2$SG<V"VG6XO>%9!#$["
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MY"OSCM3JS$3&1E+85#M")5QR\BNG4BSW\BQ1@U&(ES#>&+=P"R,D@O@*1XH
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M'N,V.%%ZS8$(_Y?G5C+KM!TK&P 2)*2R>3$#J9TG1H^A&%_B'M-*GWMQ35=
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M7K,JVI#S-9G<C3B]N4YVMM.=L1)EN8CX3GK6TY[WK%P8\;E/?O;3G_^LEHX
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MM^5%;WJI(U[UMM>]JNGN>^4[7NS.U[[4/>]]];O=^N[7O\6-[W\%;-S^#MC
MMLWO@14,W (OV,&G#?"#)9S:!D_8PIA-\(4U/-H*;]C#B8WPAT7LV Z/V,1Z
MS?")56S8$J_8Q6L-\8ME'-<6S]C&7DWQC76\UAKOV,=1C?&/A8S5'@_9R$+-
M\9&5+-4B+]G)-0WRDZ5\6/9.V<I23?*5M9S3)F_9RQR-\I?%;-(NC]G,$<WR
MF=4,TC*OV<T$#?.;Y=S0-L_9SO=,\YWU?- Z[]G/WHSSGP5MSS[_#]K0G,SS
MH17MSD(OVM$<#/2C)<W)1D^Z7Z0C7326A+96)/-)3\+:ISGB(8YH&B&+2\NG
M;;6X4U=)=R#+%.DLXB%;\= UT7 48-C#G$V_!M>NX<ATMP4:*H6K.M [3VVT
M)>QKS5H]M8YU8UHEZX0P\=7(KI2J@Y*I6+<:VJB.]:K1-N[*)-K2W#-%029V
M$4*RP-V#H D+2L""&;!BWN^66L\*$@T&TKMT\G9W9UC7[_3LP76<BC?..B8(
MQ( J+GS8=B  LR7,;(_B L+&Q3.3.#YE$S.HW,S=>#.>S01"$:QPCC)M69H]
M?.LUIK 6Q"U"\MI<0^8S$03(W3WOQ+D[_^!0 3B.H- "B G4"IL\"<"WDC,8
M2<W=,#+%O8EB!1.X6Q!KF[<)L* UZ_V)V>?&W-R\(H")/&4/ D%GNNM2.*A0
M#"Y/=)S>@.*5N7,J[AM["@,7>;%2.JTZJ28AMG4'.%-8LBCD1GS3P9UMW7$$
M<.)6SZC'W3083<=GP78%=Z8S)8Q$OE(80V+*$+^X8(_;/M<.MJ8-8K*5\'KR
M66N>05)&.HK7A?'C;KU6T*;Z@=QR86ZYC,;50PM2&X0R;*P(<_:R%Z^TOB.0
MS-E:X%BIGV.C!#:Y!DCB$@BV.[X%0@'*,X$'->; 46ZGD5Y]D(?T@40:[)-+
M-S96,#'B&=S6(/\K2_R7?@T3E+ @M].A&(*+D^@(?^,4JK"5)IJ/BF 866H9
MPPF*K5B;K+F"O/D(@3B[GQB,QO$)BKL;%6D%H&"%01 AKT 7#@R;EA"$0< )
MDX@&+$(98KJ+ELNXP4@16E@CJ'D9M($C8L+ SRD)+_"(/++ @0B)\2 FE,$(
MH3"90=@2+(@&*&R(I1C!QL$:=7&%I-BCAA@)NSB[YUN9ARB\=.FCAK@?+/A"
MF+/!+;F_@4@>AU"7QO&"LYD5*20)BL@>E6B,Z9L(SS@ZD;"*%+&>28()I*,*
MTO,+?]N=FZ"=!/S#=*NA_.LC<JJT]X,6[K,=H2 <A+B9 ' +2,2&4F#_@0!P
M-]9YN\*)'.RXG0OAPVL@.SA2B:D1"G_[NPBT0EM:(UOA)1Y:P8RCA2A &XJY
M(!@AQF#TO(Q[P:"PI)S3PAG8P(I)FQ?<0!B1N&=KG+ @B98;P4 H->2Y@F>4
MN6O@1M!K.2T<OHSS17&$B..0B!&L&"O4F9(@P4&PE62<@<+KB'4LB<3A"(FC
MN+XP!2=$"!BQ K1AP*LC0;1SA5W!&"TL1H21"9FHQDIA0(& D53AI?.Y M"K
M#-LAQ8)8 9M8FQXBQ;BI(+7#!A/@#NV["9\K"U8( $%R%,3PN=))"87#H=<P
M-TNLG/@;B84HB%&3HS[$/Z]PF-P1H=)Q)8-(_P_%&4 1\AVJ2(^I&,!9JXB#
M<8MKF$-!2(2KO(:*J$9;V9(KB,+G@$:)N N7P8(J',&O1,>O=+6'A#>!L!4:
MK(^K7#FT$83"X\:+\ )4:H4HR B#*,9]C$>0X1D:'*+VL8F #$C#G J(F$>=
M^4H:++PJ-+EH\ CCL,LJY,HMX4:'E,?"P\?"^XJD>""4 4V<?,R$N!^[H860
M>8JF8P&BVXST$!NWD)ZCRXN9H#>P($2H>)^;4)VKJ,WZX,.ULXB%Z,4]&I?F
MJ#*>["#"\8JF"8 6F(5'5![UJ2$8B88 D*'IVX.GN+OIX[>ZVYA]&\_2L20K
M" !:4!&$J(E:[,N^A/^9;]1 /J@2?$P*[Q1&OT#'RNL*6QF,L@R$98P&/AC(
MM]1/BY'&@[R+)\D^F3A,5;K%*/S*#;2V"(S'<DP(T"O,!,RE8,3,1+!,2PH_
M6V.-E9 XKMS'7M09BK.U@%30 *T/B!O!'%4,5P!&M)D%+6R-RD.;OIC((A*(
M*H018.R\&I7"S ! J( ^%LHX&#J)%+&"BK@^@_A"B^ ^BR +1!@CJ+"8:UB!
MMK&()P492K$(]Y-.HO')G? ,FL3)]'NB*2U =Q,(?G.WXFS*J?&Y@@,*H5B<
MH2"ZKBNB,TP1P/C"$2'&K)'(=PQ0AC,D:OR9+8F8\5S"ERF<ILL9AK/(B8#_
M-^5X4E41A#DT1RE=0QF"C+M!)W34FK.QRXR[)%K@ YD S15Q3!$,U<Y@/53-
M2(<XCH:HGKW\"7-\S ,-!)+I"(2X'Q:$I97@2R^ .V7E(8S8"HF$".QKUH[X
MT4M"Q[+DR "$(I_CB#^4&K?X0_69A3]MA9MQMY"0RMH<A,)H'-?Q.:ACUW3%
MB^?<C$ILTU+!M&#;-)B[#%DSV$VS%=\KV(#U-FQ+BVG#/,YH3&IKO(LHM940
MO5(#IL;XG4X##&4J$42TV,;PM+3(O'$S!81(P"(B'5M9%>:HI9(@/E=[-7&;
M#AXJ/7(KTLDC-V4J/>9H/8-]"9D0MQ)!O9+ M(NP_XF??;W+@#G'2Z:8A;JE
M7=K7:QJ#11N7H]@(; S>$Z9CW+9:6QS O#]4JY++0-M-,]N7F)*XD)S/V,E_
M-1H6J+H_=;>ZM5N\_5.]]3F^O5N[_5O ]5NZK4E$R2(AV0J7FY/M09NY4US*
M\5>Y52N/ Q&:0Y3 FPESRAPVE=S.%15QBES/9:BOFZW.&,51#);2B%O1_:@B
M[8G01$?U>-ML"T$$R8XJM!!'F2[<O0WA8Q!\=,V.%!2W/#S"W RW5 _V Q#<
M*$O=D)B@NU?IB$[6K2F* [F+:%#NT-P1;%Y?VXSNK0W>I=G::,TU617A2\;R
ML%&#J-'P6)'TK;E3)1_EG?^-K2#%^SU=4O3=S>!<ZATHMJ!+AJ@(C&"(QE0)
ML8S=QFT%+V ([F"(DSF?Q9@YQN#%GB#@><RCH!F9/;""EP@9Y N*0;A2 Y:;
M@M%2AM ;>B48$AS,3/$EEW$%@E&7G,%!3:R:\W$9[K UELGATA0,M..(J_,<
MHR!@/1I/B"A@XT48I/6"M7$9TN#"0&U@MUP,]N.)*]Q!@_D<PD"D E;1B4B$
MC1Q5 V(=7SHFMGB)-LP4=RO)TV7CZ:4^TO7?@R(Y&$&<:W11K$A>>9RE4G)#
M*"1/J^#>@B#-N5N1RA-(Q'F2HUC@L@3>$+;13S,%69*;6]+%!=TC$=S+PTN*
M)XG_"'WTBRN$Q@WL&HK!F+I<"6"LO)RCF VTI6GCI<' 3.RK2^192V?=MK\9
M!)+ T"%:$1Z*/QB9S=(AOE7EB!;80(1YP26>ITH!BA=TT<MH.=H[BF3>RT1@
M&+E)FP2&Q@5^S)8+FV^.O<IX8_PU9\IM/SF>8X/"B9IP47\<F8F[QL)LW"5>
M8+S 9EU-PN'Y95!+X&W,B!D\C) A"^1$).:(PO0UQ[E($>1)D1F 3^T8)JN(
MQROP&;\HRRHL1_@<2(*FG>]#X3_^RHO..'QTT>?X2B=BO<!$&;=$7E!M38HK
MO(VL&+<DQ@4=RY@>Z6=FOR<Y.E:( C].4Q'U"^#]1B?Z_\S8M=[D8^ .I,>C
M8& @7 VI(\5YD[K]];IU3JE,2@H:Y,H$A XC5<;L/52W?&3N;59NS-D-Q#5P
M5MG4D]:Y\]*BT QI2PQ0K12$!-#GP)HA?0EZ[D7>9</F+,;'K,M/D]7DFX@$
M=(X]D+B8UFC H(@L)*.Y2PT!G8F_=!B+D]3P6]^DJ%'(V&QO3B:DR^9D7)P1
M<J;$S;@JK.D4L<'!P.2)V&S0"PL*S5G,2 ESSE]Y0V=LZ%^MYB<EA RPAJ;V
MQ#X[U@R*0YC:Y=V M.>_!$O*0)F*:=$@MB2+)L'[D6:BO=;.ZT_)3 C\G![M
MF.[*&PFNE.6)9E];14=E3KZ7V/_HL>Q6(DJ*)<8+B'[O)K9(J[B:)RJ\.X:,
MBGAIBL"(V-RDAJ )UKE*2RE,_(0(6][ L]O0)=8:$#6( _ULS3 )J+$=STY@
MXJ5'H#CE?B1Q5ILK-U9Q4D22T!5N;5I"'O:\LRO8H 6*4P ,0Q)!YRAN)+J&
M!N2U(4QC+46F:Y#B[6G9B1C"3H,95X:94%W9BV"80;A">KR(&PR\: C$Z&&=
M#B9:)$*BQ<'Q;6.%(;R(#DXYU>$W%<6"F 50)M?RC'N9/"4/E F9N&"9ZZ7+
M09"YOHFE&[Z(UC,*0[H+CZF2DLGK\QGS-.Z)(B+Q@5CTF1@U$B>-F%V9:0H/
M0:@ZWM;_W]A8W1<?L$<NE&L@#SB91;[];;2!8U#_,+O0W'=B")08(VT);E:W
M]:U:]5O7]:11YUWW]3AQ\5\7=A"I]6&'DUY!]F19EF6O-69/=F=7]F:7]F>?
M]FBG]FNW]FR']FVO=F['=F_7]FX7]V\?]W G]W,W]W0']W4O=W9'=W=7]W:7
M=W3/=6-_EMTFW*H^W4T'.%+D]WGS]],%^'SO=X(?^'_?=X%/>'T/>(8W^(4O
M>(1O^(A7^(D_^(I_>(N'^(MW>(G/^(_W^)#'>)'O^)$W^9)'>8I/>8Y7^99G
M^9??^)C7^)D'^9-W>9G/^%ZW]YTODF#G^9\?#J 7^D?Q^:$W__K<^/2C5_KK
MJO>E=_H@*?:GE_IT:OJIM_H)2?JKUWKXJ/JM]WHP^OJP!Y&B%WNIS_JR1_M^
M[?JT9WO:B/JV%WNRA_NA/_NY3WNYM_N??_N\UWJ\YWM[K_N__WJ_%WQAW_O"
M?WK"1_Q=#_S%MWK%=WQ;/_S(-WK(I_P7;_S+7WK+U_QUGOS.YWG.!WWJS?S1
M%WK1-WW/_?S4%W;49WVY+?W7MW?7EWWI7/W:OW7:Q_WWB_W=]W7=]WU+N_W@
M%V[@)_Y'Z_WC9W7C5WY%&_[FIU[FA_Y!2_[I7V?IMWX_>_[LEUSLY_X[J_[O
M%UWO%W\YV_[RYTGR1_\U"__U_U?U=_]_,SO_^+<T^*?_+VO_^W\_^]=_+9O_
M_@<(; ('$BQH\"#"A H7,FSH\"'$B!(G4JQH\2+&C!HW'FS%HA7'D")'DBQI
M\B3*E"I7LFSI\B7,F#)GTJQI\V0 D#=W\NSI\R?0H$*'$BUJ]"C2H1YU)FWJ
M]"G4J%*G4JUJ]:K4 %BW<NWJ]2O8L&+'DIVXM"S:M&K7LFWK]FW;G'#GTJUK
M]R[>O'H;GMWK]R_@P(('$YZIM3#BQ(H7,VZ<MZ_CR)(G4ZYLV:?<RYHW<^[L
M^;-!R*!'DRYM^C3<PZA7LV[M^K51T;!GTZYM^W;&S+AW\^[M>[;LW\*'$R_N
M6+7QY,J7,Y__&[PY].C2IT?53?TZ]NS::3[?[OT[^/ 4D8LO;_Z\^>[HU[-O
MK]RZ^_CRY]]63_\^_OR=R>OO[_]_8_8!.""!!=(%GX$)*K@@60(R^""$$3;%
MGX056GCA3PYBN"&''9J$H(<ABCCB11J2>"***6)#H8HMNBBBB2_*.*."(-)X
M(XX%QI@CCSVVQZ*/00JYWHY#&GFD=#8BN223T!79))11W@:DE%5::=N35VJY
MI6=*<ODEF)UE&2:9919&I9EIJEG8F&NZ^:9;7L(Y)YUNM5DGGGE>A::>??J)
MU9U_"CIH4'(2>BBB0@6:**.-KL2GHY%*VM*BDUIZZ7A,8;HIIR-5_]HIJ*&N
M*"JII4;TJ:FI-FJHJJURBJJKL?H)J:RU.@JKK;F^R:JNO?Z)JZ_!@DFKL,7.
M":RQR4;)J[+-DHFLL]$*2:RTU5H)K;79SLBLMMT>B:VWN%W!0@DL!& NNN6>
MNRZYZ+*KKKOMLGLNO._&2^^]\L9;;[KY\HOOO/K:&_"_ O=+L+\)([SPO@HW
MS/# #TL<,<4'3VQQQ0!?K''&!G.,,<@?B^PQR06;G"^UX:K<([@KVV9**X+$
MW(JF";7BBDFFE*AI-#7O=8W/&]'\$"L+">)0*[28E+1!/6?D-&9!NZP=*X($
MPH(@@BC-$"M8C&1*(MCL$79%T5Q!D-EPR?_<$!0EM?U0((,<M ?.46R]T-L7
MF2+W07S,C?- >T\4S0P^M3QU;5T+!/31H0UMBLQ#8W.-(*[@#-+: D5S-%-:
MHRV(UU>XDKE C1=$,]G8T*RXZJV8XG7K2K,B.3:5X]RSZ01E#A+--=\M$,R\
M#P32-=BP KA -)O>>^"T+S^\ZK4##D4BR!/$_#57\$X[S7RWWOG-I\<\N?;<
MFP\2W<D/?\71+$B??"O>+QX%\P+-SOO6-7>/S>:P#T^S-."GD[C%CW^@$Y_W
M]@<_UO4D98AK#N$$$@CVB8X@IJ#@(%B!M4"T !L7%,05O" V"HJ0%10\FPE;
M<07O9<\+K=@#"8W_-P,0RF^"(!3AZT!X-AM>H7!7^"$M]I UT65/$'L0H1 %
MT8*[J="(7F-%"XQXMH%<(6S9PP;[0.B*M&$C$(F(!@O8-Q 39JUP33PB%H=(
MBPF:P@IAJR K1/A#04!A$"KT'T&@@$%L1,%X[ O$$]FW!Z\%P@L@!$D6K_"[
M1&)#CS3L(A8.*;9(:B]NT6@!\EH!!:TYD@5O'&)!P@C"L!U1DE"@F2(' D(G
M8A$+3(&A(MWWP1Z.D)57<.5 ;#C(6H:P=A0L7$\.]T#8*.X:'>0?, 4RMM:]
M3B!0H$716G%);%B!>!U\VS2?*1#W!4YN5L"9,1M)"Y!P$WX>=&4%7V<V_Y#$
M\85A8UW<4AB]CUQN(-5TIBOVIK1R(K.+B3"%"+MH1RPHC6XJ_!W05%=)N=$,
MH#C3&3?#^;96>$V;$:R@0:JH.G2Z8@]RRYXT>:?(0D9/$ %=IOV\!C05@@1R
M+#4>%M:INB JT2![(&=*%=>*N!%$>S U(?!4&D9-#8VE "5(((X&4C@6CJ?K
M/.K_8'H-GJH0I#"5FF&P.DSJ1)!U$1Q(WF"J3%>H\(>%6Z;9KM%'_EWA&GK\
M82HE2,JPI=610!PC7&>@UL6U=:U7A&,8Y^A+%C!T7%,4B$\%"E6,(E:%^0QH
M*V; 12]>\7IP=1]CH<I6OM(BE7'$(LX4A]*"'/^V<&U[*Q#+.B[^[6&H'(2K
M]W@*UI2"$:XQ/6P76\!8@7R3CTH#*"Q'V=/%M2 :L NGV)*9/+AV4!#R2U\C
ML5'.#MYT<AV4K?V8*S9P=M"ON+V),+?:FF(>\ZODXYT@H/I,%B@MG!64:'NO
MJ4H+'NV]'61OZ08BTPO*M)T^;68@V F[FTF.O9Q#(V(!]TW9\E-L(/1@0 F8
MRF^VP@N_\ZA"=RJWS9E4@AXA;G3%BLVS];8@5NT:2)>Y4@RS-'R%=*[]",(Z
MF/W7A3[M72IA1K?773ALW.R:5YF2O8>Z$G:*8\4,,+RX>R+9> &5*UMGX5.@
M4O5LFNUO4QF*3@'_Q('_XC7.5P>I10L*,H.P$UT(07A6NA:.C+2<Y9,]J+WJ
MJM"/JR2(%8;8P1S^T)<ZQ.+6$MF*:V -A)W-VBG7)T4()QAM'T'L$'&VR5%R
M<2"#-,75QBE(.:J1AW+CH1Q#2TA%DJZ1% Q;'\GXX%*N5LPK+.*8^0I*;2H.
MD(]TM8;%]EP+KQ6@L%[K0%A 25(:TJ?L-1ORK&#(/>PYL=O=IIVO0%TK-ILI
M>38B=<%9N%DJMR*M.$76TAMN<&<-<EDC=WJ#%MXOHR8:3,S=_X2G/MQ%CREA
MX]TU"A<-RKGB=QZ,GOI*9[W2T8RLWQNCY*YQM^"I,GS*.TCD "[QY2[<>09G
M_UI!(KX][\D,G)O#1GO')^_H]4R:\JOBT!+:.N\%S]T>=![M-#<^_HV\?B\?
M>>KR>PKHT=MQ3+F?Q&O6\6@\]'3F[-V !0(XG>DN:3V[QN4 9_.+",($JZ3@
MU;..]4<?A%OLSH\052@_KNPTSH;[G=T8$W8$\T00#7:(LZ_']:\S2'E:K<K'
MD8+QQ61M[.!]>T/F7A OT[TW>4<(*][(%Z> S8)W=P@>.S(Y>$OD\*JC/%#V
M0)+L_3"2JO/[TA;B-)@MY/$-<?M$XCX\P1?>20,OB!=G6OK(&Z6ZELXY18#F
M;X* %+D5T2RCB3+DD1".=T<T+DM47Y"C[M8@L<<(ZO\EPH)H(,3KK>=--.0F
M"#(F#X9)K5WIV/=;&(;-[?>^I= 7=[0+WIAL6MN<1I.7B F2384N!'_MV$E4
M&#;NA5A@\1%A6-;@T ]=S@]MV)UE7/ZQC_5HD,Q@G>;\$.[%# ,:$/MX#?P=
M$"CM5&*!$$$I%!;@'BO $'K!D-)$ PSYCPT!3P5>SRHIS2:)D04>3?;)GR^9
MW4'XWNL<U37PWW+U$@CJQ MF'/==W@JI#@M86!-IRC58P9Q)$>!,D.B83?--
M1/1%A/(AH>E=WV\ E"8=C1N9C8]]D2(!V""\#DYUC31UT$O=GC^A(:&M$=^T
MC2G,$$%  PNX@@F159M5DH__#4(/,L5+49BQ)0)+$1I9;=(Y#9I\O9#K(!%1
M*=(N*=ERD1,J^=@XC9:NZ5H/>I,7="(U"4+V8 %9^104/!;-> U[4113R-0.
MN5(K7!-9'= I:1A0O0[R9 \I>2(G'N$*'90X%=(:EMX,&)\7(%\MDE0>EATV
ML&$9>@V/#81;@2$9OI$A5M$TM>'DB9 5N%*3C4TK?.,@[)Y$?)CT20WA<:%M
M* XW 13R>9#<N(\5B \=2=-9N5 KN)$% :(DDDW<+!8T11Y 'A'-N-'>Q-'9
M?-?E68&9E4Y#^A-R$:0*)<(/A<\'U8Q[&6!!=! 7C<T%T0S;+8XI#!)R4107
M*<XI__H1S0@CUNA$11H$%."20#4:*ATC;C&DS&C3_XQ@Z&B.9 %3.-%-VN09
MS:1D0A :7!U-.[6 \@!3.+X:%+@0#":"S#18.WJ!5YG6&AG21"+5IUG1%('D
MMH&>1%PA1&3ANJGC9OC:?YUAA"7"4BE-2Z$?>]6:]D0<0127#P'.V# 8//Z.
MXJP3(,W,H+%/(@C1.*Z/]A@DWP28;-V4<8$$3HI<6=V;V\D/*U87 YT7<CD7
MDLU,ZD3#!+V0"Y&B\6R?D=472-A:S-#"OJE9Z[RD[K36LS62*V01Z/C>$G:<
M-)+@$66/7%Y!UYR@]AC745&/S& >VL2=<1':S,C-I'48*O\M9G+N'7#"(U35
M626Y$EX"3Z@)!'5%4BSZ4T:8Y4-,7_5MH5KN!C1X3:]]XC$)$1]AT;W]WX;E
M8;X%'W196HTU5F">XF=94$!9 2UTF-@H39]QD*:PS@IQ$39.T:M-48<%(A\4
MU/R)%.\EY.U\U]ETY#4JC2"D3F?N9>U4%,X<4%A*:")4S7F=F8C"SMB4@DII
MSQ2AD4_%C9+AUE<!4B.UE"K*SIG5Z(8II(D=4^!\8A2$UO8!T_$-Z&V"94&\
MC:\=4S,1:#/5I@3)#5H53I)Z4.' &/0!'D.@)>NM9W&PPB"8#8@R5&"1(0SV
MF0FQSS=1(19=@2(NWPS(I12*$ K_)J&5C=T[!EB=8HT$\:F1=M^I>9"P)9H&
M%2!%)<^>=E'G25-@_<ZCKDV +LX>^!#P?)J=FJ;ZD= XO14-!A8@5M<UF$)@
MJ8X4'DUPY:(@1$&?P9(OSI&5=1[._)#@H2 )]2!<)<^J*A-D!1<62<VCH@TT
MPI5D8L$%UNF=ZM&NYAB;]EGM8):=>HY^?01T7=<<-1M90H0Y1D29"D0ZFNEZ
M9.IP8)=QF"?<J=NXFFM^;(Z8]L;S)0>[!A[U=9UZPFM[Y*NVW.N8NNN^\JNX
MI,3=H<_K6021#JPTTEY&%) "FH72."REK(2F!$+"8F%#4(Y<REY"E!KO82M'
MA"M$O&NY_Q(L;*3=TA!I+FDI[I6(06PFN%(LU;WL-="L0G DSJK$H9[$H=9K
M1:ALZ<TD\!D$Y-C,2 #L0I IPZ)L:S21CY&1[*P2YDCM:6H/0PE7G>*1VXD4
MZ:C0$JT0^Z!7^2"<Z% @IAY2V/A-U501Y3S:$AJ/8Z$MV3Z8_=P10WV0W,Q.
M"+E.!\(0%?'/17K8\) 1YL1MZ;0 %AC3(WF0) T/U1IA8P(NT+ /0R4"B*K.
M_/42!SW9]JU0V_)5G[4"YAH/\F0-X"H4C'&0Z0C1V+(@Z5#.ZTY1#;* "?$-
M%MPNIIW-S$B;)FE4(/#!%!51_+T<P34.7)%C6<ZK0J"GOCKM</\0CJ;-0AUA
MD=SXU-BXU?7"I?8T(3^BS_S)C> LEQ\I%/+PU"[E)O:F#A3=S/>I4_?6T5\A
M4D"6[T&9 E/2%*-AV"X!3Y[>KPC=;Y[B[S"B89T=59T%*'8UTT$I6Q<]63AY
M1-B<XCH-7V-U47W-E4GI84QATD2^(V1^A&/Y7BA2DRN1U(V*4'PB3QV]4)K^
M;W'^;!\^</EZ)SS.9^U IY;JL%NY$$^Y#T]UF'P"59+F(\<-:3.*3=A<4'DR
M;T(P+?0*!TKAE).55"_]F$UZIW.FUPQHD!WQ'HDJ<>" (> 4%U.643=M4\QH
MT(RIL DW3@1=FR;EFG2ML?M$U&'Y9?'_9 T0?U0'I1AW5A$"5^36,)!.?I-%
M)1.R(5<\%:/5^ _F[)*1.F(NN9];\A8'\Y9KQI5T96GP%>2GR8V1#A]P^6.:
MXA9TM8TG567@]-(^V7!$W9<RA4W< .=1U?+8KA+LU&M0NFEL=AM%D.QYHF,4
M"X>Z2JO9N)"-_M89PHXI?('A%I4'KH\8UX[IH"]=7<%'SLP8\2GUS Q4@0T7
MC60>BA8^-M2&?;/,<%$T/-EBY1/[X"\M'-4[DECD',WS^>T472EHS?*-Q9G.
MSO)@<C/YG/!MY9'4R98[UB@9SG(2#T3:+9/BX&8)84'CS19,*;0;YY(B8/(F
M]<Z[A1 C7V\$_^Y5/Q]5'_'4T9Y2Y,Q8[MQ4*O41_T%1$Z>>P!:S;T#5'=O/
M,<:G"%UE)Y-F4,>1X+ BB"452!@EH[U7X6#Q0)3"'()36[$A&F&6 0%B4ZW-
M#D4U^=BFW[:L,]DF__3QY.B;Z#33YH0C-/*-4RL36X=8I54P,%D2E?(-H96.
M5D8#0"&P17^@&ZFA=-4O-6V1LW&32F/E%#FP=.U66U[IG#H;AMVU&R%H+EE3
M)]/P*AX5-RW3W@"P0+GP1@UBSEV0U["43SVN10A" !A6&+4V:[]V:_OKX#4M
M3I<&+"D>/')>%E564<.6'Z467(GH+8W0$>+5A?)/(%&K_<"QLOYVA/_*69^U
M$'$K)=]0X8W!U9.A*6)I6@B)CG8?:XT*EH,>X%CUE 0^6X7U5)$Y-/OA4:L&
M\*_ZZHT*%G$+Y2Z_D?^D$L96<5+"S@$-5Q43*Q9Y+EQ)]7F+[G_I%H;!%826
M]]'R[B]ZDG4OL6\C-&))*@4];.]L.(=W^-3)'6W7-FF$N%)AEWK*]N(I1.=X
M\O5('D+H3XK'>%P)X@>VN$4$C;_53"89'4;4S'XBK8KSN) ''/1H1/$@C5"<
MK(CWAO>QK$S TL[R1#L;[<N&A7+71EHNN6+ .$-0'U:-'$.$^(LW18ZOA9CO
MQYEK^68H)1ZA:^ZY:I6'AI,/4Y:K>6"P%/+_"6*1"SF73Q.%#;GJY.?U*;F=
M6\;59)!NP2D2_5"<F= >1.6O8KBK$A:MGI\DJ5:43TV=%[I?U-DTT6=S_G'X
M!)5 F(!_EG;V=A#*95-[N0^M 3.[61^G;T9^,FC]7DWQBE5E$6AP44_:H%5?
M45$KK-4[%MZFSWI>(!\(?U%I^Q)3Z/3DC(UT!KJJE_%E=W)$P?J7$3JR1X8Q
M9?)@^U=1WDTQK14ATHS=Q*([;19)\2CH^)_FTMVQ=[M=7 .+]M^@B:^A78\0
MFE/;1B%5SM=3&N+DI-#ZI7FSR#J]+WQ]O"O#/_QP<#O$3WQIS#O%7SQB*#S&
M(\;V</CW;/C',X^'_X=\474XR7<\R(^\RIO\RGM\RZ<\R\>\R\L\S,^\S=<\
MSHL\S>O\S?-\SI=\SP/]SZ.\SQ>]T!L]T1^]TB<]TY^\T[\\TI^\PV_\9.@J
M;%^]:V<]UF^]UG<]UW^]UX<]V(^]V)<]V9^]V:<]VJ^]VK<]V[^]V\<]W,^]
MW-<]UE,]WN>]WK=.=?;]S/@]X/^]X <^X0^^X1<^XA^^XB<^XR^^XS<^Y#^^
MY".^T-2;Y0L/YE^^YF<^YV^^YW<^Z&M^IW\^Z8>^Z9<^ZI^^ZJ<^ZZ^^Z[<^
M[+_^ZH]L[->^[-L^ZC<'PJ/'[GNX[_\^\ >_\ \_\<]<7D1.\2>_\B\_\_\W
MO_,_/_1'?_*#;&I+O_5?OX<KYW#L_GG$7&J#!?>3'81PO_9;1?G_AO<;R/D_
M1/C_Q/JWQ?OK1_I[6UBTOVFT0@#5G4;$/U38_U7X/T!@$SB08$&#!Q$F5+B0
M84.'#R%&E,BPU42$@BQFU*@1XT:/'T&&% FQXDB3)U&F5+FQI,>6*V$J[!B3
MILF9-7'FU+FS8*N7+'GF_!F4:%&00XTF5;HTH4^0-YF*1!JUZ%2J5[$*#0DU
MZT:N7<$2=1J6;-F1IHZ:S?A5+4RV;>'&/6AU(EVY<^_F-6E7;]^P?!V^]2L0
M\&"+A0TG3HJ8H6##CA5')LA8<F6:E)M:'@A9<T/_SIU!IQS[$7/<TJ';GD:]
M^K#J@I_SN@XMFW5MA[0WAX9M6^UHWK^WINV\FS=QX,>;XB8\.[6I*UB\8#/E
M"F*BC5<&#6QUA3NV:+041FO9ROK<EJ; +VPE#7E[C259";HBZ*M=XW!+MA(4
M15!%/A%=VRZ]:P2Q0I#L[!LHFNP.NF80Z@3"XC;W**Q+.OGHPZLQW=J*1D)L
M]B@/HBLT8B6Z@4B4S@L3P_L0F_XN:DD0$152KD+6X(LN&D%.)"@0NFS,JJ,]
M*FI%0O8>,H5&B:Z \$+OKMC.R8,$<3+%@ZZ\YLJ%[KOQ.*=,R2Z:0+ABA<$:
MF5.+%2R*E,X5_:[8H[_Y_TC<<;[^6-"/.C-9F:^5/?S4CKO^ FDAO6BP0S'*
M[7A\4;Y$](O4.?FP@=.+5I344I \"9POD6NBB%([+TFML:0P!4*4%D9)9*$_
M#"NZLLO>!,*N31+)?*X5/N:3,#Y= YD!&Q*OX0/.1.B[@L9<!^G311Z+C(:%
M0>"<<5A*]WAQ$$2O""2Z7!/Q4+KY6L#FURHQ[*G4=?$*I#PC,>T5&RO8A!7$
MUSA,;8\HH@OS1VP"&0155!&4D,2!D<WN0.G.=-?<9GNL5+XHHXDN12*O &\0
M+44-F&$B&:YR#^H"9A%>%PD+DMW*T/*NQXR+S#@05QPV)>)*09LI$.YB%7=8
M;/^B  ]F\(C,-$42Z\QXV$./IF7+%P==&E4/I_ZST9^U-++68<5%%,2*9@89
MWY57/O5,$C%254F341X5-)5A:FD/@5NQ(E4O$+:34K2I"Q-5 ^]$42 M?<99
M(%.P8 72#S$6M$F& 4[$;FRT5!+D*@/!0DXLKFD;;K(5@V\0\+*>E 40:3&0
M/JAF-2L_G$F,0MQK?N2#.K1Y#=%,H"DWE@]:KG%5SI*T%&C&D=T>UA42D1\6
M58'V\*+.#V7_L'93.B(1"@R1'>IST T#^UTL:)FT7'>]#=R@ULUB7Z<U#\=;
MX.SF5O)A%N$_F/Y$[%^8E99JUJPO#$1+X$$4BRXFH&'_&:EX56)8 '_TKQ!I
M;4?Z,<CWP->7'!U.0E&@G,Q<X;^?8' IV:L(HF81I8P%[V?W>ER3[+="I'T0
M/#,IWL^4)A"/12YC^,,"JLPTLH4=;3M;NT+QO'8Y5^PA/01Q7P8E Z;L$$@0
M7O,:GZ+3BC--)DUFN88IH/ <-]F)3 MRTY^4A31J >I Y)%8H @#JQU-ACLD
MVDZX O>K-R%($(J3CD\P]";KT&E/GGJ1NJ#HI;'T:3XGFA3:ZA4H6;V-,&S,
MSL$FIA^B.6H^&PM:LEX%'NPIBR"CK B,XLB=;[TJ4')"FW="^;-DN6*.K'IC
ME4SAO422JB+.>4[:Y#,(.T;)_U[9<F*^]/*_K_'&-[MLSQ,-IQG!"((67OL-
M-)WIEV:^IXNQD4\KIK2:]6230LK!9E;H,LHOD;.<P<D9.Z-"0GB213GR3,HY
M)8//>:;&1O9<S#X7$ZE7"92@ S5H01%Z4(4FE*$+=6A#(?I0B4:4HA.U:$4Q
MZM"M.,4G1>+H1ST:TDJ!=*0B[6A)47I2E9)TI2;5IV+HDU&97I2F,[5I37%Z
M4YWFE*>1LM%+J0)4@ Z5J+?A*,Y4BM2CFE2I;6+J4U/:5*1&E:E%M>J-?"JI
MK/8GE_T!)*:V"E:O:G6L7 UK5SMJUK**-:UL_>I5X1I7N<Z5KG6=9TN:R$V[
M6B:OB/\,B3_WJI.^6F2P@35L9N#9"A;TJVTO0DR?Y',I:G[DI:R@A1\/>TP7
MF=$@T6B!?+ 03B9],#M*>EJ2EH22TPZN1\:LU)*4><Q %/8ANRO(:ETF.(<\
M+SPSP>S8)-**Z/2I(HV3"&<1XEJ>;'.WJ17(S1RH'=$*)+8/<= AG^*9G<RL
MNA!![D9RR1!O%41"C677-4K  E>8HEROI1R]O#,6<![$?@M,D7Q1.1;QO*2"
MAO,J2B?SNN]4ZDQ.(9-P7Z>=CD3C%%,J"7C<:#B/#N1-^?DH*RJ<LI_D=SPG
MO886*4>+*ODD/?CMR4<[LEX+4^?##"*Q@B;;T2;:#%ZO"^__0&P[LY/F=Z0L
M1DB=,C2S16FG(A_VS4D#AIZ40;@5P)OO2 DBGG>)%$7RY2A&R*/<IQ+(%5I"
MUIN60Q CQW'%"&Y)UBQ<D=T!$CRQ/:GQBG0I"X>Y(A+RR<P("*,TCW2+!Q&7
M<ZQ#)#;MN15S##"$2[JJ5F!8JHDN99/CN^$34N>$)I8PXE)&N6:V.%6+WE9'
MG3+FZ'891HT*-8PPO5\ $QEL<[+.BV5\XZ1&$TJ?>G.1^^/E'L?QQ%1&Z8"Q
M06F0DL=^>YKOFT]L'3^*I\0DE5BOIZI4,4-!OM?P0N>@**W%(FX[W)E!\.C$
MG>Q88;KQJ121HD,?!$J)2#/:E7Y$_Z1"6HPL2M&#;(@VL[I9S(BKET):*]PU
M-\4!&4(T_O>5-*E%;L]0X?,92)[F1D7L>;854!A$P/03TRJ'"'$SN1.;C&4S
M5LQ L1>G5I+[V!\7%>U2WBHBQ!,1'T'8+J8D,E!)$%5$[%S-7!*">*&]X*Z%
MW>W<:-S.T7.>N-'5MR!,G.T,+9XA=7,N3X^CW.HP17(/$K./#J_W$N&=;_AM
M+^/6$@@4$G%@/M#G4XF[U.FH2RTLL%U)@F!3N9K$1#NR3A#8RYK,^M[W^>!;
M("Q(.\3@73$:XQW@>)P)D7YT;TSY^V=:K)C,25DKG8,(62JDS\T,@C1L^_Q/
M,1^HRZ\D=/^Y%TL0WAIY*[8^K$'P*!IK'R_T])-NMF]\T7W?F)P.E',2^2KM
MZ%(Y-EPUI9@:K&YI]P*&#M0YYR@68,O[$RT.['4I81P+"9O^9%XEL.A (83T
M81//6B"ELG>OA0,A/_"S9]_EE1][BZ8\=>O5^?PD:UOI7B+_SF].*FZ]+@Y9
MR,?NBBC*YH/&-D:%.(_;!LK@<$SPNB?7.,<!"4-9)FOXV@]T@D>Q]F &6.%T
MI&5Y!*;J0*^4ZFB0LH92,&5NOLE<HN3VKN64KN8**D8Z1&1XF@11I@A.A&L@
ME$2+^.1,/NR;X AZYLUI=$AK""0(!T="L.W.5H1^NNR'+F5N>&W_6&P+>FYG
MI+P%55;("W+.[IRCS^*EA02M5EPN1,1C;YJ(B1Y&::[$3+"M8J0O2IS$%&9
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MEA)? LT(UE4+IE04+2L6:M%5(M+9BBE>I"47-F(2=4T+V%0DVJ)2+03?9]A
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&)!LI(  [

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g21422bki001.gif
<DESCRIPTION>G21422BKI001.GIF
<TEXT>
begin 644 g21422bki001.gif
M1TE&.#EAIP.X!'< ,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E "'Y
M! $     +     "F [<$AP          ,P  9@  F0  S   _P S   S,P S
M9@ SF0 SS  S_P!F  !F,P!F9@!FF0!FS !F_P"9  "9,P"99@"9F0"9S "9
M_P#,  #,,P#,9@#,F0#,S #,_P#_  #_,P#_9@#_F0#_S #__S,  #, ,S,
M9C, F3, S#, _S,S #,S,S,S9C,SF3,SS#,S_S-F #-F,S-F9C-FF3-FS#-F
M_S.9 #.9,S.99C.9F3.9S#.9_S/, #/,,S/,9C/,F3/,S#/,_S/_ #/_,S/_
M9C/_F3/_S#/__V8  &8 ,V8 9F8 F68 S&8 _V8S &8S,V8S9F8SF68SS&8S
M_V9F &9F,V9F9F9FF69FS&9F_V:9 &:9,V:99F:9F6:9S&:9_V;, &;,,V;,
M9F;,F6;,S&;,_V;_ &;_,V;_9F;_F6;_S&;__YD  )D ,YD 9ID F9D S)D
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M&*:0R]G1"ZWRPH@$,+X6F$)KB$+FUDXAB-?_H@I]S'PF]QZ+VL%1LZ]KU25
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M]$J_]$S?]$[_]% ?]5(_]51?]59_]5B?]5J_]72(@IGX4%X?$4IXA&.O'=>
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M53Y5U55EU59UU5>%U5B5U5FEU5JUU5O%U5S5U5WEU5[UU5\%UF 5UF$EUN+
M"(L(A,-RBHG C'DA)FQP#(*K"F=]H^V@%6S@%5Z:ET2(!I^BUI!3C&XIGY\0
M5U0]$7(MUG2-B;'X",<(B['8B)7YCD!Z+A-H 7NK$JOX#B@8%23AD>CP$/HZ
MF9-)"+08*V6IB2M0E,)@A8NRDL.0GQ8QA?\9F-B>N-:2P(B%70CFV)'ZR(E6
MV AA01=U)=F2N(:CL AU4I0]J(@K.1*]"!.&*($9"(MH. B+F(J651!%*1!
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M .XDM \BNLX@# []0@:&QJ]<)J[%A,]0MJ1./FPY;.0\_P)PK38BE5;BHZQ
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MS9<FG6T/AG6<?$1[X=>8:.+?3, ;Z==^VZE^E5%_F21_\?=7_Y=_=\)_]S>
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M"B2YDF?'/XSV()J1F>3$3@,F@7/'1W=+<5; +*M/$ SQ+E4"ESH",1,T8KR
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M!9AP!PM(J]4*8,@4(9*K5C7)6%*@1B\7-LHI-6/%I0@2@/][@4XIURB!#5O
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MV3NA[G0#&V"-I/]'G'J(P Q&L/4<I@4"0Q^\L."7:EFG.8\:"G0,0A3TN"<
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M?A%XF\*U0,-]5+F,%8SF:!G'T8TZEM>IWE2."+[IFA17<.'AY31 RJ#DRJ[
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M%J!G;8$0EA\C8HH'%C*1M<NA1_82@/8I)!!0( M9!""(!M5G()I\F2DFJ<D
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M5E>87';Q2G\CUH7QI2W_168H-UK?'G<$OWC>,Y^1F!VPV396@AAT=GY4)A,
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MVMNWC#$%Z4O[)0S\#5RZ#/)!RDH=+P05?8L&'RY!@K%XTBF(W&Q8Y: 0VTK
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M 7)BU\R+%[!'. VJ:42'-U4+6+<&7W@IL^S%-DG.Q:U*_CE.R8ZG%P1Q-+2
MH7S/:<"-:80/:8'LD>4%7T2LDG369+#Q6MM74G,V2QM@,COUUD U0%5&A?JR
M*.6OR%Q(B'RHM\*'XB:'__G8R.*6:(\H"9GI[&CMMM"4;JQ*1GN>2UU^-H_%
M='$O-4V[M4UO#<D,JB_5AT;8R0I($8 ZV.KDH6%<PTLUS^,.; R]=JE8CK)X
M)%-D"$B,#DO)!X7@#2L$,-P4B+G0+W+SUU;T'@E)T'WG-PP)W]/V]W_[=X #
M^( +>($3^($+>/ -GX(ON(+O(X,_N(,S./$%WRU;>"U;#-'5\H9?>(=S>-7M
M9=M!D0ZZ:=OM7XF'^+J:N(BON(K78!6]>(S#^(S+>(W3^(W+LT-#C!$9L&$D
MK/[9!&F!Z:4DC]MP+@L1CZ4T1F(,"(U1:")8R+(4YL"M"?ITMYB]QU7J3"+B
M-O]]YY<F+=[D#5.8/][EB;F9ESF9:\688Q[CJ;F;MSF;G_F;RWF:QSF:KSF>
MP_F<WSF=ZWF=Y[F?"WJ?$SJ?&[J='WJ@%SJB,[JB)_J>-[HF0=X$3KJDM[GK
M77KL47JF5SJFMYZF6_JG=SJH>[I6O%8X<TAB^Q)&Z'>[('+[O(9^6NI:[NS
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MH4NR(OSD2?]#</S)U6?^O;80ASOY\=?/F961IS:I(/@G9^D:4/B+39H4#8+
M[SWFBP9+HB% _KV/+:HR!>18T:1'F01H%GS?6<X2",%!4'KLFV!,\E<2U@E"
M=-%H ="4A[+\T0*$:<D5UVA80QK^:GC$<\J;\A-  ?#/)+1 FQ?,UXJVL>1C
MX2L)M(9#D$!9RV]DN0+I.A@;TH&F;((HP>/*!KF5L.(*+2"+^4S"LO^5A%DK
MXQSK5D86BPF"BE,C"[82$2L6;(PL HGB_$P2B)6US0M7L (4P'6-;L%Q9LQ*
M74XD=H5M*0Y;@B C2B2'K9>Q1%Q8B./.6E SRY%N9>#RH- \J)+_:VCQ"B2Q
M0AMYMA(V4LL$UCHDM<ZU![) 3UUIW$,)*G8- :P,6SE;92BGU@(60,$+GEM=
M)"G6N#9^KA4;JQD6SJ@2U;4B8ZI39OZB^91$1..7:JSF7EYGIC2=DTUJ,F<Z
MT;E.=ZH3GNV,IT3<E$/BX61"95%7 _E"BVX)3FVJ4\D>! "S0,WL8Q&KT/FR
MQ3F736M;AXR6(&2F1)H$4'.FT)])K !0DS0PHQD3%\S0APTHP"P09]D#N5CG
MBFN,BWN?:RE+'*>NC<5*HVH3VDK#U8( YF0/2&L+XT8&-0!RSH$K>:EO2LD*
MY[VLA*LKI.I>.DZ3HBQT)<$H2Y(:S)GV_\VC@^,<-BZ9N7)EC'6:*Z4?M7K2
MM')/E*);ZDROY5*!7L&J)S'K'BIF5K.RSEJ@:8OFK+ ]IN3)AHE5[*X"Y45[
MZLPM$C+B#P/K%*@& *"31:)I%.>41-QM$!M#@/G\EKRFP92#)2G;A:" @)#P
MT81[8X'S4++4A @V>5!X4UL^&H4+M>Y\%9/F>YK9"E84EJQ"4R0V3&#54O94
MJ\#=GR#VD+'*C6N?R#3(RXPH&Y<T%QMF78GG L,*RDH/CH-XJ1?H$U1L/'<E
M*XB5>TO"4[BM4*L_A*\O60)?07R0DW:+9;D>M[*"H,]<JOV<=HU;.FH1!VHM
M&&!,@@HUK&+!PO_ALISJ %L2\:JE49@"U8A)1>)320I2)Q9QB5FLXE&YN%0I
MEK%G4O78M13/04D\B17DQCKIAFNV+/GG2;!5L;:=Q67"O"1*M)>2BKZ7+Q8]
M2=M@JA)QM=&6KK!DQK(*OYR:SA51[=LCF?6ZE[+R"B@[Z5E7)ZB!YL04+&V!
M33D&+G'5#&5GOH(MJQ7-V!PU5E: K6H;>04^T )J#[YD*_;0-G+EM*1(-/+2
ME*F2#EMKSO#]:DK^V\>622P0&</F1UM7Z,Q5%:XD$V,;-==H6JZN9M2*"38[
MS+I1*Z_-L1(S?4%,R\7^&MA'PJ&-T2(L":'M<=(KBYJK3%:WL62RIFW_%LK\
M)K2/?>Y:<HL?E#^HV@# K%A%H]5+33*K;6OT/=%8Z:7;THI+E]2TH2;KA4QX
M%H%6SJXM>6Y4R8WNJ>6462FS5E*Y-;6\$3PES;U&I%7BN:J=!;G6@K=62R"T
M%? 6-B[E=5 GN41!12.6;#7ACU%BWVN4LN*JG3-_%3QF(&+3-\H4H&]FM;^S
MS-PW.S,LW/:,-)\Y\JRIVZ=T&2[#LCC'7^-).L"6/C"#/1UA34\8TP^F]*I3
M'>H*JS&QBXW/">VR+%:(V,@*9;(@MR36@9+6]9;L8[8?DR\1S584K#LS;D5,
MRC,IW7LW6L9D^SG02-O#YW:]K:Z"2Q!S!K)=_\^&UB6K!.C<BMJ<Q35TPH^L
M=+9$LEG*EVNE<LX*/%0;YL!E7_!Q4WE,?79+0L^T%K)$\_RTF]TCWO!%+XYU
M*$MTF\$%M8BV@(,ONW0INP4TL^1^=>A;ZN@JUAV7D"5\11[YP"OVPE2OY6K!
MUO[V=>,UKA=;;*+/3S1<9H+(F[!M(@GK\PYZ0,55[9^TL.2TE-4]^K>B6S!3
MG&-3PFAJ*7Z@ F4&<L;_5L:$].>O3 8+SL* 3 ;<<B;.U 7Z5N)HEDBN6B<:
M\ @J6B?.="W-PDN*>JE;)I E5$=<=JZMR&(!-8Q:L" 0ML66'LPD1DIC8,J/
M9+ EIH@%S&OD;NE<_/_HBIA*BIBE%:Z!05JPCZ1H6W9&:"I'EDQ&<\K, )7G
MEF+%@_*J\F90NL!HOI#ITO@*+D+L=WH'>,:0=\[0#-.P#->0#-L0#3-$>+XO
M.+PN0N('=?9GB4((B/*0#_5PV_KP#_%0$ ,Q$)>BFO+J+CIN+OB/?_HN* X%
MNO80[93E9MH"$=WE06:(^S:1$[UBV.00*8P-0GC#LD3"%$L1%4]1%5.1%5?1
M%5L1%E>1Y$"1>.2G*-1-62IG_5K"OER"Y7((2^;IG>2)&-G)&(?Q&(51&8O1
MG>J)%D.1#A^$6:8QE:J1&J_1&K,1&[=1&[N1&[_1&Y^1+GQ&_'HB U>F'.'_
M)AUA[;$0JQ/?$1ZOHK'$\2@*!1+I$1_S41]#[,5F;,5@S,3\L1]1C"#_42!C
MK" ',@[U\2=PC"$?$B*!T=?BD2(K\A,C<B=$T4IL2<(4,3CN8R!6POE.XH P
M<B4N,5S&;81FXF90\B=<DIP69^J<+NJNCB:M+NNPKB9S\B9U$B=W$B@/8B%-
MDB8<<DA.4!!8 0H&,"VLP".10Q#RSN6(# 4C4H5(J"K73#Y:*26N<BF@X"E!
MK#\JDBSCT?N(,B/##TC.Y?'(ZEC@AC3@LO_X1RM-"=KN4B3CTH)L0B>82G "
M32J[4A#S\'_V<BZ9YZ(&$R_E<C%[HA ET?KZL"18_^@PK>7#\I)_2.X]-*IJ
M%LA\X*4D'BXN*W-GEH81F^)UW% -59,-WY U7],U8W,U9;-&AA(M9RT:'T1Q
M5J;CY.TD:BYE7@UJTLZ$U BOT.C_#(I9CJQO1&;07M DE&9JJ"PGVD2KJ@4E
MTFZG H4DR%&*7B4&%0F,HE.XX&P(7<YGJ,T+KB$*"/ X3^(&HZ"57 T[M7-U
MU(BEI,ARPJM(F.QM3&$) X5<6$%PJF4/X*CO#K1M+(<<G\UE6L"%F!)J: $Z
MN<>BJC&,=H9Z5(LLY--NKN"78B50J@5J(HE D;,L<J(NN](X9T_6=L9DW.T*
MS"^7%E0YO_,[">W5P@N19O] 1*GE0O S+C2Q+(M4^R[R-F=MAR8DJPS)$;LL
M)2I/("0GD^1H6] G5APH"RV1/Z=&WO0F,"N'@Z#"MEX*93I-;?ZG6_XM8U;J
M+!+/WE:PHU)"\_C3W:3+@4JI%:*@^GRKE&BO8NBKTF:PSQRH3MTTIP8BFP8A
M\+@%VP(NJ%1*$":'W'1*;Y:0IT1NX8QL!NIH<H()_S#P1<OG3EU!W1:L8L#)
M=/Z'+& (6QA'WD!*CNP,^,)K!3VH"(>C@[# %1*5=1#M,E$BTK04N'A*41T5
MR3Y03,FJ6DCG>K9%2GDK&JQ U++*B-1L$-1E1=$B&)EQ&9/16\,57,<5&<OU
M6[/_Q!F3E"5S,T&6;W6@H$EZ$24(;MT$RKT&#T%:K[X,3W.B:JQ6 HOJ3W!R
MRN3<C/F Z!KR!JGZU1&3ZJ7"# #WX M<#DI52I/>QKTJ#5X/<ZOJ\N;TS[AJ
M%=="!T%"[5Q*JH3$K/*^[*K":^?T]:J,T-K>II0:: I)YGMH*[BNSZGZL'0
MRTRCRU3'*N#N\/6VE<B2;0;)SB1R*JIJKZ0.K^4<-I7FC<V2JV^P<TC-QDB[
M-MCF45U9,K(B1%Q,9HSV( IH"4KS<%.C<P%%MM/\3(R2SVPIQF<T!["N5=_
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MK,@T)=*,UW:>;'AP$*V:"P6HM!H 6U2/K#!^;<7"9Z"MV)A*]!EWK:NKV%;
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M)!_W4AM_ 2+O01 &$34@(H:!)S(8@SZF 4F%H3E@TB;5 R?OL8AK]Q*6IX6
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M&(4PMA$SQ =441\3Q<$!E5$>%609\3#]1,'^9,%PTS9_L<([=118)F84Q<+
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M@#PT.,>YT"=N<2?U*>3Q,LA[=MLVJ6,DH?G9*U!XHNR/5XM>!N.W(&"E=8H
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M5WNS9_NT;WNTA_NU=_NYC_NWE_NZI_N[UWM"U";Q\?N_!_S %_S!)_S"-_S
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MBC[1H%<HRP"J4P9ZQ:G<V,+4":@8X'/$&4%H2!?%G]>(DQ>,X$#P1ITL#"M
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M0)I>PYIF3U%<TFL,4!A1D)ATV=G_C11#M)Z*2@2>2I%.T*E"1 .%&%LFK5,
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MRJS QT3+D?Z*H8%-GUHN?D1#P8J-R:49PT;#EB8,K2HLF#)=P7IL6N'K0*P
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M8!LO2)$&(J22$1QD*[8BHZT0K2X)2]'27,$7T8C0>=(+!$KP4R']S9*640M
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MIW29HLP)@] 0\:@2>^%Q2461SP$5=8U320]8$#E71UHCEFIS)-AOJHM8)A1
MW(SPE16Q3ODN\DH(N<<[ 3"FZYQD[T0<^R=>F45(9M(A&<'R5.1B)"N"QQ:"
MJ&<P)VE+L^G85F EG==-G]\MG1YU^1'1%"\IY$5SA)QKGI$@?/AP5GY3'>F@
M[TG*C$ZZI+2D:RH'"R'66MO*C!LND=9CXI';GH\"Y]TD9,X'*\Q ]HYWE^C9
M!!#:>ZDLR/#B& 4PM7$HRP3!BJ2,S7'^65IH3"$AG R8K RB2'5BB1>C-,F?
M,L585'"\I/_C5(G5Y([IW>"'FZ^\ZSBZB[>I"G^\AX7%/%C8.G1LO0<LT$[J
MQ:^:KHV?_*:M^MR(0_RI^#P\8Z'J3W?92&6"M4*2U<T]+FO%LW+4?*4)H"X!
MO="(SG^E=O4Y/,:</E4@,J-RE=TFTV+:?& [JZGD,?,U"KCU1D.25@+[HJ,O
M$JD@^$PU\N]XP ,L1N5"+@Y2/B<I8"*)B"*EBLV"5 (WL,].5$OU3 4!6H%O
M8.[5VF4&7 'Z*@/00'#FJ,]^>L*<Z*DJ9B##<.)-0,0 Z84C@D?Y?-!I@.P'
MA7!0KDDL,(C19H8\F$[*VDX05JF-V*EGVJH VZZ$EHFB"*LB<&[_SV*%)KXH
M&DR'^%)#ED*B-,*E(A" ]=HBRK1O)]A0?-QC/?2L/$)")1S$], FC1YO-X+-
MB-0(+Y;I&E8@$3:"8$YB 8ECUBHP#HU*$.7CZ P#!),C[UB@!(^M19C,(Y30
M<?SFV%BO2QA-0P -7D:-$8\"^/K+*\C#HH:P%?T$D5PQ%CV#\<2'V/CN)6@N
M+YCGDG DCY3#R$CEE3"&^,[B(Z!$D,:DAK@CE%R/:SSN(FCC3I:E-*QOC8K)
M)8IE1MHJ$%J"%OEJ2WJ$V(SD3P0.W)@M85:'0E:B+<3#18JE,$!C,"9.(" B
M-1@B=C[P7?K-0LYDT/#C+>+Q,(8-+]H'_RLDPEU2SOU& R6*@MB*PC(H)!>G
M4$U B2LBKF5*)#5 *.GFHUVT:,=D,2050[I$LB0Q@SQZ:@*+JR-L CJDCW6\
MI&U28S:"*6A@D6RX["8JRI)DRFSPZ5C68X)TDM5*!4*6*=UN MB"B=DZ8CTH
M(B/ YN#  BDE"BV +B?S< >UR2;V;N0$,LP<1\M )W7^A(Y*CW6"R3K:)MO.
M<G$(0X>Z4"%J@^V*9Q%;TJ#\)2ZWSL]8X,Q8YD^@P 3JYGJP #JP,DJ@Z/],
MDK?PHW0:,Y8<$R2=!OD6LS+5JA6P"0PC[!K\AA5.[$I8#,(BRL8X#R9H9"Q.
MLS1C"<32:[YD"?^]6L,SZPL_NLR^5J+%F 3E*@)W//.\8NG@,@PW07,G3G,T
M^ K'0NO%+LPB5$3#3@P,(0S$I*<53L0S2[,[#D,SZ8LS86=U.LPT1Y/!\ LY
M*T+9,#-'8*,E0RP:6@*]R)-4_LLR<8L\HJ T[/,^2X-JZ"<(Y;,__7,QE.<_
M!71 R4H_/_!^*)- %71!&;1!8Q$WC&L$[P?J'+1"+?1",1376L$$U I0XB=!
MJ<HU%VO&E#,B[JLUW-/!Z"L:,HXTMY/I1)2L6I,U(2)%B1,\8V*5BO-G<#-%
MG1,A.E%'FW._1/-*6HPU.:Q$#2<\"VC"?K3"3@3'@A,O\$L[Y:-&2XS_1'&L
M=&B$%LJK2'-,OL)JOFI,3-'+?<R+Q1ZL@$KL.F>"-1%K-,UT/$GL,#PSPE++
M1B."CK@4=D!L=:P3Q<"#/6/,1:E43"'LX&P,.F<E.*\4)AAU-!2U,^&4,^LT
MOTKSOO!4EDQ!445#3XU4P(03Q=+T2QT,)LI+QL9S=5K"5$6,-B,".;FSOLAS
MOB1,47/$QOQ&>:QS15\S1P@+O1S5-F."-8D3D>@K60U4?OA3MFRF,@CB\,Q"
MSI#&SHB"H5[",/GLB_;L3UIB:*@I7?!,^+2GH" * :-BSZR,.R9-EI0#=P(R
M+[@M 7&,G%80+?G,"P9MR@:AEQ0N 5'0)5'D_URUU<E\TN5NKQ(#8&TB#I]\
MBLI,H: 6%DN(8@5$1(6Z9SB@X NB1&*%:#B"2L[4[9XJXR7^1#3N4&G*LB-2
MTJ.&\C>>U7ZZU>5ZT=$(T6#&!Q7/B/NLK!4V0I9,"H_,U3L2<"T)8U]9#<Z,
M9=)$1.[,*9AH 3KDK'%2@V$]Y'/,Y\C^I$A$0CGT@R1N#Y)J<D3,:#<B-LL2
M!Z/>(EQ_1&MSH\F,YT-X1R%@IENA2F[Z RBH0LYB<BM?S<IPA)I*(&_ZKH#8
M+R]0#07=PB;?D74X]LMRAQ5R#^@:QRPR)%R]$V(4Y1"[QB?7: -!QVM XV*_
MR%\)(IU<#J70=OVNL?^G#/37SHA*/92[;C*VP-9YKF-E^*Z$4HX%^FUF%$)5
MS$B6!.G;^/ W6L%L6>#?E)9)Q/7H^&)+IJCHF$>6?&4E!S!=K" L=F/G<,0Y
M1O<9[0IX=VYRPN+\+NAF*^@ HV1]W^0I:V,$$T$@*+*-$! MMJR?W/<($:=\
MPX]H]:-F[">&*C>&&$F51J(44RMGFG9$K  A^8)<"*+:\DXAHT&!O@\L;@[0
M_N]V+0*!!;%TC78$?Z,=J07@/*B/]"]PPRXP/@APO$ F)+,=>R9Y<:K?Q"(D
M>G!G$V@0!-&"YD9F66 %L#/DU"?#2BX&$^9.WD00A$;@1"00FL^;&*)_*@+_
M$EDVCG2G)5YH)N1R:T94E:X/]:HG>KI&(OE.1#Y(E=BJ&-<1+6@#S+Y(9&+&
M6>QE)VP&3$*C8[A")5(-)K9"(!"R%:PH-T!)BK32HD8E@=Q.CLKCA;$Q0C),
M@=KQ.-+E;9?72YLWCLRW><3*BD](CSY0++JET"1T/V=7JZ),1VCQ6AU%Q@9"
M;J;$"5U9O'"$[?SF/(9&*Y_$W=3'\/)F?'QG<4L%O7YF<]38G;*'I!@F?>X&
M]$H'+R07+_92X2SJ@X1#!LKC#5&Q0^0E;'O)+^0E- )A/9SX-[QY1'XW;OVB
MS#*6<BKW;^+D.J D)(Q9* ZBP:# 1QR$H[C'6 23_Z*:$HB9PC%O(@QWL$48
MKGW@#'[L\#5*)UUODJ?NY@[SXXH"M#"HA24WFFQ.[CS_8^]N2GE 3SY6QUX\
M(O-<1YAM:CCB>$;V#7!"ZO"6:=."ZBX;9WO.HZ-U%B7W0SY*9P?G%]7H-J%]
MEHK8&7S+8YXS&CK\!N?D9I$;(MAHYG/=[4L,9I]WPBL^QWK?@D%\UFX(A"F=
MY&?Y3C7":I%X%2?DPRN$#M*:23PJYV?WC-M$&*@5;NXZ%7!6"7N$"$^G<"P8
M!C<0-)6SRF;:A5+P-F?^) K218S[Y<@"R&7.1L>4QGYWXT7L14*X!"P4TWDM
M B4E8O9FQ3D2QK&OREYT)_\F1#!X",=G&.9SK,P)WP1JHZ7-5L9B\P+[6F#H
M5.,LXN("8X5K'GA;F>)XVFU[K\ +Q(,LAEMV2TEW;T( >>(I9H \!H'<,$)-
MR(+/ H"#UA5YLDP@]-4CS@U7Q.=<'P]X]P!8WJ*>;J,O@@UL&"1@!: BP\=5
MXF\I\>/1W,9OM&+F(,;E?-;*'!LQR*E=,FTL*/MDM1B2C^6[$2*:"FU1OJ5;
M7">00;<#-24!-:A=YJ+,]+NZ.P+[ N@B+%8B*$+$HSAP!"$ 4!MF()L\L""X
M8X;/TK" I%NWK:>[6># WR^BSIM>'X4 3U&[=P4KGAA2BWM]86(059PV+D[>
M."7_5_9I:-BB*J0)=M:/@[S;H,P(>&[V6WJBF0*./&*C;@D0(0<-M0F"^53E
MGAP[N/ 1112HK98U?IHUMNQ9>:3U;Z::$5G(<-@GG@.+8'09?U?#(]*M#GTY
MCH!Y  7$>%XDG,&N=7XC\UPA)'0Y..;,(*9EC736S_#"=($#_U@G!=WC7&4/
M-B!DGU'=X'1O(H9%(BRR"=5M."A6*'Q93,J.^/[&^7Q=JCK7?*<$\P(GO19[
MU(LP(JCDS\TZB_5V!UDO_8PBRNY0RBH$$C_H)# 1<"33>5J$961<#..P! :=
MZT8]/+P 4A(A>T!C8[X,^ JQF/',+GN2;("HW\SVOC^M_W=]6H6N,(/^>2>>
M>9O=HV[;)C#V<B2*;JF-=@J+ V08#RJF*7X59<ZR_ IX!-"ITRV$**26%H(L
MTA 75CN<-U+B"MNR%.,X=V1XZH49A&CAG>,J\8O(X]5/EVF.#8M$)/T*XY3/
MJ$IPA[#I!T2GZG9A1[IQ8J_ D1H;C^$H(LSA(X""[7@S[-B(UD7PTGFC8ML6
MI42<,J>HE]AGA%VQP"0<"5CZJ7LGCM?Y3G%WN'>9\]$\SOZNF".VYW,$$/R@
M$= ^)Z?BUW[%(V&$:'O]OO/J HT=V)=K!BUJNW*7/&9VY"#HF#!XG"BVM\0+
MAB >,D+X*C5LPSJ@1.*(3>E7F/_O1!A:+BZ&3AYP[!?<LT('*ZG:T(7U=W&!
M->3$G020]4/N>J20@P;4!_'OFFAY+?R"ST2*_W&_W]PG-'(G)')T>>+<>&=:
MCL**HW\'T?VG*T(88VXA"P.R)<:HVM?P,$^Z81WT$3A7M(T=\V9+'D62WL97
MSM$JV-51//$Y'F*TD]+W 2(:%"_8]K 0@,T4BT38 K$0A"UB-(."K@@JD4@A
MQ%969D2,& B!Q  96;2*>,6CP4'8HEUA$7%/@"L12[ @&*B%*VPK6'C\R$H
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MC(4P.=,##7I\O&!9$&[9OO990&Z:+WR"(>_A.?0Y)22,,T39B"E3-"$S#,
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M&U4S9"!9KZ6QE8C1"(F(B+WXD^2)4%1=.D'9F&[TQA.]B C-#KB[AA=\#Z#
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MKEZ_@@TK=BS9LF;/HAT9P*/,AX$&U8QF!8O)1$5IF71XLE6@G2<%F10$^*C
M5@$2F9HAF 6V/8.@8 GDQ3$K+-@""<#&8A!@I5Y:S=PLR&K:TJ9/HTZMVF,
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MV%@)8C6(E1>%KJ XW-.*HD65(5UA:[G0H4.-'$4V%(3M&A:4+:^<C/GS&I0
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MA*V'WW)CHU(BA?]1^&#4]J8,A8?MHZ(YHT&@F4_<8TKJ%I7E;H.APZC*XK-
MZ(_Q]KVPRHD%Q[/<Z93UA-+<HRC,+<W4N62PH2A\XI19VJN.NB5.N5UFN7#/
MN)RY1(W9V&)VM[R88[=HYI37ZI17^:L5;"L.JZF+@F9N;YZ=Y#A0[.90[',G
MI7,C"RJL+B.LYN<D67-,HZA-0G0RF7M3(G-&)8ID>;WJ93WNYB%6P[-:6NKR
M^"($:G<Q+,(L:&D(^V^R2=?,;6IWF8C<6E10K(;@15 &PKO<>)"162NVMFX*
MN2TB> 9DF6PF&9MIHBS2[PIJAX:G+B,P)*/;+9LS@K2 .6;*=ZH']TC_(+@
MUY>I0$(K^H91MAB>6X1^6T2+7VI]!064:9B,H61UD$N ;6*?+2*)5@=(G"*'
M+UA-[D>!>?NN=\2>+GBM-"9MVA;W3,$LR$N!0SB'TS<B /BBI8ZQS@I+7)C]
M8AB^G]BBD5M3+BZY9WF'5QG !?C%@ICRT AA:.&I_>Z"GQHU!!B?;U@R^"5B
M<(2ID O%AMJ]Z/>H+<C$Z<*I2CQ<<(*Z^<9BEO84NC"[?./&?2/'!6''S4.6
M#%=;H\&!-??=TL-3WHV&,D+\?L52,JA(5O=83FMIO UZV><:8D1U@9>,ZB*'
MD/>GM5QTK1R2OKQW%2R;KL&?*N*"A B *"@:_] HQ,;G:<]<=HG<($37: 4H
M.ZP(>?]'=6=(_G3HA/@\8/XG>J5<_D)IE)1VAU)H:;0"*A9FT6T%2 K(B\@Y
M+@3!!,B8;SP=U#\=+PVVN%/F@._WE.C%L0HWBFQ:MD[=KETF:0+CQ"]/TTM]
M,=7ME.@O?+(VMGQ#<,5GK_MBU'%=3'B]+FIKEMQ(!,7+,,87@!Z(,)"=H;@'
MV!J#K*8&IRHS+ZS(V:WD,&8=,&I=BJ3:V!<CF^[B\'P]8*#=VJ\*I/\"(<JV
M;'IZ,#)Y/%9=>U;;G-&DKJ7+W1F#W VI)I#VGL-]V/F"!0ZJ+DC]W.$BSNN*
M@VL/W/0O6\['03HLB?]96(7R1ZWF12SF+Z<S(A$82RQ00E30.EKL2HHF4"8@
MF+ 11I9]0[!^:K<UY5>V>]"+8\A(AN<Y6*]*$#NR!?K(>". Q7MWF%Y.O*CJ
M)SI*L/M >X(KHD%Z+ZFR0XN#EXPK0F. ?KLCGN2?0]_CPMX/2?%X9>(;2R:B
M X$N7OYFKSQP?C4:)7G#CV .V$&0@K%:SN8+0]S_8N!EPMP?'C',RXBOAE\*
M@C7XA1;>.C:LN,!T0H_7ZR=TN54.J;Q'V#1*PD@Z"1J4HCXB2[I#6?$WQ2?6
MOF"6SYB)KKPC2V,*.:RQ6_%.?^U?XV#0B/*5QO\D0Y$K_\5,WX\!3):=*E/_
M@HORH>"A(YWWK3BM5>)I'"XM(LM[H[B1,233F V?@S]%-@7G-47B=DO7UH28
M+\K?_RMJJ%\D'D77C'JW&U]V2GM)-B:OV&_.0VSR:]U21,)@6F&V;XO_WQD@
M!M'"1K"@P8,("[9BD;"A01:M&@9P2+&BQ8L8,VK<R+&CQX\@0XH<2;*DR9,H
M4ZI<R0H+-H;83'F)YC+FH)?8K!QLU4H0E%;19F#;XX6GE40&30VZ=H76'J38
M @V22;!IRX-4L34E:C214E9>KFA%V-/*H*O8!)VM&2C1M18$N;:ZDNC*E5:N
M8EX1%-'@6ZUYYQZ$&TWL4*]W6Q$]>,W4'BQ_L;7"_U*8X%4H>5DE#E24!=^J
M=Q%"P=)7:M7 <V<:)FB6+Y2!"ENQ>CP66]"@!/_N<579"M]6F"E>8V%W+S:P
MK5KP%"14LN:E4(H.A)*(+\R",&6BQ?V:,U^Z!DVWQ<:4(,\]0I6.%'1=8VBR
M$%?*GT^_OOW[^//KW\^__T:93$6D5%9M!=B49'J1Q@(M5P5RUV^#X79%7H>9
MAI-2L%GF4F&M!$+:;TP)DL@>:F4XUUU'J1=5AS<-!11I.0W"ER"2G8A43RRT
M:!YI>T2$5FYW1:86*S/TU I4MCFH6%%89"8(6JS0&)J',](2S36"7"$43W;U
M59 @>S"T&T&8[26(()#!9?_>7D922-X>=Q'%U$!SM300AS111=V,%7%H$$W#
M&7D3%&<*XD6-7?IF9(9SVI258'=Y:*27,1TZ(4%P/<877..)Q%Y'+$0C$:7^
ME6KJJ:BFJNJJK+::$30N14$0@&J2B(VLX$VVQTW1L.#*->D=.I2;<866U5U7
M18,96%@):P4MAL8UD%U1*6<06E<,4IE6B6R;;7EI'7I-CWP,]%0@$0E64'F7
M;EN06-L^-== (JZK)G. I>52<&C6IJZ(49)W5TW@Y5;34Z6X9&!<ED8DU:Y5
M_=F<A]C\%)-+"QY'L&$0N]M09 4!&(631#(<C;.N@ =N05#,ZD5DIKCT;,QQ
M$6O_VE.V"35R3$*IM5Y[&;VW4WRN%FWTT4@GK?32I;*B[8$^+V17MP="0:UF
M>UG!&[5V$8J0*3/0Z> 5AT839E@V'4030>AJ=85G;)>MID)P9HF4*2Q@83$K
MQ$TXF7EC'SHV:;W:E:%D+GW&[+KHU::>@Z.YB>5>9-,"G%TT%OYMC^3A36V'
MF ^%N>2"1$$MG';=5%R6>EW1I-M$$V0VY2^C;IC4JRTF&>I2DJI0306M;4IQ
M$5F!Q5XN=4UCQ6]36MA ZN%.T*?*']ZK8A1RBCE<P^OXT4*@^D[01$R7;_[Y
MZ*>O_OHD+<[^^QM9"/_\&GW*D= &+20^_?SW[___  S@_Y_L)\#_=:J  "2@
M1D(U*@0Z\($0C* $\2.J"5KP@D938-#$IS\,>O"#( PAJE8CG_TI9%@F(>$)
M.W(-X)FD%=Z;GD=:,1 7\L>$**%4((CE$15^3!!TDLSA$/*9A&!IB",!'T=B
M=Q#RB?")4(RB%$42!22>1%T-N1F2DHB0'VWD;RBI%V-LB!'"D%$_<Z-/&@_X
MD2I>Q&$WR4I#3+&\A.#P(QK$"/X4PL0I^O&/@!3A7.K% LT \3A9^LR3]C*0
M*-WE)CTIF%U<R)YTL4DA5V@!+;)UR4CRI""LF(LK(JFX+!T)&WQ )%VP%)]!
M^DB4I$Q7(E<32M=!<G@^JV51AO_7%S"M!EZX+(V79'/)[Q0Q+2U(4Y9:1$?\
MQ5(RRV0;G,@S2$@F@EZ2282#!-<"8:7E.8X$TN>N>1PWG6F:DMG+30+1@CJ2
MZ))Z.>;D/F.8:-RDD-DB"!:>8PH'07,NRK$:4@+!!\.$J& QZ65/0',@3P$-
M(PQ,2 #N&,B*6O2B\PN*Y:XP"RBH3G41><HU/,JM %W#+ &J4!QU)!C-I---
M-TL<9$*#,\LHQQ6!H%',.#32I8@E-%9QB4OG90KE.$6GAX(8;685-J(>BJAA
M*RI0N$<:P5"EI<*2'\WF907!>?,O"T$*9GAZJ:HX3$I(>8JA7-&2:+1@E'19
MFXNN)TK_D.6$1L;K4,.B<JA:N<FCBM%64^_BUO (Q:6<.<YJJ*(>6:5E4#>!
MF$='6A33,,0TT;*52T?6"K-\B5=BR=3=?-B1/%YDC^;I(T97R]K6EJ^F$8$)
MLR*2I4/)5C4N"Y0@P,:W05 *6/DZ3,CPFCVW]@1?LVH11)Y4R)I0!2[&6QYN
M?.,:%A%DN7S#B< *8B&&7",MGS+-7P+TF$AZY:E=@LV/7L,:5[ 7-[*;4&2D
M0J2>4,P\::'-W!3CI4ZI)2M:0\NSGH<=ML516$99YTWFQI2\R*2F4O'8F"KV
MDNHH42^'&DAV;)L;N, $9U*9$U5"S*9$L@5)NJ$:G>;2G)!<_WB!^W.B:V=,
MXQJK2GY:@=[3BK*8 PW(N5\P)$]DZ3I,"A>\W(TL4@K#2R.!LFS4,5)63$&U
M686)K2Z1"T_4HZQ$&&E;)PN9L":$RZ+2@BIR%8NB%MJI5@S/,#0[35SJDBYO
M8L.,<Y:4DP5&&@]Y+#B2L9!,XE5EX:;1C3B[BIFBU1(J&Z1E&A-T7\.CB/82
M:L@FJNU\51??:SCV4E21E6GH6+%)H874!>G1@615-U:D$8\//2T'56OC6MOZ
MUBK)"D-N6]BA<+A2.%E2L,$2/1B1AU.? 32P+P7<VQ:D%"T*#E/ NAB&P$LM
MP,UI1,1B(6F+!3-N7DVW*Y:77D7E)O_ +8PK:!8-OEQ%1<Z.BW(I;)O5\'1B
MVE*3BH8S/:&\)AHRN2H68C:0H[0DM@RJB=;\=%T#5\JE.1$6<8AEK*DH?&M>
M@AB_CS(M[D;D+S!)[(+<_&N<*<6IYPXLXN92O"T.SR4L#XTI/16 M]F<.#B_
MN<XCBI")XOKG0 ]Z2%"'%#C[%'." %?TBG,3K#7E1 AE2I93=RVZM&UM3K^6
M=(FGV-25Y\UB84I20^>T^'8IG7;Q9MES?**PL!62!"N6<;Q%=12^:VHH;(6=
M70=&DT\R/)A#+[7&=?:Q+0]UNY'K>(I<E8'L\#B6PEQ-^F40PS"+=U7Q9I;L
MDA>FX%V<QFK_P14@5AS#<,S!4DJG;UE -;R#/8: YC;F2,N1(=O^]KBW?4,Z
M*/3>^_[W=L0C>>1'T>!]L2)>6AZ.$406AY"J^,7';^.EC[@A1M_Y";'^0=ST
M?"X:9,(4N6/WFY^_G93DNQBY/G]D#/SVN__]%8&3/U>%NC,6+<Q8V>(#J07_
M+]*Z_P 8@( T?GW"?,%W?>KW1N>C?1:4@ #H<P(8@1((133B1>[S$5AR9,A'
M>Q/8@47#>QX8@B)80"RW-L.T0N9'?=)76%I#@.8!7",8@ZW"?C)8@S9X/H&0
M(ZY6') G.F13=7L0'3P8%:$3)H-@.S=".9;T=S?8A#?T?TX8A5)H_RJ"T6MQ
ME2;4Y"9Q9@)F=16*X19P01=353$#P6_L53)3F(;S 8%JV(9N>!_ A2T)%Q7$
ML457 2[/PCO441DX4QB>]BZMX%AR]8:$Z&)06(B(F(@;L39R]10FF!9"HVMO
M4AU/)1E_458>5F P 8.*V(D808.>&(JBB!!O@67MA1R)P5X:0AZ.U8*)447)
M\87UQE=1(5.* 7/Z-XJA"(*ZV(NB> T!LSP\<0UQE"6'\TEI81X^DB44TA9U
M1"/$Y&7DH1D+90H.Z(M1R(;8N(W<V(W>N!*\^(WB.([D6(X288[HF([JN(WA
MN([N^([P*(7:&(_T*'3I@GLU<GOYJ'NYM_^/0^:/G]2/ HF/ ZF/!<F/!)F0
M!JF0"+F0#MF0$/F/!RF1#$F1#VF1$1F0%:F1%\F1&7F/'0F2'PF0(HF1)NF1
M)UF2*+F2*MF.]?B2M687.3>3.U>3-'F3-IF3.+F3.MF3//F3/AF40#F40EF4
M1'F41IF42+F42MF43/F43AF5.PF35%F55GF56)F5,;@<1C(C7?F57AF68#F6
M8EF69'F69IF6:+F6:MF6;/F6;AF7<#F795D2Z8(@=YF7>+F7>MF7?/F7?AF8
M@#F8URA!@GF8A)F8B+F8BMF8C/F8CAF9D#F9DAF9+U29E)F9F&F9BEB8[^B9
M.Y%[HCF:I%F:IGG_FJA91U/T&ZC9FJ[YFK 9F[(YF[19F[;)E27!FK>YF[QI
M>ZI9B*"YCLCH*20X@%JY>[F)0+])B,-YG%]"$L&9-,M)@<X9FG:)0-'I@:T@
M#=59?NM1G'^4G>DHGLE80-/YAN19CN*9GJYRGB+DGEC9G"Z&G9W(GN,HG\(G
M0/;)/_LICN0)G_,#H%.(G\=I"M!IGH DH%69GOVY*@T*?P_:C>*IH.L3H>QC
MH>R8G A:G]V)@O,I0!1Z02'ZD@0Z0_39F1VJC"0QHNB#H>KCHK[XG\I9GS"J
MBRR*?2":H"E:(]<)GHFXG3LZH3XZ136JBS*ZH2B:HNN)I*L9I.19I#=D_SY8
MHU,\A'PAD4]F!W-6I! LM3_#*0A52GX=BHQ3:F<>FA W:CY]\4RII!&@.2_F
MD4C06!%U1(P_9!#V)Z9C&A-R&GP6D:;F ZC]\3=F$Q%A^C$<>!$7"&=><(&D
M"#QM@Z9:&$-V!*6A:*"V(2QQQGR1BIPY*EQ_TQ?H5Q&.]A$-Q:<" Z<. 7XJ
M-*JKL3)T&J3)%6B4JB+A=Z)+<W (8@JC5%"<84AP,3G:!A&\>AQGP7>)Q'V)
MU"&^LB:0)#K$U"_-Y%M>B4MBT0H%Q1=4%B+@EDAN\7D&N*?&6H;(0CDO,2,D
MLFW/J9]5(8WJ>B9=DJTNT4P\(A1AQQ=PTB%V$_\>=J,9WD1'Z=(KU'H%?+!M
MK+,'9^9;DA<5=G,-!8M+<.%(-))(*:BD40$5?X-+,O,AEX2P!B&H3 .R_#$;
ME:,4X_%?*X67R1,3=^,5ZW0W.C(>VO$%^;-YLL%I+F(8@E 84]*RG&.RV'.Q
MH4H:9&2IGM@7[B,6!CHG.S1J,62T^/&,>'<7IE<;UYH7N^%H<2<K*65O!+-)
MA_-F4I*PB,-EBA$MMV)6<7<%Y<$N#C,B52JRZOA)MGJMZ62LLW5&4(L?>]L1
M_:5-=2$[C1I'7C9+8]$V3J,>OF$F[_(N^&> C4:M<8%%)^)@ Q6XY#%P1Y@7
MZ,(9R--"%=N=R*@BZF;_2&)""XM[)@<AMTBSI@7&MCJ+K1W73'11=O!R%^4R
M',LJ.R?6J5Y"M787!:4Z%*SCL ,1!7+%%_O4(F+A&>I4L'HJNA>[(Z3$/2-R
M/)2WNC/*-'$V(#(265,!LUXX4VFC5D@1-<FW4NZS+75B*69U*6Q+OFUCLN<K
M(ZZ ,_("<WR2/WV+B,NS.#03=DV!+KFD?_U+'\L3&@;28-& *]("OVY6=,<V
M%MM21]ZR21^K?'7!($_E!:0&0UF;>EH!1C]5'H+QLTZ!1*R+CG0+2216;PF;
M+)0:K@!TP&X*=C$Q2HE4%'<#%(:;+:3D9;R2K J12+1P#5\%=>E$-:KK2#RQ
M_Q11<DJ\&DN?1#FCA$MN\9M :K&*-1K0:*UGQK'TM*X!M*8YB 42[$@/$E+@
MA078)A:&XL8+Q:=W84ZF- M@&CSL81PY-4\A=;#DL;]*:TI8PB6L0TIGYCLV
MS)RMH[KS)!;4&$Q#<3@K?#25[!^LD%:'.J35N:2?:D1 Y#$1=,GD6*)^BZLO
MNJ\3Q)5RV<IT^<JN',NP/,NR7,NT?,N5#"$6F8^\O,N^S)&]#,R_#)+!3,QS
M/$>L(Z*VO,RXW,S,_,S.',W0K)9'^LD[2H\2B9<!J<U]N<W&S,U\Z<V]#,YY
M*<[9?,WO-RE2IL[:RLYNYL[6R)KM+,_O3,_Q/&3SC/_/]:S/]XR;Z/S/ !W0
M CW0!%W0!GW0")W0"KW0#-W0#IT2A5&,UK>E"5$8=G/,(7%(5\2C$1@1P&-/
M%4TY,[P198.XV#I#N9@2;8JF9'Q*_&M^(IO)"&%_=BI#Z4=1(*VB1.01(#T9
MM$4+>4H1.=T0>U J-.01K'"H9FH*Q^@0%71\K% 246T1ELK4H=01T9#2'5&L
MI*I"-&*F?S0<Z=%BJ0;6#E&J34%:U_?4*4%E,.00FQQ%%$T13@.Z9SJKP66J
M D.XB4H18,K6*D%[;\TV)J(V"(&PQT35"/&X!6%_:S<4&?'8% &I<<T18:89
M6 M&M9<J51HP&'$XDGT1%13_VJ TTF>MR20!?JLZU[EFJ!TAT]Y7$:WZ,F9-
MI"S >H$P ZRT%]=0 BUPA,016V&J(@3,(.JD%<8(KSX,3\C-;;204WO1$GP'
M2@5%K1$\2-QF2EVE%-<&&]C=W*!$(X6,/&,!0V#Q2\PX3T\S2\O!W.]T9OS7
MW$F7);MBT4JH%P5KT9I'L3O<W)93-VQ%WHQ;%:PCTB'3 KH[5KNERIDZ/=I$
MM8?L!7A<+X-]$$J;,F-!*.!A2$E'.;#AQV##.M#M6\<#WLV$)+AD*22RNV1R
MT<N*Q!9]'4X#.NULK16&L/<:ML?MX8YTK&=W72[.)B<S2,@V(>U65M"];I-D
MR(<"_W/:PA<%A5#F.LC(6G<.(18]XK[.J\.,9&+AG2WM-D^-NA?VVMQ+T=_3
M$TTL3KQP7+AX?$GD+537&ZU28FRSLA>6(@A' :]A(5+[9*X[]-Z/@37^7>6D
M84@#U"6Y'5;2S1<.8DC7NJQY3$+#\>!N7$/-'5:D)#!H"TULTCUQ>@41-K'K
M)ND0OBQ>8<1>GN@B$F;FVDPSXCI;T^F11!=5,A;F>N=GHJX_=5&ZRP)2M2!\
MXQ2-&H9/-=S%L;)-01,MC#.R<2C[%AJNP!=E0QGSBB1M@[#^BB !4A,1?#)4
M]K@?1[6D L=@NR(*TZA[U^#+>'FM@,2D5JIAUD(7."9VJ_\=JO,KUHXX:C&<
MXYYC(ZPPFKLB$5$99145EFOO7%H9)]-"'PQ*I9=C9;<V#L)I19T05(:P!9L\
M>='KW6ZL@"@JX[%#!7\%6-?!IG&"?_-TA_+83=%">F>L/>&Q#74R >,TN_%X
MB TMZU:X%KYRM 6WV' *,=\I;3OP7['!(RS M3%GV#!*A_(=YO(W2(P- X?:
MME%5::$NL-N#%!$(T +S/I6ICZ/TBP6-+7394[%.*>,4':_V)^2V3SWD*[_L
M,.<%C\<397,6.#LPS3<9-[_V:0M#-%$O"$METE[78??N7\'WD,=&U'2Q,HVP
M;;-#UPKMB< L3M/J,534];(A'?[_24#$.1.R&T&;-DH!?H]SLRS;%[WN: #C
M6T>,Y2$U1/"R3]6Q4JX_+]NV4;#A:#V"L+N1R4[;N!P#XT$-1=<3)EB0VP11
M K1 '3G(A TQ6[;Q'8Q+.85K=5Y0*,.U%:'Z) +QV*DKW.GD$RNS0YEL7R;R
MZO,W*V?BL)E]K>%;>= T3Y3AOGKW3F(49M' !P!A*A$V@MBN$!342M 505A:
M#3*(+9H@4PP%"<*V$$O!0!>O**05<6,T+'L6)F3%<$;$@GQ<83,UZ."U@P2C
M><&VDM6@5E@F0H%H$V<KA*UV2MQXS411C 6=/CR8$.?!GC09\J$)<Z#-*Q]C
M8ML#]J)#_XBL9EQLI?#*5I@,#QXTY85AT(@*X\Z]AH5/R)K8=@9ZF5=0HL$1
M#^ZAI1#QTZX7#2YLU??H48)4!>T)[-,+'Z)7KK&XR!-G084L6GT5R!FL*ZJB
M%[-B:TI0BXA1BB;=Z%1WQE93"Q_<:3*T2Y;8U/+$(A#;-2]'$;]=?D4Y<XX+
M9W;=&NWL6IBT36&Q&(@HP8VP!5XC?C"WTXJ"9DQ.!!B;0^9YE5^A!9C50EH"
M'U9>*!%36I'/(.6>"N2*0)J#"#J8!DDH+ZU*D4N0!@\LZ*! $AL-N-EH.0B*
MBQ+: XN%"L)L.1/'6\VO06[*R)41/\)).5-<B<FC*V3L3#>%"/^*XJ'V,)LQ
MK2L<NL*+$PEZC;!6;A($1X929.HE]8K;+4LMM^2R2R^_!#/,@CY+C(49HF&!
ML!9HV:,YT\2+,4L,#5N.(H@"&<046FCJS:_QKL%HI\&HN@)&#.'$*)!$H./S
MH(G\:W"]B/B$Z"NN($KQ(^#(&A,WDF!B$*R0L-@/IO$^)8DR)JWL"=2O$*O/
MT3RM#&G2MZR,QE$OODK(T8/X<$K1C!;EJZ"=)+S)/BL+LK0RI(S;Z*/RN'MI
MMRL@B@:*9>D$%$95 X7P)?%\I:[/5@0L-CKCKNP3M@PK:S>1A^3#SR92:QP$
M,/D00RQ*L"1U]M&!%(631JT*PJU4@8+_<Z71.N=S"J.\CA)O,4W]PHE43*N-
MIM)$,-NCE:P<;6K+:(+T:Z:1=JV4-6<)&M"@O"049->!60.1KT\[>O<:V@(=
M#=5!:(I)PH<*"WFCF":R%4;="#4TSX&H\@)*H@ ;#.B=HLYHD*UQ$K1:8^\4
M<.#\.G.Y7='\&F@/1X.EQ5_@J@87,43!(DJ06EG!=T-C<=I#7HP"MQABY]*2
M*R3;%@OK:>.:$["LR/8L--%%7RKYJ!WK+?%!4]]%+-=D1Q.S=--/1_WTR%YJ
MTS@6/LIH+5-8<,@@L9]BZYI!$F-H:K3V@[T]%CW*R*^3SI6(+;72PJCCR$Z4
MS;*$,'8JI1,[_^J+("L(HLG"C&I.A)7;-SIW(AH[QB:0Y,V?'J$3Q8^X3K5J
M1A^C_Y[OS#'WE<RO=VQ (]FUI"23XCF%(8!#B %;!1OG0:8@Z"M(4[#'-@JR
MP#ALB=A T%,L0$ED+M@ &XNLEY:!I6]$R/N>AV!7IVMM1&+"0YA$AB:\#KIE
M;.PS2EJN9L*F\$U4I.E=]Q*RO+1<,(8/N49[&M8@Z/'G&AB,'BU8091S=0\B
M%_%"(IXX/Q:9Q(7&L<Y_.DBZW0"*BDTAGQ9/TA^B- Z,'T'?\SBEM[ TSGX'
MK,Y%I,B0X9T(5E$:X6,&AY96A"Q7A<%)@=I"0(^ I(/%\P+RU!<EXO\I!(46
M,=)I&.**(O9E?@WZWO*85CSQ)9&/7>--!/7WO$1=+R$! E#)3!FE(G*O/4SL
M5T,2LA63X&>*6$Q(S,+2EUSQ47=B<:$N-2DW_2VG(H&+68&\.":]"1&$UTQ=
M-K6)NH6X;2%\<(LWKP#.DVS3G-QT1:G.Z93%A*E5ZX0G//LBH7C6LWHELV<^
MX^E#,:6H%;729T##%*6L"+1+&"G,08=ET"ZUXG8,[1(&SZF0E[ "HDY!7SO7
MR2*(F1-Y]<IG9,1)SBN,-)P71=T56!" E;:4I2]UZ4I1NL^&V+-]8#+C3'5J
M'(#B<Z=BF@A'?SK4EPWTGT2=J4+(^-/(2%3_2TU%:E2S)%2/^A2EUT@)5;?)
MHFAH5745.6H^50I3LL;TI5+EDDI;6@(6L)4%:VWK6RVHSVBX(HX%M*F6.EB1
M6N4-H UU*ICTMM-H)(8N8IKB.:V:I4!(2G?'M*=7M_E(A>IFL5PB2LQ,=MBG
M>G5!,.3F7P?;4.Z0AC  ]>L_:UE/=W'IC@_U$S?7>0W):@F?P +3C<R9V"[Q
MUG2UM2UI. M/")ZNKO^I;$.'.U2ULI2M;H4K=-&ZI;&:U;K.#6BI>M27OQK'
M1]]]2D&6I=65S/.5 T$M>+T;#=)XER!"!>A+M"I4KK97OKIY"7N)PMZ08(9%
M++K&EL:#7/7^=ZK+_VDOB\06&05##& &?J]W(>Q>]]ZTC 66R)A\%,F&^BO"
MV5-O2'KDW_9&>+\4%JJ%__26Q)08Q0<.27K%%E_V0(1% C$O4?HC+VP=.,*[
MF>][<0);T-W.P.QE[X]?#&0?:SB\[X41%5W<8-O0-TOZA=E K*SD($\XR>W%
MLE->DMX/(WC"!D;/A)T2X"UGF,NZV0F+NOOFOWUJPM)XL=@6_*DGBW?*+A9Q
MZJI;5D++=+I9N@)+WZKHEBY:KBP-J-OL(JUK>%%LV+O30JK5O6C5J=(-B8P7
M]L#9O+1"1#:!PL<4-!0\OM<BQW+;6A;2V/3)161=J=:&&AE!N;"%%> 9VO\>
M$A2W:W7$)!D!CY$<8B)-:>PQ;[F,3[OGE40<T@O],5$R=P0\NO2D9A)R2Y[<
MTE<6$! ;6*G:>CA]2+@<:9R.Z67#NO(\SP"%E0:\S-#<<AIF:_K>W -@?SS&
ME1/5!"/2&8AFGRVCD(S+(R<2Z50..)'9(/LCTZ;+@CXRFX4HR:X6>7;Z&/(T
MR(1,91M:T(),2&OM.41B"<E7K;+UL5 7;9HH"I!B2G:1P+E+/\!.25?F#*\C
MJ7+;\MIW1VIFPAU5I"^>L2'.2_L8/#U;0$F2M+MO7=.N0$C373DVU#6MF_9L
M!##1JU1)!<%I9 ?.6"65&KU!M!"Z!#/J'O2W#1O_8Q$;1@_IFN(ZW><%<NZY
M92 U"_R18-E+KD8!,LKYED;.[:RNI 0\ RM)@]92.4%8(9&V?G;)V/UQ!^X=
M,O1.F0-/)PA&M_[1KS\THJ\[^P $M&/@-LBGFI667&$C"BV&V?0 ]1+->)<V
M/W*<>>,V-=M9DB"_-DZJ-H:9:X@GDEFA300)9+_VRH9[T[/3L.HU/6D]+B92
MWI&NXU/1?/7H*;FYPDZ\CS5H%5++(2L.GJCH[)OX4*.<&:PKZ0M_JI>8. HH
M( @^^(JL6 DJ"IDH>16QP;^#&)CXF)HG41),Z2N<^!0'$95" @DZ\4"'B@;9
MB)G#:)%7:B.7H0Q%(8G._RB5 @E!Z#@,$#&.T^ )OO&>B!&9'"D;J_F-K$ ^
M%ZD+KUD4:HJ;TZBVYK <F]@_'V*1C\BLA%L_W@"<H8N(=JHT+9._MK%!].";
M6^.G!/PU*2.(A*.+"<2&2LF7@8"1E8@)_QJ,">2DB/@4SL -W1 6@8@)V*$*
MO[@7HN"3X@B<J\&9]%D=0G0%P*B^32L/GC .DVNC%A&/VBD4I9F>R<D]$]'
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LZ(9VZ(>&Z(B6Z(FFZ(JVZ(O&Z(S6Z(WFZ([VZ(\&Z9 6Z9$FZ9)FJ(   #L!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
